The 88th Annual Meeting of the Japanese Society of Hematology MICEnavi

DaisukeEnnishi{ENNISHIDAISUKE}|NancyL.Bartlett{BARTLETTNANCYL.}|MamikoSakata-Yanagimoto{SAKATA-YANAGIMOTOMAMIKO}|StevenHorwitz{HORWITZSTEVEN}____KojiIzutsu{IZUTSUKOJI}|RobertS.Negrin{NEGRINROBERTS.}____YukiShimizu{SHIMIZUYUKI}|SakurakoSuma{SUMASAKURAKO}|YasuhitoSuehara{SUEHARAYASUHITO}|ManabuFujisawa{FUJISAWAMANABU}____JSH-ASH Joint SymposiumRecent advances in lymphoma biology and treatment development____Genetic subtypes of B-cell lymphoma and potential for therapeutic development|Recent advances and future perspectives in the treatment of DLBCL|Comprehensive dissection of the tumor microenvironment in angioimmunoblastic T-cell lymphomas|Tailoring therapy for T-cell lymphomas; recent advances and future perspectives in the treatment of PTCL

ASHSY

JSH-ASH Joint Symposium
Recent advances in lymphoma biology and treatment development

Chair：Koji Izutsu, Chair：Robert S. Negrin

MasashiYanagisawa{YANAGISAWAMASASHI}____SeishiOgawa{OGAWASEISHI}________Special Lecture 1Deciphering the mysteries of sleep: from basic neuroscience to real-world applications____Deciphering the mysteries of sleep: from basic neuroscience to real-world applications

SL

Special Lecture 1
Deciphering the mysteries of sleep: from basic neuroscience to real-world applications

Chair：Seishi Ogawa

Speaker：Masashi Yanagisawa

SeishiOgawa{OGAWASEISHI}____MotohiroKato{KATOMOTOHIRO}________Presidential LectureMolecular genetics of myelodysplastic syndromes____Molecular genetics of myelodysplastic syndromes

CL

Presidential Lecture
Molecular genetics of myelodysplastic syndromes

Chair：Motohiro Kato

Speaker：Seishi Ogawa

JeanSoulier{SOULIERJEAN}|MarcinWlodarski{WLODARSKIMARCIN}|JaroslawP.Maciejewski{MACIEJEWSKIJAROSLAWP.}____SeishiOgawa{OGAWASEISHI}____ValeriaVisconte{VISCONTEVALERIA}____Presidential Symposium 1Germline predisposition to somatic evolution____Germline predisposition to bone marrow failure and MDS/AML|Somatic evolution in bone marrow failure syndromes|Extended view of somatic gene rescue.

PSY1

Presidential Symposium 1
Germline predisposition to somatic evolution

Chair：Seishi Ogawa

HartmutDöhner{DÖHNERHARTMUT}|YotaroOchi{OCHIYOTARO}|MasayukiUmeda{UMEDAMASAYUKI}|MoniqueL.DenBoer{BOERMONIQUEL.DEN}____YasuhitoNannya{NANNYAYASUHITO}|HirokiYamaguchi{YAMAGUCHIHIROKI}________Symposium 1Acute leukemia, recent advances in elucidating the genetic, epigenetic and molecular pathogenesis____The evolving landscape of targeted frontline therapy in AML|Epigenetic heterogeneity of AML revealed by large-scale chromatin profiling|Novel molecular mechanisms and classification of pediatric acute myeloid leukemia|Clinical impact of genetics and bone marrow microenvironment research on children with acute lymphoblastic leukemia

SY1

Symposium 1
Acute leukemia, recent advances in elucidating the genetic, epigenetic and molecular pathogenesis

Chair：Yasuhito Nannya, Chair：Hiroki Yamaguchi

ToruEbina{EBINATORU}|YukiNakajima{NAKAJIMAYUKI}____NaokoHosono{HOSONONAOKO}________Clinical Debate 1____－

CD1

Clinical Debate 1

Chair：Naoko Hosono

MasatakaIshimura{ISHIMURAMASATAKA}____AsahitoHama{HAMAASAHITO}________Educational Lecture 1-3-1Inherited anemias: current approaches to diagnosis and treatment____Inherited anemias: current approaches to diagnosis and treatment

EL1-3-1

Educational Lecture 1-3-1
Inherited anemias: current approaches to diagnosis and treatment

Chair：Asahito Hama

Speaker：Masataka Ishimura

HiroyukiTakamori{TAKAMORIHIROYUKI}____TatsuyaKawaguchi{KAWAGUCHITATSUYA}________Educational Lecture 1-3-2Molecular genetics of paroxysmal nocturnal hemoglobinuria____Molecular genetics of paroxysmal nocturnal hemoglobinuria

EL1-3-2

Educational Lecture 1-3-2
Molecular genetics of paroxysmal nocturnal hemoglobinuria

Chair：Tatsuya Kawaguchi

Speaker：Hiroyuki Takamori

DaiMaruyama{MARUYAMADAI}____MotokoYamaguchi{YAMAGUCHIMOTOKO}________Educational Lecture 1-3-3What is PPI (Patient and Public Involvement) ?____What is PPI (Patient and Public Involvement) ?

EL1-3-3

Educational Lecture 1-3-3
What is PPI (Patient and Public Involvement) ?

Chair：Motoko Yamaguchi

Speaker：Dai Maruyama

AkikoHashimoto{HASHIMOTOAKIKO}|ShinsukeAmano{AMANOSHINSUKE}|SakieOkunaka{OKUNAKASAKIE}|SamanthaNier{NIERSAMANTHA}|KeikoKatsui{KATSUIKEIKO}____AyakoArai{ARAIAYAKO}|KotaOhashi{OHASHIKOTA}|DaiMaruyama{MARUYAMADAI}________Patient and Public Involvement SymposiumConnecting patient voices to society and international networks— patient organisation collaboration, PPI, and global perspectives____－|Activities of group nexus Japan for patient and public involvement|SHAKE HANDS ― “Connections” and “Collaboration”|International perspectives on patient advocacy: sustainability, participation, and support for rare diseases|Patient and public involvement (PPI) in the Japan Agency for Medical Research and Development (AMED): toward social co-creation in medical research and development

PPI

Patient and Public Involvement Symposium
Connecting patient voices to society and international networks— patient organisation collaboration, PPI, and global perspectives

Chair：Ayako Arai, Chair：Kota Ohashi, Panelist：Dai Maruyama

AyakoArai{ARAIAYAKO}____HiroakiMiyoshi{MIYOSHIHIROAKI}________Educational Lecture 1-4-1Chronic active Epstein-Barr virus disease: current understanding of its pathogenesis, diagnosis, and treatment____Chronic active Epstein-Barr virus disease: current understanding of its pathogenesis, diagnosis, and treatment

EL1-4-1

Educational Lecture 1-4-1
Chronic active Epstein-Barr virus disease: current understanding of its pathogenesis, diagnosis, and treatment

Chair：Hiroaki Miyoshi

Speaker：Ayako Arai

AkiSato{SATOAKI}____ArinobuTojo{TOJOARINOBU}________Educational Lecture 1-4-2Reference guide for the clinical management of adult Langerhans cell histiocytosis (key points from the first edition, 2025)____Reference guide for the clinical management of adult Langerhans cell histiocytosis (key points from the first edition, 2025)

EL1-4-2

Educational Lecture 1-4-2
Reference guide for the clinical management of adult Langerhans cell histiocytosis (key points from the first edition, 2025)

Chair：Arinobu Tojo

Speaker：Aki Sato

YasuhiroMurakawa{MURAKAWAYASUHIRO}____KenichiYoshida{YOSHIDAKENICHI}________Educational Lecture 1-4-3Long-read sequencing: new frontiers in hematologic malignancies____Long-read sequencing: new frontiers in hematologic malignancies

EL1-4-3

Educational Lecture 1-4-3
Long-read sequencing: new frontiers in hematologic malignancies

Chair：Kenichi Yoshida

Speaker：Yasuhiro Murakawa

SoichiSano{SANOSOICHI}____SusumuGoyama{GOYAMASUSUMU}________Educational Lecture 1-4-4Y chromosome loss in hematopoietic cells and its clinical implications____Y chromosome loss in hematopoietic cells and its clinical implications

EL1-4-4

Educational Lecture 1-4-4
Y chromosome loss in hematopoietic cells and its clinical implications

Chair：Susumu Goyama

Speaker：Soichi Sano

MasayukiYamashita{YAMASHITAMASAYUKI}____AtsushiIwama{IWAMAATSUSHI}________Educational Lecture 1-4-5Dysregulated control of hematopoietic stem cells in myeloid malignancies____Dysregulated control of hematopoietic stem cells in myeloid malignancies

EL1-4-5

Educational Lecture 1-4-5
Dysregulated control of hematopoietic stem cells in myeloid malignancies

Chair：Atsushi Iwama

Speaker：Masayuki Yamashita

DaichiInoue{INOUEDAICHI}____HiroshiMoritake{MORITAKEHIROSHI}________Educational Lecture 1-4-6Targeting leukemia-specific transcriptional hubs in AML: menin inhibition and beyond____Targeting leukemia-specific transcriptional hubs in AML: menin inhibition and beyond

EL1-4-6

Educational Lecture 1-4-6
Targeting leukemia-specific transcriptional hubs in AML: menin inhibition and beyond

Chair：Hiroshi Moritake

Speaker：Daichi Inoue

AtsushiOtsuka{OTSUKAATSUSHI}____YasuoKubota{KUBOTAYASUO}________Educational Lecture 1-5-1Generative AI in medicine: current clinical applications and prospects for next-generation technologies____Generative AI in medicine: current clinical applications and prospects for next-generation technologies

EL1-5-1

Educational Lecture 1-5-1
Generative AI in medicine: current clinical applications and prospects for next-generation technologies

Chair：Yasuo Kubota

Speaker：Atsushi Otsuka

HironoriHarada{HARADAHIRONORI}____HideakiNakajima{NAKAJIMAHIDEAKI}________Educational Lecture 1-5-2Advances in the management of myelodysplastic neoplasms____Advances in the management of myelodysplastic neoplasms

EL1-5-2

Educational Lecture 1-5-2
Advances in the management of myelodysplastic neoplasms

Chair：Hideaki Nakajima

Speaker：Hironori Harada

SatoshiOkada{OKADASATOSHI}____ShinsukeHirabayashi{HIRABAYASHISHINSUKE}________Educational Lecture 1-5-3Update on the diagnosis and management of severe combined immunodeficiency____Update on the diagnosis and management of severe combined immunodeficiency

EL1-5-3

Educational Lecture 1-5-3
Update on the diagnosis and management of severe combined immunodeficiency

Chair：Shinsuke Hirabayashi

Speaker：Satoshi Okada

RyosukeShirasaki{SHIRASAKIRYOSUKE}____IchiroHanamura{HANAMURAICHIRO}________Educational Lecture 1-5-4Genomic aberrations in multiple myeloma and their therapeutic implications____Genomic aberrations in multiple myeloma and their therapeutic implications

EL1-5-4

Educational Lecture 1-5-4
Genomic aberrations in multiple myeloma and their therapeutic implications

Chair：Ichiro Hanamura

Speaker：Ryosuke Shirasaki

YoshinobuKonishi{KONISHIYOSHINOBU}____ShinsukeIida{IIDASHINSUKE}________Educational Lecture 1-5-5Toward a cure for multiple myeloma: multi-omics insights into disease pathogenesis and early therapeutic intervention____Toward a cure for multiple myeloma: multi-omics insights into disease pathogenesis and early therapeutic intervention

EL1-5-5

Educational Lecture 1-5-5
Toward a cure for multiple myeloma: multi-omics insights into disease pathogenesis and early therapeutic intervention

Chair：Shinsuke Iida

Speaker：Yoshinobu Konishi

KenkiSaito{SAITOKENKI}____YasunoriUeda{UEDAYASUNORI}________Educational Lecture 1-5-6Acquired von Willebrand syndrome associated with mechanical circulatory support____Acquired von Willebrand syndrome associated with mechanical circulatory support

EL1-5-6

Educational Lecture 1-5-6
Acquired von Willebrand syndrome associated with mechanical circulatory support

Chair：Yasunori Ueda

Speaker：Kenki Saito

MakikoSuga{SUGAMAKIKO}|ShoTakeyasu{TAKEYASUSHO}____EliasJabbour{JABBOURELIAS}|KoichiOshima{OSHIMAKOICHI}____ShuheiKida{KIDASHUHEI}|YoMizutani{MIZUTANIYO}|YutaYamaguchi{YAMAGUCHIYUTA}|NaokiHosen{HOSENNAOKI}|YuyaKurihara{KURIHARAYUYA}|KenSasaki{SASAKIKEN}|TakashiOyama{OYAMATAKASHI}|YutaFukui{FUKUIYUTA}|MichiakiSato{SATOMICHIAKI}|HirokiHayashida{HAYASHIDAHIROKI}|YosukeMasamoto{MASAMOTOYOSUKE}|MineoKurokawa{KUROKAWAMINEO}____SETP1Clinical Challenge for Leukemia____Cord blood NK cells with a high-affinity CLL-1 CAR eliminate CLL-1-low AML cells|Heterozygous loss of ETF1 represents a therapeutic vulnerability specific to del(5q) AML

STEP1

SETP1
Clinical Challenge for Leukemia

KotaroSuzuki{SUZUKIKOTARO}|KenSuzaki{SUZAKIKEN}____AkikoShimamura{SHIMAMURAAKIKO}|AyanaKon{KONAYANA}____YoshinobuKonishi{KONISHIYOSHINOBU}|MasatoshiIkeda{IKEDAMASATOSHI}|AsamiKataoka{KATAOKAASAMI}|KenichiIshiyama{ISHIYAMAKENICHI}|MisakiHada{HADAMISAKI}|HiroakiIto{ITOHIROAKI}|MasahiroHirata{HIRATAMASAHIRO}|HironoriHaga{HAGAHIRONORI}|YusukeOkamoto{OKAMOTOYUSUKE}|JunyaKanda{KANDAJUNYA}|KotaroShirakawa{SHIRAKAWAKOTARO}|AkifumiTakaori-Kondo{TAKAORI-KONDOAKIFUMI}|KeitaYamamoto{YAMAMOTOKEITA}|JakushinNakahara{NAKAHARAJAKUSHIN}|Yu-HsuanChang{CHANGYU-HSUAN}|SusumuGoyama{GOYAMASUSUMU}____SETP2Genomic Analysis for Hematologic Malignancy____Spatial analysis reveals hematopoietic niche disruption in relapsed/refractory myeloma|Artificial coupling of mutant TP53 with RUNX1 induces anti-tumor effects in acute myeloid leukemia

STEP2

SETP2
Genomic Analysis for Hematologic Malignancy

TsuyoshiMuta{MUTATSUYOSHI}|YasuhiroShingai{SHINGAIYASUHIRO}|EmiYokoyama{YOKOYAMAEMI}|TomaSuzuki{SUZUKITOMA}|ShogoMatsui{MATSUISHOGO}____DaisukeKaji{KAJIDAISUKE}____TakeshiOkatani{OKATANITAKESHI}|MasayaUebo{UEBOMASAYA}|MichikoKida{KIDAMICHIKO}|TakuyaNunomura{NUNOMURATAKUYA}|TetsuroOchi{OCHITETSURO}|KoheiKyo{KYOKOHEI}|RyotaImanaka{IMANAKARYOTA}|MitsuhiroItagaki{ITAGAKIMITSUHIRO}|YoshiakiKuroda{KURODAYOSHIAKI}|ShinyaKatsutani{KATSUTANISHINYA}|YutaKatayama{KATAYAMAYUTA}|KodaiUeshima{UESHIMAKODAI}|FutaOda{ODAFUTA}|YutaNakagawa{NAKAGAWAYUTA}|MasatakaHamada{HAMADAMASATAKA}|MakoHosoya{HOSOYAMAKO}|YumaTada{TADAYUMA}|SayakoYuda{YUDASAYAKO}|ShigeoFuji{FUJISHIGEO}|TakafumiYokota{YOKOTATAKAFUMI}|ToruMiyajima{MIYAJIMATORU}|MasahiroChiba{CHIBAMASAHIRO}|MinoruKanaya{KANAYAMINORU}|KohIzumiyama{IZUMIYAMAKOH}|MakotoSaito{SAITOMAKOTO}|MasanobuMorioka{MORIOKAMASANOBU}|AkioMori{MORIAKIO}|TakeshiKondo{KONDOTAKESHI}|KoheiOkada{OKADAKOHEI}|YudaiYamaguchi{YAMAGUCHIYUDAI}|FukaHorikita{HORIKITAFUKA}|KoheiTakada{TAKADAKOHEI}|DaisukeHidaka{HIDAKADAISUKE}|ReikiOgasawara{OGASAWARAREIKI}|JunichiSugita{SUGITAJUNICHI}|NaokiKobayashi{KOBAYASHINAOKI}|ShuichiOta{OTASHUICHI}|DaisukeKaji{KAJIDAISUKE}|MikaKuno{KUNOMIKA}|RikakoTabata{TABATARIKAKO}|OtoyaWatanabe{WATANABEOTOYA}|KyosukeYamaguchi{YAMAGUCHIKYOSUKE}|KoseiKageyama{KAGEYAMAKOSEI}|YukiTaya{TAYAYUKI}|AyaNishida{NISHIDAAYA}|ShinsukeTakagi{TAKAGISHINSUKE}|HisashiYamamoto{YAMAMOTOHISASHI}|YukiMori{MORIYUKI}|GoYamamoto{YAMAMOTOGO}|AtsushiWake{WAKEATSUSHI}|NaoyukiUchida{UCHIDANAOYUKI}____Oral Session 1-6CDLBCL: Salvage Therapy____Association of prior therapy and epcoritamab in relapsed/refractory diffuse large B-cell lymphoma|Treatment for relapsed/refractory cases of untreated DLBCL after Pola-R-CHP therapy|High efficacy of polatuzumab vedotin plus bendamustine and rituximab in transformed lymphoma|Epcoritamab for patients with relapsed/refractory DLBCL: A single-center retrospective analysis|Clinical outcomes of large B-cell lymphoma relapsing after CAR-T cell therapy at our institution

O1-6C

Oral Session 1-6C
DLBCL: Salvage Therapy

Chair：Daisuke Kaji

KeisukeTanaka{TANAKAKEISUKE}|MasaharuKawashima{KAWASHIMAMASAHARU}|TakutoTachita{TACHITATAKUTO}|DaisukeOkamoto{OKAMOTODAISUKE}|ToshihiroMiyakoshi{MIYAKOSHITOSHIHIRO}____HidekiTsujimura{TSUJIMURAHIDEKI}____KaoriAkita{AKITAKAORI}|AtsushiTakahata{TAKAHATAATSUSHI}|MasahideYamamoto{YAMAMOTOMASAHIDE}|KotaYoshifuji{YOSHIFUJIKOTA}|YoshihiroUmezawa{UMEZAWAYOSHIHIRO}|KenshiMinamisawa{MINAMISAWAKENSHI}|MarieYagi{YAGIMARIE}|TakehikoMori{MORITAKEHIKO}|MoegiKurachi{KURACHIMOEGI}|KenjiroMitsuhashi{MITSUHASHIKENJIRO}|HiroyukiSato{SATOHIROYUKI}|ToruEbina{EBINATORU}|TakahikoFujii{FUJIITAKAHIKO}|TomoakiAkagi{AKAGITOMOAKI}|KohmeiKubo{KUBOKOHMEI}|NobuhikoNakamura{NAKAMURANOBUHIKO}|NaokiHayase{HAYASENAOKI}|YoshikazuIkoma{IKOMAYOSHIKAZU}|TakuroMatsumoto{MATSUMOTOTAKURO}|HiroshiNakamura{NAKAMURAHIROSHI}|NobuhiroKanemura{KANEMURANOBUHIRO}|MasahitoShimizu{SHIMIZUMASAHITO}|YasuhitoSuehara{SUEHARAYASUHITO}|FumiakiMatsumura{MATSUMURAFUMIAKI}|KenichiMakishima{MAKISHIMAKENICHI}|SakurakoSuma{SUMASAKURAKO}|YusukeKiyoki{KIYOKIYUSUKE}|KeiichiroHattori{HATTORIKEIICHIRO}|TatsuhiroSakamoto{SAKAMOTOTATSUHIRO}|TakayasuKato{KATOTAKAYASU}|HidekazuNishikii{NISHIKIIHIDEKAZU}|NaoshiObara{OBARANAOSHI}|MamikoSakata-Yanagimoto{SAKATA-YANAGIMOTOMAMIKO}____Oral Session 1-6DDLBCL: Other____Impact of novel therapeutic agents on treatment outcomes in DLBCL in real-world clinical practice|Potential role of intrathecal chemotherapy in preventing CNS relapse in primary breast DLBCL|Retrospective analysis of Pola-R-CHP versus R-CHOP for previously untreated DLBCL in our department|Infectious complications and febrile neutropenia in DLBCL patients treated with Pola-R-CHP|Transient spontaneous regression in intravascular large B-cell lymphoma

O1-6D

Oral Session 1-6D
DLBCL: Other

Chair：Hideki Tsujimura

MikiJoyce{JOYCEMIKI}|YusukeKubota{KUBOTAYUSUKE}|JonathanCStrefford{STREFFORDJONATHANC}|TakutoMori{MORITAKUTO}|YujuanGuo{GUOYUJUAN}____AiKotani{KOTANIAI}____SakurakoSuma{SUMASAKURAKO}|KyoheiSano{SANOKYOHEI}|AyumuTsubosaka{TSUBOSAKAAYUMU}|KenichiMakishima{MAKISHIMAKENICHI}|KeiichiroHattori{HATTORIKEIICHIRO}|YasuhitoSuehara{SUEHARAYASUHITO}|TatsuhiroSakamoto{SAKAMOTOTATSUHIRO}|YasunoriOta{OTAYASUNORI}|MiwakoKakiuchi{KAKIUCHIMIWAKO}|ShumpeiIshikawa{ISHIKAWASHUMPEI}|MamikoSakata-Yanagimoto{SAKATA-YANAGIMOTOMAMIKO}|JunjiKoya{KOYAJUNJI}|HaryoonKim{KIMHARYOON}|SumitoShingaki{SHINGAKISUMITO}|HirokuniHonma{HONMAHIROKUNI}|YasunoriKogure{KOGUREYASUNORI}|AmiInokuchi{INOKUCHIAMI}|YosukeMizukami{MIZUKAMIYOSUKE}|SaraHorie{HORIESARA}|KotaMizuno{MIZUNOKOTA}|MitsuhiroYuasa{YUASAMITSUHIRO}|YutaIto{ITOYUTA}|KentaroYamaguchi{YAMAGUCHIKENTARO}|YukiSaito{SAITOYUKI}|KoichiMurakami{MURAKAMIKOICHI}|NobuyoshiSasaki{SASAKINOBUYOSHI}|AkikoMaeshima{MAESHIMAAKIKO}|DaisukeEnnishi{ENNISHIDAISUKE}|DaisukeKaji{KAJIDAISUKE}|FumihitoTajima{TAJIMAFUMIHITO}|KensukeTateishi{TATEISHIKENSUKE}|MotooNagane{NAGANEMOTOO}|KeisukeKataoka{KATAOKAKEISUKE}|KazuyukiShimada{SHIMADAKAZUYUKI}|SuguruFukuhara{FUKUHARASUGURU}|DaisukeKawauchi{KAWAUCHIDAISUKE}|HiroyukiKomatsu{KOMATSUHIROYUKI}|NobuhiroHiramoto{HIRAMOTONOBUHIRO}|RyosukeKoyamada{KOYAMADARYOSUKE}|NaoeGoto{GOTONAOE}|KaitoMimura{MIMURAKAITO}|JuneTakeda{TAKEDAJUNE}|NobuyukiKakiuchi{KAKIUCHINOBUYUKI}|HironaMaeda{MAEDAHIRONA}|AiOkada{OKADAAI}|KenichiChiba{CHIBAKENICHI}|YuichiShiraishi{SHIRAISHIYUICHI}|YoshihikoUsui{USUIYOSHIHIKO}|KojiIzutsu{IZUTSUKOJI}|YoshitakaNarita{NARITAYOSHITAKA}|AkifumiTakaori-Kondo{TAKAORI-KONDOAKIFUMI}|SeishiOgawa{OGAWASEISHI}|AkihiroTomita{TOMITAAKIHIRO}|KenichiYoshida{YOSHIDAKENICHI}|HiroshiArima{ARIMAHIROSHI}|IrohaMorita{MORITAIROHA}|KensukeNakao{NAKAOKENSUKE}|TomoyasuJo{JOTOMOYASU}|MomokoNishikori{NISHIKORIMOMOKO}____Oral Session 1-7AB-cell Lymphoma: Basic Research 1____Antigen-presenting-like epithelial cells contribute to spatial niches in gastric MALT lymphoma|The regulatory mechanisms of CD47 expression and its therapeutic targeting in CNS lymphoma|(Epi)genomic definition and characterization of high-risk splenic marginal zone lymphoma|Immune evasion and molecular evolution in intravascular large B-cell lymphoma revealed by WGS|Dysregulated RAG1 confers DNA damage tolerance and vulnerability in high-risk B-cell lymphoma

O1-7A

Oral Session 1-7A
B-cell Lymphoma: Basic Research 1

Chair：Ai Kotani

KurumiIizuka{IIZUKAKURUMI}|FutoshiYoshino{YOSHINOFUTOSHI}|TatsuroJo{JOTATSURO}|YumaKawamura{KAWAMURAYUMA}|IrohaMorita{MORITAIROHA}____NaoyaMimura{MIMURANAOYA}____JoujiShimono{SHIMONOJOUJI}|YasuyukiHosono{HOSONOYASUYUKI}|DaisukeEnnishi{ENNISHIDAISUKE}|SuguruFukuhara{FUKUHARASUGURU}|JuneTakeda{TAKEDAJUNE}|MarinaTogo-Ohno{TOGO-OHNOMARINA}|YuichiShiraishi{SHIRAISHIYUICHI}|NobuyukiKakiuchi{KAKIUCHINOBUYUKI}|SeishiOgawa{OGAWASEISHI}|KojiIzutsu{IZUTSUKOJI}|KenichiYoshida{YOSHIDAKENICHI}|JunTaguchi{TAGUCHIJUN}|YasushiSawayama{SAWAYAMAYASUSHI}|MasatoshiMatsuo{MATSUOMASATOSHI}|KunikoAbe{ABEKUNIKO}|KazutoShigematsu{SHIGEMATSUKAZUTO}|YasushiMiyazaki{MIYAZAKIYASUSHI}|MikaTakai{TAKAIMIKA}|KazuyukiShimada{SHIMADAKAZUYUKI}|HanakoOgawa{OGAWAHANAKO}|KatsuyaFurukawa{FURUKAWAKATSUYA}|MotokiEguchi{EGUCHIMOTOKI}|AkiraWatanabe{WATANABEAKIRA}|HitoshiKiyoi{KIYOIHITOSHI}|NatsukiKawanabe{KAWANABENATSUKI}|MizukiWatanabe{WATANABEMIZUKI}|HiroshiArima{ARIMAHIROSHI}|WataruKishimoto{KISHIMOTOWATARU}|TomoyasuJo{JOTOMOYASU}|YasuhitoNannya{NANNYAYASUHITO}|JunyaKanda{KANDAJUNYA}|MomokoNishikori{NISHIKORIMOMOKO}|AkifumiTakaori-Kondo{TAKAORI-KONDOAKIFUMI}____Oral Session 1-7BB-cell Lymphoma: Basic Research 2____Impact of HDAC gene mutations on sensitivity to HDAC inhibitors in diffuse large B-cell lymphoma|Whole-genome sequencing reveals clonal evolution of donor-derived DLBCL after allogeneic SCT|CTL dynamics and treatment response to epcoritamab in relapsed or refractory B-cell lymphoma|Metallothionein-mediated uncoupling of caspase activation confers resistance to BET degradation|Molecular characterization of follicular lymphoma based on immunoglobulin isotypes

O1-7B

Oral Session 1-7B
B-cell Lymphoma: Basic Research 2

Chair：Naoya Mimura

MinoruKanaya{KANAYAMINORU}|KazukiAsazuma{ASAZUMAKAZUKI}|YuYagi{YAGIYU}|RisaNishiyama{NISHIYAMARISA}|RikakoTabata{TABATARIKAKO}____ShinichiMakita{MAKITASHINICHI}____AkinaoOkamoto{OKAMOTOAKINAO}|HidekiGoto{GOTOHIDEKI}|ReikiOgasawara{OGASAWARAREIKI}|KoseiMatsue{MATSUEKOSEI}|KoEbata{EBATAKO}|ShogoTakahashi{TAKAHASHISHOGO}|ShinpeiHarada{HARADASHINPEI}|EmiYokoyama{YOKOYAMAEMI}|SatoshiYamamoto{YAMAMOTOSATOSHI}|HajimeSenjo{SENJOHAJIME}|TomoyukiSaga{SAGATOMOYUKI}|JunichiHashiguchi{HASHIGUCHIJUNICHI}|MasayoYamamoto{YAMAMOTOMASAYO}|KaoriUchino{UCHINOKAORI}|MasahiroChiba{CHIBAMASAHIRO}|MutsumiTakahata{TAKAHATAMUTSUMI}|TetsuyukiIgarashi{IGARASHITETSUYUKI}|YuzufumiSekiguchi{SEKIGUCHIYUZUFUMI}|KosukeMiki{MIKIKOSUKE}|YutoMori{MORIYUTO}|KeitoYokoyama{YOKOYAMAKEITO}|KeitoSuto{SUTOKEITO}|MasaoNakagawa{NAKAGAWAMASAO}|AkihiroTomita{TOMITAAKIHIRO}|YoshikiFurukawa{FURUKAWAYOSHIKI}|ShintaroKinoshita{KINOSHITASHINTARO}|MidoriIshii{ISHIIMIDORI}|NaokiWatanabe{WATANABENAOKI}|YutakaTsukune{TSUKUNEYUTAKA}|HajimeYasuda{YASUDAHAJIME}|YasuharuHamano{HAMANOYASUHARU}|JunAndo{ANDOJUN}|MikiAndo{ANDOMIKI}|YusukeKanemasa{KANEMASAYUSUKE}|YukiSasaki{SASAKIYUKI}|SayuriIshibashi{ISHIBASHISAYURI}|KahoFujino{FUJINOKAHO}|TakahitoKuga{KUGATAKAHITO}|NozomiKanai{KANAINOZOMI}|YusukeMasuda{MASUDAYUSUKE}|KumikoFujita{FUJITAKUMIKO}|ManoMino{MINOMANO}|AiTakahara{TAKAHARAAI}|TaichiTamura{TAMURATAICHI}|ShoheiNakamura{NAKAMURASHOHEI}|ToshihiroOkuya{OKUYATOSHIHIRO}|ShotaKusuhara{KUSUHARASHOTA}|ShinichiroMatsuda{MATSUDASHINICHIRO}|AtsushiJinguji{JINGUJIATSUSHI}|ShuheiKurosawa{KUROSAWASHUHEI}|TakuyaShimizuguchi{SHIMIZUGUCHITAKUYA}|DaichiSadato{SADATODAICHI}|KaoruMorita{MORITAKAORU}|TomomiToubai{TOUBAITOMOMI}|HiroakiShimizu{SHIMIZUHIROAKI}|YuhoNajima{NAJIMAYUHO}|YukaHarada{HARADAYUKA}|NorikoDoki{DOKINORIKO}|TatsuShimoyama{SHIMOYAMATATSU}|ShinichiMakita{MAKITASHINICHI}|WataruTakeda{TAKEDAWATARU}|ShotaroWatanabe{WATANABESHOTARO}|YutaIto{ITOYUTA}|SuguruFukuhara{FUKUHARASUGURU}|WataruMunakata{MUNAKATAWATARU}|KojiIzutsu{IZUTSUKOJI}|DaisukeKaji{KAJIDAISUKE}|ShogoMatsui{MATSUISHOGO}|MikaKuno{KUNOMIKA}|OtoyaWatanabe{WATANABEOTOYA}|KyosukeYamaguchi{YAMAGUCHIKYOSUKE}|KoseiKageyama{KAGEYAMAKOSEI}|AyaNishida{NISHIDAAYA}|YukiTaya{TAYAYUKI}|ShinsukeTakagi{TAKAGISHINSUKE}|HisashiYamamoto{YAMAMOTOHISASHI}|YukiMori{MORIYUKI}|GoYamamoto{YAMAMOTOGO}|AtsushiWake{WAKEATSUSHI}|NaoyukiUchida{UCHIDANAOYUKI}____Oral Session 1-7CAggressive B-cell Lymphoma: Cellular Immunotherapy 1____CMV reactivation following epcoritamab for R/R LBCL: results from NJHSG-Epcoritamab2024|Phenotypic analysis of long-term persisting CAR-T cells after Axi-cel and Liso-cel therapy in LBCL|Impact and mechanism of immune reconstitution after CAR-T therapy in B-cell non-Hodgkin lymphoma|HBV-DNA monitoring for HBV reactivation enables safe management after CAR T-cell therapy in R/R LBCL|Causes and risk factors for early readmission after CAR-T cell therapy for B-cell lymphoma

O1-7C

Oral Session 1-7C
Aggressive B-cell Lymphoma: Cellular Immunotherapy 1

Chair：Shinichi Makita

KenTakigawa{TAKIGAWAKEN}|AyaKomura{KOMURAAYA}|ChitoseYoshitomi{YOSHITOMICHITOSE}|NaoYoshida{YOSHIDANAO}|ShogoTakahashi{TAKAHASHISHOGO}____KenOhmachi{OHMACHIKEN}____KohtaMiyawaki{MIYAWAKIKOHTA}|HidetakaNakagaki{NAKAGAKIHIDETAKA}|ShihoTaniguchi{TANIGUCHISHIHO}|MasatoshiShimo{SHIMOMASATOSHI}|TeppeiSakoda{SAKODATEPPEI}|FumiakiJinnouchi{JINNOUCHIFUMIAKI}|TakujiYamauchi{YAMAUCHITAKUJI}|YasuoMori{MORIYASUO}|KojiKato{KATOKOJI}|KoichiAkashi{AKASHIKOICHI}|YoshikaneKikushige{KIKUSHIGEYOSHIKANE}|HideakiFujiwara{FUJIWARAHIDEAKI}|TsubasaAndo{ANDOTSUBASA}|ToshihiroIsami{ISAMITOSHIHIRO}|YusukeInoue{INOUEYUSUKE}|TomohiroNagano{NAGANOTOMOHIRO}|RyuichiroHiyama{HIYAMARYUICHIRO}|DaisukeIkeda{IKEDADAISUKE}|KentaHayashino{HAYASHINOKENTA}|ToshikiTerao{TERAOTOSHIKI}|ChihiroKamoi{KAMOICHIHIRO}|TakumiKondo{KONDOTAKUMI}|KeisukeSeike{SEIKEKEISUKE}|ShuntaroIkegawa{IKEGAWASHUNTARO}|KeikoFujii{FUJIIKEIKO}|NobuharuFujii{FUJIINOBUHARU}|NoboruAsada{ASADANOBORU}|DaisukeEnnishi{ENNISHIDAISUKE}|YoshinobuMaeda{MAEDAYOSHINOBU}|HidekiGoto{GOTOHIDEKI}|MasanaoHatase{HATASEMASANAO}|MomokaInomata{INOMATAMOMOKA}|YoshihitoHaseyama{HASEYAMAYOSHIHITO}|RyoKikuchi{KIKUCHIRYO}|YutakaTsutsumi{TSUTSUMIYUTAKA}|TakashiIshio{ISHIOTAKASHI}|KohIzumiyama{IZUMIYAMAKOH}|MinoruKanaya{KANAYAMINORU}|JunichiSugita{SUGITAJUNICHI}|DaisukeHidaka{HIDAKADAISUKE}|IkumiKasahara{KASAHARAIKUMI}|KanaNagashima{NAGASHIMAKANA}|MayumiHatayama{HATAYAMAMAYUMI}|KeisukeYamaguchi{YAMAGUCHIKEISUKE}|KentaroWakasa{WAKASAKENTARO}|SumioIwasaki{IWASAKISUMIO}|RieHatase{HATASERIE}|SatoshiOguri{OGURISATOSHI}|KeitoYokoyama{YOKOYAMAKEITO}|YumikaSaito{SAITOYUMIKA}|YutaHasegawa{HASEGAWAYUTA}|TakahideAra{ARATAKAHIDE}|ToshihiroMatsukawa{MATSUKAWATOSHIHIRO}|MasahiroOnozawa{ONOZAWAMASAHIRO}|DaigoHashimoto{HASHIMOTODAIGO}|TakanoriTeshima{TESHIMATAKANORI}|TetsumiYoshida{YOSHIDATETSUMI}|TaroEdahiro{EDAHIROTARO}|SuzukaNakatani{NAKATANISUZUKA}|RenChishaki{CHISHAKIREN}|SayakaSugihara{SUGIHARASAYAKA}|TakeroShindo{SHINDOTAKERO}|TatsuoIchinohe{ICHINOHETATSUO}|TeruhisaFujii{FUJIITERUHISA}|AkinaoOkamoto{OKAMOTOAKINAO}|ReikiOgasawara{OGASAWARAREIKI}|KoseiSuenaga{SUENAGAKOSEI}|ShinpeiHarada{HARADASHINPEI}|KoEbata{EBATAKO}|EmiYokoyama{YOKOYAMAEMI}|SatoshiYamamoto{YAMAMOTOSATOSHI}|HajimeSenjo{SENJOHAJIME}|TomoyukiSaga{SAGATOMOYUKI}|JunichiHashiguchi{HASHIGUCHIJUNICHI}|MasayoYamamoto{YAMAMOTOMASAYO}|KaoriUchino{UCHINOKAORI}|MasahiroChiba{CHIBAMASAHIRO}|MutsumiTakahata{TAKAHATAMUTSUMI}|TetsuyukiIgarashi{IGARASHITETSUYUKI}|YuzufumiSekiguchi{SEKIGUCHIYUZUFUMI}|KosukeMiki{MIKIKOSUKE}|YutoMori{MORIYUTO}|KeitoSuto{SUTOKEITO}|MasaoNakagawa{NAKAGAWAMASAO}|AkihiroTomita{TOMITAAKIHIRO}____Oral Session 1-7DAggressive B-cell Lymphoma: Cellular Immunotherapy 2____Albuminocytologic dissociation as a supportive finding for ICANS diagnosis after CAR-T cell therapy|Afternoon infusion of CAR-T cell and clinical outcomes|Peripheral blood T-cell-based prediction of ICANS in axicabtagene ciloleucel therapy|Blood lymphocyte count dynamics as a surrogate for outcomes after CAR-T cell therapy for R/R DLBCL|Association between epcoritamab efficacy and peripheral blood lymphocyte counts/CAR in r/r DLBCL

O1-7D

Oral Session 1-7D
Aggressive B-cell Lymphoma: Cellular Immunotherapy 2

Chair：Ken Ohmachi

ArifPamujumadi{PAMUJUMADIARIF}|ShojiSaito{SAITOSHOJI}|KotaMizuno{MIZUNOKOTA}|TakahiroYamauchi{YAMAUCHITAKAHIRO}|ChantanaPolprasert{POLPRASERTCHANTANA}____KenIshiyama{ISHIYAMAKEN}____YamaSPutri{PUTRIYAMAS}|MuhammadTAlfarizi{ALFARIZIMUHAMMADT}|MiyukiTanaka{TANAKAMIYUKI}|AikoHasegawa{HASEGAWAAIKO}|YuFurui{FURUIYU}|EriOkura{OKURAERI}|KenichiSakamoto{SAKAMOTOKENICHI}|RyuYanagisawa{YANAGISAWARYU}|SayakaNishina{NISHINASAYAKA}|HitoshiSakai{SAKAIHITOSHI}|HideyukiNakazawa{NAKAZAWAHIDEYUKI}|HidekiMakishima{MAKISHIMAHIDEKI}|YozoNakazawa{NAKAZAWAYOZO}|YasunoriKogure{KOGUREYASUNORI}|MasatoshiSakurai{SAKURAIMASATOSHI}|AmiInokuchi{INOKUCHIAMI}|YusukeKubota{KUBOTAYUSUKE}|HaryoonKim{KIMHARYOON}|TomohikoTanigawa{TANIGAWATOMOHIKO}|JunjiKoya{KOYAJUNJI}|YuyaKoda{KODAYUYA}|EriMatsuki{MATSUKIERI}|KensukeHara{HARAKENSUKE}|YujiNakayama{NAKAYAMAYUJI}|KosukeMatsuda{MATSUDAKOSUKE}|ShigekiSekine{SEKINESHIGEKI}|TakayukiMitsuhashi{MITSUHASHITAKAYUKI}|HiromichiMatsushita{MATSUSHITAHIROMICHI}|KoheiNakamura{NAKAMURAKOHEI}|KenjiroKosaki{KOSAKIKENJIRO}|HiroshiNishihara{NISHIHARAHIROSHI}|KeisukeKataoka{KATAOKAKEISUKE}|JesB.Hansen{HANSENJESB.}|SudhirUnni{UNNISUDHIR}|YvonneDuong{DUONGYVONNE}|AhmedAli{ALIAHMED}|KristenTecson{TECSONKRISTEN}|AkashNahar{NAHARAKASH}|KristyBurns{BURNSKRISTY}|EstherN.Oliva{OLIVAESTHERN.}|HarryP.Erba{ERBAHARRYP.}|QuocNguyen{NGUYENQUOC}|ChinadolWanitpongpun{WANITPONGPUNCHINADOL}|ChantiyaChanswangphuwana{CHANSWANGPHUWANACHANTIYA}|ThanawatRattanathammethee{RATTANATHAMMETHEETHANAWAT}|WeerapatOwattanapanich{OWATTANAPANICHWEERAPAT}|SmithKungwankiattichai{KUNGWANKIATTICHAISMITH}|PirunSaelue{SAELUEPIRUN}|JakrawadeeJulamanee{JULAMANEEJAKRAWADEE}|WasithepLimvorapitak{LIMVORAPITAKWASITHEP}|SupaweeSaengboon{SAENGBOONSUPAWEE}|PanachaiSilpsamrit{SILPSAMRITPANACHAI}|KannaditPrayongratana{PRAYONGRATANAKANNADIT}|ThanakritPiyajaroenkij{PIYAJAROENKIJTHANAKRIT}|PimjaiNiparuck{NIPARUCKPIMJAI}|AimwipaSasakul{SASAKULAIMWIPA}|DusitJit-Ueakul{JIT-UEAKULDUSIT}|AnothaiChintabanyat{CHINTABANYATANOTHAI}|AdisakTantiworawit{TANTIWORAWITADISAK}____Oral Session 1-8AAML: Clinical 1____AI-powered early classification of acute leukemia subtypes: unlocking routine lab diagnostic value|First-in-human clinical trial of GMR CAR-T therapy for CD116 myeloid malignancies|Clinical utility of comprehensive genomic profiling in myeloid neoplasms at a single institution|Healthcare resource utilization in patients for FLT3-ITD+ AML: analysis from the QuANTUM-First trial|Determinants of prognosis and outcomes in CBF-AML: Thai Leukemia Working Group

O1-8A

Oral Session 1-8A
AML: Clinical 1

Chair：Ken Ishiyama

TakahiroYamauchi{YAMAUCHITAKAHIRO}|TomokiTakahashi{TAKAHASHITOMOKI}|YuyaKurihara{KURIHARAYUYA}|AyakoKawakami{KAWAKAMIAYAKO}|KanaKato{KATOKANA}____YasuhisaYokoyama{YOKOYAMAYASUHISA}____YuichiIshikawa{ISHIKAWAYUICHI}|MasashiSawa{SAWAMASASHI}|TomomiTobai{TOBAITOMOMI}|YuhoNajima{NAJIMAYUHO}|TetsuyaNishida{NISHIDATETSUYA}|IchiroKawashima{KAWASHIMAICHIRO}|YunaKatsuoka{KATSUOKAYUNA}|KazutakaOzeki{OZEKIKAZUTAKA}|KensukeUsuki{USUKIKENSUKE}|ToruKiguchi{KIGUCHITORU}|TakeshiSaito{SAITOTAKESHI}|SatoruTakada{TAKADASATORU}|KoFujimoto{FUJIMOTOKO}|ShinyaSato{SATOSHINYA}|TomoyaMaeda{MAEDATOMOYA}|HisayukiYokoyama{YOKOYAMAHISAYUKI}|HirokiUchida{UCHIDAHIROKI}|TakumiLee{LEETAKUMI}|TakashiIshida{ISHIDATAKASHI}|MatsuoYamamoto{YAMAMOTOMATSUO}|AkikoSaito{SAITOAKIKO}|EmikoSakaida{SAKAIDAEMIKO}|YoshinobuMaeda{MAEDAYOSHINOBU}|ItaruMatsumura{MATSUMURAITARU}|HitoshiKiyoi{KIYOIHITOSHI}|MasahiroOnozawa{ONOZAWAMASAHIRO}|ReikiOgasawara{OGASAWARAREIKI}|DaisukeHidaka{HIDAKADAISUKE}|NaokiMiyashita{MIYASHITANAOKI}|TakeshiKondo{KONDOTAKESHI}|ShotaYokoyama{YOKOYAMASHOTA}|HiroyukiKimura{KIMURAHIROYUKI}|TakashiIshio{ISHIOTAKASHI}|ShinichiIto{ITOSHINICHI}|KoichiroMinauchi{MINAUCHIKOICHIRO}|HajimeSenjo{SENJOHAJIME}|TetsuyukiIgarashi{IGARASHITETSUYUKI}|MasahiroChiba{CHIBAMASAHIRO}|TomoyukiSaga{SAGATOMOYUKI}|ToshiakiHayashi{HAYASHITOSHIAKI}|TatsuoOyake{OYAKETATSUO}|ShunsukeOzu{OZUSHUNSUKE}|SatoshiIyama{IYAMASATOSHI}|MasahikoFukatsu{FUKATSUMASAHIKO}|ToruMiyajima{MIYAJIMATORU}|RintaroNozu{NOZURINTARO}|FumiakiFujii{FUJIIFUMIAKI}|JunNagai{NAGAIJUN}|ToshihiroMatsukawa{MATSUKAWATOSHIHIRO}|TakanoriTeshima{TESHIMATAKANORI}|KenMorita{MORITAKEN}|YosukeMasamoto{MASAMOTOYOSUKE}|MineoKurokawa{KUROKAWAMINEO}|YasuhikoShibasaki{SHIBASAKIYASUHIKO}|JunNakata{NAKATAJUN}|DaisukeMotooka{MOTOOKADAISUKE}|TakafumiNakao{NAKAOTAKAFUMI}|AtsushiSatake{SATAKEATSUSHI}|ToshiyukiKitano{KITANOTOSHIYUKI}|NobuhikoUoshima{UOSHIMANOBUHIKO}|TakeshiMaeda{MAEDATAKESHI}|ShuichiOta{OTASHUICHI}|YutaKatayama{KATAYAMAYUTA}|MasatoYasumi{YASUMIMASATO}|HirokiHosoi{HOSOIHIROKI}|KazunoriMurai{MURAIKAZUNORI}|HitojiUchiyama{UCHIYAMAHITOJI}|JunyaKuroda{KURODAJUNYA}|AkihitoMatsuoka{MATSUOKAAKIHITO}|YoshiyukiOnda{ONDAYOSHIYUKI}|MakotoOnizuka{ONIZUKAMAKOTO}|ManabuKawakami{KAWAKAMIMANABU}|NorimitsuKadowaki{KADOWAKINORIMITSU}|TatsuyaImi{IMITATSUYA}|NoboruAsada{ASADANOBORU}|MasayoshiMasuko{MASUKOMASAYOSHI}|DaichiSadato{SADATODAICHI}|ChizukoHirama{HIRAMACHIZUKO}|KotaroGaran{GARANKOTARO}|KotaHasegawa{HASEGAWAKOTA}|KairiKojo{KOJOKAIRI}|RikiYamakawa{YAMAKAWARIKI}|KeishoKyan{KYANKEISHO}|YukiMori{MORIYUKI}|KoheiShinmura{SHINMURAKOHEI}|TatsuyaTsurumoto{TSURUMOTOTATSUYA}|DaisukeMurakami{MURAKAMIDAISUKE}|AtsushiJinguji{JINGUJIATSUSHI}|NaokiShingai{SHINGAINAOKI}|TakashiToya{TOYATAKASHI}|KaoruMorita{MORITAKAORU}|HiroakiShimizu{SHIMIZUHIROAKI}|TomomiToubai{TOUBAITOMOMI}|KyokoHaraguchi{HARAGUCHIKYOKO}|HironoriHarada{HARADAHIRONORI}|YukaHarada{HARADAYUKA}|NorikoDoki{DOKINORIKO}____Oral Session 1-8BAML: Clinical 2____Mini MEC and gilteritinib showed high response rate and long post-transplant survival in RR FLT3 AML|A multicenter real-world analysis of FLT3-ITD-negative NPM1-mut. AML: the Hokkaido Leukemia Net study|Juxtamembrane domain disruption unifies diverse FLT3 activation mechanisms|Analysis of FLT3 mutation diversity and prognostic factors in acute myeloid leukemia in Japan|Clinical outcomes of acute leukemia with FLT3-JMD point mutations: a single-center experience

O1-8B

Oral Session 1-8B
AML: Clinical 2

Chair：Yasuhisa Yokoyama

KenSasaki{SASAKIKEN}|－|ChantanaPolprasert{POLPRASERTCHANTANA}|YumoDu{DUYUMO}____MakotoYoshimitsu{YOSHIMITSUMAKOTO}____TakafumiObo{OBOTAKAFUMI}|YuOyama{OYAMAYU}|HirofumiTakano{TAKANOHIROFUMI}|SeitaroSaito{SAITOSEITARO}|HarunaFujisawa{FUJISAWAHARUNA}|AkiraHonda{HONDAAKIRA}|YosukeMasamoto{MASAMOTOYOSUKE}|MineoKurokawa{KUROKAWAMINEO}|KamolchanokTanchotikul{TANCHOTIKULKAMOLCHANOK}|SiroratKobbuaklee{KOBBUAKLEESIRORAT}|PitchayutBoonyabaramee{BOONYABARAMEEPITCHAYUT}|PonlapatRojnuckarin{ROJNUCKARINPONLAPAT}|ChantanaPolprasert{POLPRASERTCHANTANA}|ShuangfengXie{XIESHUANGFENG}|ZhenDai{DAIZHEN}|WenjuanLi{LIWENJUAN}|LongZhang{ZHANGLONG}|HaijiaoZhang{ZHANGHAIJIAO}|MeipingWu{WUMEIPING}|YiqingLi{LIYIQING}|WenjuanYang{YANGWENJUAN}|JieXiao{XIAOJIE}|YongxunZhuansun{ZHUANSUNYONGXUN}|JianguoLi{LIJIANGUO}|WenyingZhang{ZHANGWENYING}|ShanpingJiang{JIANGSHANPING}|DanianNie{NIEDANIAN}|KezhiHuang{HUANGKEZHI}____Oral Session 1-8CT/NK, HL, Other: Rare Hematological Disorders____RBMX Y214 coexists with MAPK mutations and affects differentiation in Erdheim-Chester disease|Withdrawn|T-cell lymphoproliferative disorders in adult HLH: frequency, outcomes and diagnostic evaluation|Prognostic factors revealed by 77 cases of Castleman disease over 11 years from a single center

O1-8C

Oral Session 1-8C
T/NK, HL, Other: Rare Hematological Disorders

Chair：Makoto Yoshimitsu

WataruMunakata{MUNAKATAWATARU}|ShinichiMakita{MAKITASHINICHI}|SenzoTaguchi{TAGUCHISENZO}|－|HeLi{LIHE}____ShigeruKusumoto{KUSUMOTOSHIGERU}____ShigeruKusumoto{KUSUMOTOSHIGERU}|RyosukeKato{KATORYOSUKE}|TakashiTerauchi{TERAUCHITAKASHI}|HiroakiOnaya{ONAYAHIROAKI}|MasahikoOguchi{OGUCHIMASAHIKO}|ShinsukeIida{IIDASHINSUKE}|KisatoNosaka{NOSAKAKISATO}|YasuhiroSuzuki{SUZUKIYASUHIRO}|YasuhikoHarada{HARADAYASUHIKO}|KanaMiyazaki{MIYAZAKIKANA}|MasakiMaruta{MARUTAMASAKI}|NorikoFukuhara{FUKUHARANORIKO}|TomomiToubai{TOUBAITOMOMI}|NobukoKubota{KUBOTANOBUKO}|KenOhmachi{OHMACHIKEN}|TokoSaito{SAITOTOKO}|ShinyaRai{RAISHINYA}|IshikazuMizuno{MIZUNOISHIKAZU}|SuguruFukuhara{FUKUHARASUGURU}|MaiTakeuchi{TAKEUCHIMAI}|UkihideTateishi{TATEISHIUKIHIDE}|KunihiroTsukasaki{TSUKASAKIKUNIHIRO}|HirokazuNagai{NAGAIHIROKAZU}|DaiMaruyama{MARUYAMADAI}|JunjiKoya{KOYAJUNJI}|MomokoNishikori{NISHIKORIMOMOKO}|AkikoMiyagi-Maeshima{MIYAGI-MAESHIMAAKIKO}|AkihiroHirakawa{HIRAKAWAAKIHIRO}|SatoshiKawashima{KAWASHIMASATOSHI}|YukariNagasaka{NAGASAKAYUKARI}|YutaIto{ITOYUTA}|YasunoriKogure{KOGUREYASUNORI}|AyumiFujimoto{FUJIMOTOAYUMI}|KengoTakeuchi{TAKEUCHIKENGO}|KeisukeKataoka{KATAOKAKEISUKE}|KojiIzutsu{IZUTSUKOJI}|NaoyaIshibashi{ISHIBASHINAOYA}|KoichiIsobe{ISOBEKOICHI}|HitoshiIto{ITOHITOSHI}|MichikoImai{IMAIMICHIKO}|HirokiKawaguchi{KAWAGUCHIHIROKI}|EmikoShimoda{SHIMODAEMIKO}|ToshinoriSoejima{SOEJIMATOSHINORI}|HiroshiIgaki{IGAKIHIROSHI}|NaokoAsano{ASANONAOKO}|RitsuroSuzuki{SUZUKIRITSURO}|MotokoYamaguchi{YAMAGUCHIMOTOKO}|YasuoEjima{EJIMAYASUO}|ShuCheng{CHENGSHU}|KeshuZhou{ZHOUKESHU}|XudongZhang{ZHANGXUDONG}|QingqingCai{CAIQINGQING}|YutingChen{CHENYUTING}|JiaMiao{MIAOJIA}|YuquanWei{WEIYUQUAN}|XiangrongSong{SONGXIANGRONG}|TingNiu{NIUTING}|WeiliZhao{ZHAOWEILI}____Oral Session 1-8DT/NK, HL, Other: Clinical Research of cHL and ENKL____Long-term outcomes of interim PET-adapted therapy in advanced Hodgkin lymphoma: JCOG1305|Final results of a phase 2 study of atezolizumab in relapsed/refractory ENKTL: NCCH1903/ATTACK study|Locoregional control after CCRT in patients with localized ENKL: A multicenter retrospective study|Withdrawn|Phase I study of EBV mRNA vaccine: safety, immunogenicity and preliminary activity in R/R lymphoma

O1-8D

Oral Session 1-8D
T/NK, HL, Other: Clinical Research of cHL and ENKL

Chair：Shigeru Kusumoto

HirokazuKobushi{KOBUSHIHIROKAZU}|AikoSato{SATOAIKO}|YukaIijima-Ymashita{IIJIMA-YMASHITAYUKA}|TetsuoMitsui{MITSUITETSUO}|HinaHisano{HISANOHINA}____AtsushiSato{SATOATSUSHI}____SatoshiSaida{SAIDASATOSHI}|TatsuyaKamitori{KAMITORITATSUYA}|KazukiMitani{MITANIKAZUKI}|HirohitoKubota{KUBOTAHIROHITO}|ItaruKato{KATOITARU}|MasafumiSeki{SEKIMASAFUMI}|JunkoTakita{TAKITAJUNKO}|ShotaKato{KATOSHOTA}|MiwakoToyohara{TOYOHARAMIWAKO}|YukaIijima-Yamashita{IIJIMA-YAMASHITAYUKA}|MasashiSanada{SANADAMASASHI}|NaoTakasugi{TAKASUGINAO}|ToshihikoImamura{IMAMURATOSHIHIKO}|YasuhiroOkamoto{OKAMOTOYASUHIRO}|KatsuyoshiKoh{KOHKATSUYOSHI}|KentaroWatanabe{WATANABEKENTARO}|YuichiShiraishi{SHIRAISHIYUICHI}|MotohiroKato{KATOMOTOHIRO}|TomomiYamada{YAMADATOMOMI}|TakahikoYasuda{YASUDATAKAHIKO}|AkikoSaitoM{SAITOMAKIKO}|TomoyukiWatanabe{WATANABETOMOYUKI}|RyojiKobayashi{KOBAYASHIRYOJI}|YukiKoga{KOGAYUKI}|NaotoFujita{FUJITANAOTO}|KentaroOki{OKIKENTARO}|KenMori{MORIKEN}|TetsuyaMori{MORITETSUYA}|ReijiFukano{FUKANOREIJI}|TomooOsumi{OSUMITOMOO}|YukaIijima{IIJIMAYUKA}|NobutakeKiyokawa{KIYOKAWANOBUTAKE}|AtsukoNakazawa{NAKAZAWAATSUKO}|KatsuyoshiKo{KOKATSUYOSHI}|AtsushiSato{SATOATSUSHI}|MichiKamei{KAMEIMICHI}|MakitoTanaka{TANAKAMAKITO}|TaichirouTsuchimochi{TSUCHIMOCHITAICHIROU}|NorikoSato{SATONORIKO}|RisaHioki{HIOKIRISA}|AkikoSaito{SAITOAKIKO}|DaikiHori{HORIDAIKI}|MasahiroSekimizu{SEKIMIZUMASAHIRO}|YoshihiroGocho{GOCHOYOSHIHIRO}|TakaoDeguchi{DEGUCHITAKAO}|TomoyukiUtano{UTANOTOMOYUKI}|HirotoshiSakaguchi{SAKAGUCHIHIROTOSHI}|AkihiroIguchi{IGUCHIAKIHIRO}|MasahiroSekiguchi{SEKIGUCHIMASAHIRO}|YujiYamada{YAMADAYUJI}|YokoShioda{SHIODAYOKO}|ChikakoKiyotani{KIYOTANICHIKAKO}|KeitaTerashima{TERASHIMAKEITA}|KentaroOhki{OHKIKENTARO}|NobutakaKiyokawa{KIYOKAWANOBUTAKA}|KimikazuMatsumoto{MATSUMOTOKIMIKAZU}|DaisukeTomizawa{TOMIZAWADAISUKE}____Oral Session 1-9AALL: Clinical 1____Enhanced cholesterol biosynthesis may contribute to steroid resistance in pediatric T-ALL|Detection of structural variants in leukemia-associated genes by genome sequencing in pediatric ALL|Clinical significance of NGS-based MRD assessment in PCR-MRD PNQ cases in pediatric ALL|Phase II multicenter clinical trial of DexICE therapy for relapsed or resistant LBL: JCCG ALB-R13|Efficacy and safety of inotuzumab ozogamicin for children with relapsed/refractory B-ALL

O1-9A

Oral Session 1-9A
ALL: Clinical 1

Chair：Atsushi Sato

KensukeMatsuda{MATSUDAKENSUKE}|KazukiMitani{MITANIKAZUKI}|SatoshiYoshimura{YOSHIMURASATOSHI}|YasuoKubota{KUBOTAYASUO}|ItaruKato{KATOITARU}____YuhoNajima{NAJIMAYUHO}____RyoYoshimaru{YOSHIMARURYO}|IsamuHarima{HARIMAISAMU}|HajimeSakuma{SAKUMAHAJIME}|AtsushiUehara{UEHARAATSUSHI}|MasahikoFukatsu{FUKATSUMASAHIKO}|HiroakiAraie{ARAIEHIROAKI}|ChikakoOhwada{OHWADACHIKAKO}|TakaoFujisawa{FUJISAWATAKAO}|AkioDodo{DODOAKIO}|HideakiBando{BANDOHIDEAKI}|IsaoYoshida{YOSHIDAISAO}|TakaakiMiyake{MIYAKETAKAAKI}|JunyaKuroda{KURODAJUNYA}|TomomiToubai{TOUBAITOMOMI}|NaotoTakahashi{TAKAHASHINAOTO}|HisayukiYokoyama{YOKOYAMAHISAYUKI}|AkiraYokota{YOKOTAAKIRA}|ShinsukeIida{IIDASHINSUKE}|MasafumiOto{OTOMASAFUMI}|TakayukiIkezoe{IKEZOETAKAYUKI}|NaokoHosono{HOSONONAOKO}|SeijiKakiuchi{KAKIUCHISEIJI}|ChiakiNakaseko{NAKASEKOCHIAKI}|TakayukiYoshino{YOSHINOTAKAYUKI}|HirohitoKubota{KUBOTAHIROHITO}|KiyotakaIsobe{ISOBEKIYOTAKA}|HirofumiShibata{SHIBATAHIROFUMI}|MasafumiSeki{SEKIMASAFUMI}|ShunsukeKimura{KIMURASHUNSUKE}|ShuroNishio{NISHIOSHURO}|ShoheiAzumi{AZUMISHOHEI}|RyunosukeTojo{TOJORYUNOSUKE}|HirokazuKobushi{KOBUSHIHIROKAZU}|YoshinoriUchihara{UCHIHARAYOSHINORI}|SatoshiSaida{SAIDASATOSHI}|ItaruKato{KATOITARU}|KatsutsuguUmeda{UMEDAKATSUTSUGU}|FumihikoHayakawa{HAYAKAWAFUMIHIKO}|TakahikoYasuda{YASUDATAKAHIKO}|EmikoSakaida{SAKAIDAEMIKO}|NobuyukiKakiuchi{KAKIUCHINOBUYUKI}|AikoSato-Otsubo{SATO-OTSUBOAIKO}|KentaroWatanabe{WATANABEKENTARO}|KatsuyoshiKoh{KOHKATSUYOSHI}|SouichiSuenobu{SUENOBUSOUICHI}|AtsushiSato{SATOATSUSHI}|MotohiroKato{KATOMOTOHIRO}|SatoruMiyano{MIYANOSATORU}|KenichiYoshida{YOSHIDAKENICHI}|JunkoTakita{TAKITAJUNKO}|MiekoIto{ITOMIEKO}|MaikoSagisaka{SAGISAKAMAIKO}|TakashiKiyama{KIYAMATAKASHI}|AkitoKawachi{KAWACHIAKITO}|EriHirota{HIROTAERI}|YuKimizuka{KIMIZUKAYU}|NaotoWakui{WAKUINAOTO}|TomoyaIrikura{IRIKURATOMOYA}|AkikoHayashi{HAYASHIAKIKO}|NaoyukiMiyagawa{MIYAGAWANAOYUKI}|DaiKeino{KEINODAI}|TomokoYokosuka{YOKOSUKATOMOKO}|FuminoriIwasaki{IWASAKIFUMINORI}|MasakatsuYanagimachi{YANAGIMACHIMASAKATSU}|HiroakiGoto{GOTOHIROAKI}|YasuhiroOkamoto{OKAMOTOYASUHIRO}|ToshihikoImamura{IMAMURATOSHIHIKO}|AkikoKada{KADAAKIKO}|AkikoSaito{SAITOAKIKO}|YukaIijima{IIJIMAYUKA}|MasashiSanada{SANADAMASASHI}|TomohikoTaki{TAKITOMOHIKO}|TakashiMikami{MIKAMITAKASHI}|YutaKawahara{KAWAHARAYUTA}|HiroyaHashimoto{HASHIMOTOHIROYA}|TakaoDeguchi{DEGUCHITAKAO}|ShoheiYamamoto{YAMAMOTOSHOHEI}|HidemiToyoda{TOYODAHIDEMI}____Oral Session 1-9BALL: Clinical 2____SCRUM-Japan MONSTAR3: nation-wide multi-omics platform for next generation precision hematology|Integrated multi-omics analysis reveals a high-risk subgroup in pediatric T-ALL|Functional heterogeneity in drug response in pediatric hematologic malignancies|Revisiting classic subtypes uncovers diverse relapse biology and MRD kinetics in pediatric B-ALL|JPLSG ALL-R19-BLIN: Immune ecosystem associated with blinatumomab response in pediatric R/R B-ALL

O1-9B

Oral Session 1-9B
ALL: Clinical 2

Chair：Yuho Najima

KeikoOkada{OKADAKEIKO}|TomomiToubai{TOUBAITOMOMI}|KojiNagafuji{NAGAFUJIKOJI}|JunyaKanda{KANDAJUNYA}|YoichiTanaka{TANAKAYOICHI}____HitoshiHanamoto{HANAMOTOHITOSHI}____MorihiroKanno{KANNOMORIHIRO}|NorikoTokimatsu{TOKIMATSUNORIKO}|TetsushiNakata{NAKATATETSUSHI}|SatoshiIto{ITOSATOSHI}|IbrahimAldoss{ALDOSSIBRAHIM}|PereBarba{BARBAPERE}|PauMontesinos{MONTESINOSPAU}|AnnaCastleton{CASTLETONANNA}|GauthamBorthakur{BORTHAKURGAUTHAM}|Jae-HoYoon{YOONJAE-HO}|Chieh-LinTeng{TENGCHIEH-LIN}|FrancoLocatelli{LOCATELLIFRANCO}|YosrHicheri{HICHERIYOSR}|DavidTaussig{TAUSSIGDAVID}|BelaPatel{PATELBELA}|AdamS.Duvall{DUVALLADAMS.}|VeitBücklein{BÜCKLEINVEIT}|CristinaPapayannidis{PAPAYANNIDISCRISTINA}|NicolaGökbuget{GÖKBUGETNICOLA}|BijalShah{SHAHBIJAL}|RaghuveerMali{MALIRAGHUVEER}|YuyinLiu{LIUYUYIN}|Xu(Sue)Zhu{ZHUXU(SUE)}|MargaretWey{WEYMARGARET}|MarcioAndrade-Campos{ANDRADE-CAMPOSMARCIO}|MaxS.Topp{TOPPMAXS.}|HagopKantarjian{KANTARJIANHAGOP}|TakayukiIkezoe{IKEZOETAKAYUKI}|HisayukiYokoyama{YOKOYAMAHISAYUKI}|HiroyukiMaruyama{MARUYAMAHIROYUKI}|TakahiroShima{SHIMATAKAHIRO}|TeppeiSakoda{SAKODATEPPEI}|NoemiMergen{MERGENNOEMI}|KazunoriOda{ODAKAZUNORI}|ErikRasmussen{RASMUSSENERIK}|XiaohanCai{CAIXIAOHAN}|AkihiroKitadate{KITADATEAKIHIRO}|KoichiOnodera{ONODERAKOICHI}|EmikoSakaida{SAKAIDAEMIKO}|NoboruAsada{ASADANOBORU}|KohtaMiyawaki{MIYAWAKIKOHTA}|HidekiGoto{GOTOHIDEKI}|SuTienNguyen{NGUYENSUTIEN}|SabinaAdhikar{ADHIKARSABINA}|HiroyaAsou{ASOUHIROYA}|RongYe{YERONG}|KanaMatsuda{MATSUDAKANA}|KojiKato{KATOKOJI}|AkihiroHirakawa{HIRAKAWAAKIHIRO}|AkikoSaito{SAITOAKIKO}|AtsushiManabe{MANABEATSUSHI}|ToshihikoImamura{IMAMURATOSHIHIKO}|YasuhiroOkamoto{OKAMOTOYASUHIRO}|KatsuyoshiKoh{KOHKATSUYOSHI}|MotohiroKato{KATOMOTOHIRO}____Oral Session 1-9CALL: Novel Therapy____Safety of glucarpidase after high-dose methotrexate: pre-analysis of post-marketing surveillance|Surovatamig in patients with R/R B-ALL: updated results from the phase 1/2 SYRUS study|Phase 1b study of blinatumomab safety and pharmacokinetics in Japanese adults with Ph-negative B-ALL|JKART-1: brexucabtagene autoleucel in relapsed/refractory (R/R) B-cell acute lymphoblastic leukemia|Assessment of 6-MP metabolites conc. in maintenance therapy under NUDT15 genotype-guided dosing

O1-9C

Oral Session 1-9C
ALL: Novel Therapy

Chair：Hitoshi Hanamoto

TakahiroShima{SHIMATAKAHIRO}|TakayukiNakamura{NAKAMURATAKAYUKI}|MitsukiFunakubo{FUNAKUBOMITSUKI}|HisayoshiSakai{SAKAIHISAYOSHI}|KotaroGaran{GARANKOTARO}____MasatsuguTanaka{TANAKAMASATSUGU}____KojiNagafuji{NAGAFUJIKOJI}|TeppeiSakoda{SAKODATEPPEI}|YoshikiyoIto{ITOYOSHIKIYO}|ToshihiroMiyamoto{MIYAMOTOTOSHIHIRO}|YoshikaneKikushige{KIKUSHIGEYOSHIKANE}|YasushiTakamatsu{TAKAMATSUYASUSHI}|SonokoShimoji{SHIMOJISONOKO}|TakujiYamauchi{YAMAUCHITAKUJI}|KenTakase{TAKASEKEN}|JunyaKanda{KANDAJUNYA}|NanaSasaki{SASAKINANA}|ToshiroKurokawa{KUROKAWATOSHIRO}|NaokoHiranuma{HIRANUMANAOKO}|HiroyukiTakata{TAKATAHIROYUKI}|FuminariFujii{FUJIIFUMINARI}|TomohiroHorio{HORIOTOMOHIRO}|HiroshiNakamura{NAKAMURAHIROSHI}|HitoshiHanamoto{HANAMOTOHITOSHI}|TakuyaShimizu{SHIMIZUTAKUYA}|YutaHanyu{HANYUYUTA}|KoichiAkashi{AKASHIKOICHI}|ToshinobuFukuyama{FUKUYAMATOSHINOBU}|YoshitakaYamasaki{YAMASAKIYOSHITAKA}|ShukiOya{OYASHUKI}|YoshimiMaehiro{MAEHIROYOSHIMI}|MakiYamaguchi{YAMAGUCHIMAKI}|FumihikoMouri{MOURIFUMIHIKO}|HisayoshiSakai{SAKAIHISAYOSHI}|ToshihikoKizuki{KIZUKITOSHIHIKO}|MinoriTamai{TAMAIMINORI}|ReinaMurasawa{MURASAWAREINA}|YukihiroSugita{SUGITAYUKIHIRO}|ShinKasai{KASAISHIN}|HirokoOshiro{OSHIROHIROKO}|KoshiAkahane{AKAHANEKOSHI}|KumikoGoi{GOIKUMIKO}|ChiakiKomatsu{KOMATSUCHIAKI}|KeikoKagami{KAGAMIKEIKO}|TakutoTakahashi{TAKAHASHITAKUTO}|TakeshiInukai{INUKAITAKESHI}|MitsukiFunakubo{FUNAKUBOMITSUKI}|YasutakaMasuda{MASUDAYASUTAKA}|HiroakiShimizu{SHIMIZUHIROAKI}|KotaHasegawa{HASEGAWAKOTA}|RikiYamakawa{YAMAKAWARIKI}|KairiKojo{KOJOKAIRI}|KanaKato{KATOKANA}|KoheiShinmura{SHINMURAKOHEI}|YukiMori{MORIYUKI}|KeishoKyan{KYANKEISHO}|TatsuyaTsurumoto{TSURUMOTOTATSUYA}|DaisukeMurakami{MURAKAMIDAISUKE}|AtsushiJinguji{JINGUJIATSUSHI}|DaichiSadato{SADATODAICHI}|TakashiToya{TOYATAKASHI}|KaoruMorita{MORITAKAORU}|YuhoNajima{NAJIMAYUHO}|TomomiToubai{TOUBAITOMOMI}|YukaHarada{HARADAYUKA}|KyokoHaraguchi{HARAGUCHIKYOKO}|NorikoDoki{DOKINORIKO}____Oral Session 1-9DALL: Drug Therapy____Activity and safety of PEG-asparaginase: interim analysis of JSCT ALL/MRD2025 prospective study|Low incidence of thrombosis with routine antithrombin supplementation during asparaginase therapy|Distinct pathways determine low- and high-dose cytarabine sensitivity in BCP-ALL|Higher peak plasma concentration, not longer exposure, enhances high-dose cytarabine activity|Treatment outcomes of allo-HCT for adult patients with acute leukemia of ambiguous lineage

O1-9D

Oral Session 1-9D
ALL: Drug Therapy

Chair：Masatsugu Tanaka

NoboruAsada{ASADANOBORU}|JunichiroYuda{YUDAJUNICHIRO}|AlessandroLaganà{LAGANÀALESSANDRO}|JohannesLuebke{LUEBKEJOHANNES}|YawenZhang{ZHANGYAWEN}____YokoEdahiro{EDAHIROYOKO}____JamesMccloskey{MCCLOSKEYJAMES}|LindsayRein{REINLINDSAY}|AndrewSrisuwananukorn{SRISUWANANUKORNANDREW}|JohnMascarenhas{MASCARENHASJOHN}|PrithvirajBose{BOSEPRITHVIRAJ}|VikasGupta{GUPTAVIKAS}|RaajitRampal{RAMPALRAAJIT}|JosephScandura{SCANDURAJOSEPH}|TimothyDevos{DEVOSTIMOTHY}|AlessandroLucchesi{LUCCHESIALESSANDRO}|FirasElChaer{CHAERFIRASEL}|SrinivasTantravahi{TANTRAVAHISRINIVAS}|NorikoFukuhara{FUKUHARANORIKO}|JunichiroYuda{YUDAJUNICHIRO}|MichikoIchii{ICHIIMICHIKO}|MarcelloRotta{ROTTAMARCELLO}|AnthonyHunter{HUNTERANTHONY}|DavidRoss{ROSSDAVID}|AshwinKishtagari{KISHTAGARIASHWIN}|VincentRibrag{RIBRAGVINCENT}|MarinaKremyanskaya{KREMYANSKAYAMARINA}|MosheTalpaz{TALPAZMOSHE}|DominiekMazure{MAZUREDOMINIEK}|AlessandraIurlo{IURLOALESSANDRA}|RanaTanaka{TANAKARANA}|SujanKabir{KABIRSUJAN}|FrancescoPassamonti{PASSAMONTIFRANCESCO}|KazuyaShimoda{SHIMODAKAZUYA}|JinnyLee{LEEJINNY}|RonaldHoffman{HOFFMANRONALD}|JasonMFoulks{FOULKSJASONM}|AdamSiddiqui{SIDDIQUIADAM}|ClaireHarrison{HARRISONCLAIRE}|RubenMesa{MESARUBEN}|FlorianHeidel{HEIDELFLORIAN}|ShuichiShirane{SHIRANESHUICHI}|AkiyoshiTakami{TAKAMIAKIYOSHI}|TamannaHaque{HAQUETAMANNA}|SamahAlimam{ALIMAMSAMAH}|GiuliaBenevolo{BENEVOLOGIULIA}|NikkiGranacher{GRANACHERNIKKI}|StevenLWarner{WARNERSTEVENL}|JosephMScandura{SCANDURAJOSEPHM}|EmiliaScalzulli{SCALZULLIEMILIA}|MariaLauraBisegna{BISEGNAMARIALAURA}|IdaCarmosino{CARMOSINOIDA}|DeborahKasmi{KASMIDEBORAH}|MartinaGherardini{GHERARDINIMARTINA}|AnnaLauraFaccini{FACCINIANNALAURA}|MaurizioMartelli{MARTELLIMAURIZIO}|MassimoBreccia{BRECCIAMASSIMO}|VitoDangelo{DANGELOVITO}|GuillaumeLefevre{LEFEVREGUILLAUME}|JulienRohmer{ROHMERJULIEN}|MatthieuGroh{GROHMATTHIEU}|JulienRossignol{ROSSIGNOLJULIEN}|LeonardKrenz{KRENZLEONARD}|NicoleNaumann{NAUMANNNICOLE}|AliceFabarius{FABARIUSALICE}|Wolf-KarstenHofmann{HOFMANNWOLF-KARSTEN}|OlivierHermine{HERMINEOLIVIER}|GeorgiaMetzgeroth{METZGEROTHGEORGIA}|Jean-EmmanuelKahn{KAHNJEAN-EMMANUEL}|JulianaSchwaab{SCHWAABJULIANA}|AndreasReiter{REITERANDREAS}|ChengtaoQin{QINCHENGTAO}|YueminGong{GONGYUEMIN}|GuangshengHe{HEGUANGSHENG}____Oral Session 1-10AMPN: Clinical 1____Preliminary data from ongoing phase 1/2 study of nuvisertib with momelotinib in patients with MF|Preclinical ACVR1/hepcidin targeting by PIM1 inhibitor nuvisertib suggests hemoglobin benefit in MF|Baseline predictors of survival in ruxolitinib-treated myelofibrosis: development of the R-PSS|The machine learning-based Eosinophilia Differentiation Score (EDS)|Efficacy of gecacitinib in myelofibrosis patients unfit for ruxolitinib

O1-10A

Oral Session 1-10A
MPN: Clinical 1

Chair：Yoko Edahiro

MakotoYoshimitsu{YOSHIMITSUMAKOTO}|YokoEdahiro{EDAHIROYOKO}|YukaSugimoto{SUGIMOTOYUKA}|KazuyaShimoda{SHIMODAKAZUYA}____DaigoAkahane{AKAHANEDAIGO}____HarisAli{ALIHARIS}|JohnMascarenhas{MASCARENHASJOHN}|TaniaJain{JAINTANIA}|AaronGerds{GERDSAARON}|VikasGupta{GUPTAVIKAS}|ClaireHarrison{HARRISONCLAIRE}|JoanHow{HOWJOAN}|DavidM.Ross{ROSSDAVIDM.}|LuciaMasarova{MASAROVALUCIA}|BethanPsaila{PSAILABETHAN}|AbdulraheemYacoub{YACOUBABDULRAHEEM}|TerrenceBradley{BRADLEYTERRENCE}|CarolineMcnamara{MCNAMARACAROLINE}|AndrewPerkins{PERKINSANDREW}|WilliamShomali{SHOMALIWILLIAM}|HirokiYamaguchi{YAMAGUCHIHIROKI}|SteffenKoschmieder{KOSCHMIEDERSTEFFEN}|JasonGotlib{GOTLIBJASON}|JyotiNangalia{NANGALIAJYOTI}|ChenweiTian{TIANCHENWEI}|BettyLamothe{LAMOTHEBETTY}|ErinCrowgey{CROWGEYERIN}|TatianaZinger{ZINGERTATIANA}|EvanBraunstein{BRAUNSTEINEVAN}|ChihoFuruya{FURUYACHIHO}|SojiMorishita{MORISHITASOJI}|ShuichiShirane{SHIRANESHUICHI}|TadaakiInano{INANOTADAAKI}|TomonoriOchiai{OCHIAITOMONORI}|NaokoMidorikawa{MIDORIKAWANAOKO}|MikiAndo{ANDOMIKI}|NorioKomatsu{KOMATSUNORIO}|KeitaKirito{KIRITOKEITA}|KatsutoTakenaka{TAKENAKAKATSUTO}|MichikoIchii{ICHIIMICHIKO}|YokoKubuki{KUBUKIYOKO}|TomokiIto{ITOTOMOKI}|MichiakiKoike{KOIKEMICHIAKI}|AkihikoGotoh{GOTOHAKIHIKO}|HirokazuTanaka{TANAKAHIROKAZU}|SheenaLin{LINSHEENA}|OlehZagrijtschuk{ZAGRIJTSCHUKOLEH}|AlbertQin{QINALBERT}|HiroakiKawase{KAWASEHIROAKI}|MaiSato{SATOMAI}|ToshiakiSato{SATOTOSHIAKI}|KazuyaShimoda{SHIMODAKAZUYA}|PankitVachhani{VACHHANIPANKIT}|AlessandroLucchesi{LUCCHESIALESSANDRO}|AndrewCPerkins{PERKINSANDREWC}|JasmineSahni{SAHNIJASMINE}|MahshidAzimi{AZIMIMAHSHID}|ShiyuanZhang{ZHANGSHIYUAN}|DwaipayanPatnaik{PATNAIKDWAIPAYAN}|JeanneMPalmer{PALMERJEANNEM}|PrithvirajBose{BOSEPRITHVIRAJ}|KanaeSakata{SAKATAKANAE}|TatsumaMatsuda{MATSUDATATSUMA}|TakeoSuzuki{SUZUKITAKEO}|TomoyaOhno{OHNOTOMOYA}|KokiIdehara{IDEHARAKOKI}|SatoshiKakugawa{KAKUGAWASATOSHI}____Oral Session 1-10BMPN: Clinical 2____Safety and efficacy of the mutant CALR antibody, INCA033989, for essential thrombocythemia (ET)|Risk stratification using the AAA model in a Japanese cohort of essential thrombocythemia|Efficacy and safety of ropeginterferon alfa-2b in Japanese ET: SURPASS-ET subgroup analysis|Post hoc analyses of SIMPLIFY-1 and -2: patients transitioning from ruxolitinib to momelotinib|Momelotinib treatment patterns and outcomes in myelofibrosis: Real-world study in Japan

O1-10B

Oral Session 1-10B
MPN: Clinical 2

Chair：Daigo Akahane

KokiUeda{UEDAKOKI}|TetsuichiYoshizato{YOSHIZATOTETSUICHI}|DaikiYamashita{YAMASHITADAIKI}|ChenmengLiu{LIUCHENMENG}____KazuhikoIkeda{IKEDAKAZUHIKO}____SaoriMiura{MIURASAORI}|MasahikoAjiro{AJIROMASAHIKO}|TomofumiMisaka{MISAKATOMOFUMI}|YukaSato{SATOYUKA}|KeijiMinakawa{MINAKAWAKEIJI}|YasuchikaTakeishi{TAKEISHIYASUCHIKA}|AkihideYoshimi{YOSHIMIAKIHIDE}|KazuhikoIkeda{IKEDAKAZUHIKO}|PetterS.Woll{WOLLPETTERS.}|KajsaAx{AXKAJSA}|CeciliaKarlstrom{KARLSTROMCECILIA}|JoakimS.Dahlin{DAHLINJOAKIMS.}|StenEirikW.Jacobsen{JACOBSENSTENEIRIKW.}|JohannaUngerstedt{UNGERSTEDTJOHANNA}|HidekiMuramatsu{MURAMATSUHIDEKI}|ManabuWakamatsu{WAKAMATSUMANABU}|DaichiSajiki{SAJIKIDAICHI}|ToruHiguchi{HIGUCHITORU}|KotaroOgawa{OGAWAKOTARO}|AyakoYamamori{YAMAMORIAYAKO}|KotaroNarita{NARITAKOTARO}|ShinsukeKataoka{KATAOKASHINSUKE}|YoshiyukiTakahashi{TAKAHASHIYOSHIYUKI}|XingchenWang{WANGXINGCHEN}|ZixiYin{YINZIXI}|WenbinAn{ANWENBIN}|YangWan{WANYANG}|YuanyuanRen{RENYUANYUAN}|XiaChen{CHENXIA}|FangLiu{LIUFANG}|YeGuo{GUOYE}|XiaojuanChen{CHENXIAOJUAN}|LiZhang{ZHANGLI}|YaoZou{ZOUYAO}|YumeiChen{CHENYUMEI}|WenyuYang{YANGWENYU}|XiaofanZhu{ZHUXIAOFAN}____Oral Session 1-10CMPN: Basic 1____JAK2-mutant platelet dysfunction arises from stem cell initiated translational dysregulation|Phylogeny and cellular origin of systemic mastocytosis|Integrated genomic and methylation profiling of JMML by adaptive nanopore sequencing|Longitudinal DNA methylation dynamics during disease course in juvenile myelomonocytic leukemia

O1-10C

Oral Session 1-10C
MPN: Basic 1

Chair：Kazuhiko Ikeda

YuyaKurihara{KURIHARAYUYA}|EikoOhya{OHYAEIKO}|MakioHiguchi{HIGUCHIMAKIO}|TakaakiMaekawa{MAEKAWATAKAAKI}|KoieSon{SONKOIE}____KotaroShide{SHIDEKOTARO}____AkiraHonda{HONDAAKIRA}|KenMorita{MORITAKEN}|JunjiTokushige{TOKUSHIGEJUNJI}|MitsuhiroYuasa{YUASAMITSUHIRO}|ArikaShimura{SHIMURAARIKA}|HiroakiMaki{MAKIHIROAKI}|YosukeMasamoto{MASAMOTOYOSUKE}|KoichiSugimoto{SUGIMOTOKOICHI}|MineoKurokawa{KUROKAWAMINEO}|KeikiNagaharu{NAGAHARUKEIKI}|MakotoIkejiri{IKEJIRIMAKOTO}|IsaoTawara{TAWARAISAO}|KohshiOhishi{OHISHIKOHSHI}|KyokoImanaka{IMANAKAKYOKO}|YukaSugimoto{SUGIMOTOYUKA}|TakakoHirata{HIRATATAKAKO}|NoriakiTachi{TACHINORIAKI}|NobuyukiMukai{MUKAINOBUYUKI}|YurikaYanaki{YANAKIYURIKA}|EmiKemmoku{KEMMOKUEMI}|TakutoShonai{SHONAITAKUTO}|KotaKawasaki{KAWASAKIKOTA}|TakehiroSone{SONETAKEHIRO}|KoheiTakada{TAKADAKOHEI}|HirakuOgata{OGATAHIRAKU}|KeitaSaito{SAITOKEITA}|ToshikuniKawamura{KAWAMURATOSHIKUNI}|ShoichiroKato{KATOSHOICHIRO}|YukikoOsawa{OSAWAYUKIKO}|ShinichiKobayashi{KOBAYASHISHINICHI}|MinakoMori{MORIMINAKO}|SakiTamaki{TAMAKISAKI}|KeisukeTatsuoka{TATSUOKAKEISUKE}|DaichiMine{MINEDAICHI}|MegumiShikano{SHIKANOMEGUMI}|TomoharuTakeoka{TAKEOKATOMOHARU}|AkaneKunitomi{KUNITOMIAKANE}|KenjiroTomo{TOMOKENJIRO}|TomoyukiShirase{SHIRASETOMOYUKI}|KazuhisaChonabayashi{CHONABAYASHIKAZUHISA}|JunyaKanda{KANDAJUNYA}|YasuhitoNannya{NANNYAYASUHITO}|SeishiOgawa{OGAWASEISHI}|AkifumiTakaori-Kondo{TAKAORI-KONDOAKIFUMI}|ChisakiMizumoto{MIZUMOTOCHISAKI}|MasaakiTsuji{TSUJIMASAAKI}____Oral Session 1-10DMPN: Basic 2____Fusion transcript independent activation of PDGFRB in indolent MLN-TK|IL-1β-induced stromal reprogramming contributes to microenvironmental dysfunction in MPN|JAK2 inhibitors override JAK-STAT system, potentially driving withdrawal syndrome via STAT bursts|Altered levels of fibrocyte-related cytokines in lymphoid malignancies with secondary myelofibrosis|Evolution of CSF3R-mutated myeloid neoplasms: chronic neutrophilic leukemia to lymphoid conversion

O1-10D

Oral Session 1-10D
MPN: Basic 2

Chair：Kotaro Shide

YukiHodo{HODOYUKI}|Chien-ChinLin{LINCHIEN-CHIN}|SeigiOshima{OSHIMASEIGI}|EmiSoma{SOMAEMI}|EmanuelePacini{PACINIEMANUELE}____KatsutoTakenaka{TAKENAKAKATSUTO}____AzumiTomita{TOMITAAZUMI}|XingxingQi{QIXINGXING}|YutongZhang{ZHANGYUTONG}|YangLyu{LYUYANG}|MasahiroNakagawa{NAKAGAWAMASAHIRO}|ManabuNakayama{NAKAYAMAMANABU}|HaruhikoKoseki{KOSEKIHARUHIKO}|YasuhitoNannya{NANNYAYASUHITO}|SeishiOgawa{OGAWASEISHI}|AyanaKon{KONAYANA}|TakayaYamasaki{YAMASAKITAKAYA}|DaichiMorii{MORIIDAICHI}|HiromiYamazaki{YAMAZAKIHIROMI}|SeigiOshima{OSHIMASEIGI}|WeijiaZang{ZANGWEIJIA}|KoutarouNishimura{NISHIMURAKOUTAROU}|DaichiInoue{INOUEDAICHI}|AkifumiTakaori-Kondo{TAKAORI-KONDOAKIFUMI}|KosukeNomura{NOMURAKOSUKE}|YasushigeKamimura-Aoyagi{KAMIMURA-AOYAGIYASUSHIGE}|SatoshiTakahashi{TAKAHASHISATOSHI}|WataruFujii{FUJIIWATARU}|HironoriHarada{HARADAHIRONORI}|YoshihiroHayashi{HAYASHIYOSHIHIRO}|AnnaSicuranza{SICURANZAANNA}|ElenaBeffa{BEFFAELENA}|ElenaBestoso{BESTOSOELENA}|AdeleSantoni{SANTONIADELE}|AnnaZannoli{ZANNOLIANNA}|MattiaBello{BELLOMATTIA}|DonatellaRaspadori{RASPADORIDONATELLA}|MonicaBocchia{BOCCHIAMONICA}____Oral Session 1-11AMDS: Basic Research 1____U2AF1 mutations contribute to inflammatory and migratory alterations in MDS|IDH2 mutation and innate inflammation drive clonal advantage and myeloid neoplasm progression|UBTF tandem duplication drives dysplastic hematopoiesis through aberrant ribosomal biogenesis|Inflammatory crosstalk driven by mutant HSPCs underlies kidney injury in myeloid malignancies|Mapping stem cell diversity in MDS by flow cytometry: insights for prognosis and leukemic evolution

O1-11A

Oral Session 1-11A
MDS: Basic Research 1

Chair：Katsuto Takenaka

SatoshiKoi{KOISATOSHI}|AkikoNagamachi{NAGAMACHIAKIKO}|TomoyaMuto{MUTOTOMOYA}|KanakoYuki{YUKIKANAKO}|MasatakaHasegawa{HASEGAWAMASATAKA}____KoKudo{KUDOKO}____TakakoYokomizo{YOKOMIZOTAKAKO}|MotohikoOshima{OSHIMAMOTOHIKO}|HironoriHarada{HARADAHIRONORI}|AtsushiIwama{IWAMAATSUSHI}|AkinoriKanai{KANAIAKINORI}|HirotakaMatsui{MATSUIHIROTAKA}|TomokatsuIkawa{IKAWATOMOKATSU}|ToshiyaInaba{INABATOSHIYA}|MasahikoAjiro{AJIROMASAHIKO}|YutoHirayama{HIRAYAMAYUTO}|OsamuSuzuki{SUZUKIOSAMU}|ChoiKwangmin{KWANGMINCHOI}|ShinichiroMatsui{MATSUISHINICHIRO}|TakuyaIzumi-Tamura{IZUMI-TAMURATAKUYA}|MinaYoshida{YOSHIDAMINA}|MayumiTakahashi{TAKAHASHIMAYUMI}|NatsukoShinohara{SHINOHARANATSUKO}|MayumiHanzawa{HANZAWAMAYUMI}|AsukaKawachi{KAWACHIASUKA}|ShokichiTsukamoto{TSUKAMOTOSHOKICHI}|EmikoSakaida{SAKAIDAEMIKO}|DanielStarczynowski{STARCZYNOWSKIDANIEL}|GoroSashida{SASHIDAGORO}|HaruhikoKamada{KAMADAHARUHIKO}|AkihideYoshimi{YOSHIMIAKIHIDE}|YasushigeKamimura{KAMIMURAYASUSHIGE}|SyuntaTaoda{TAODASYUNTA}|YutoMatsuhashi{MATSUHASHIYUTO}|YukinaIshikawa{ISHIKAWAYUKINA}|HanaYamamoto{YAMAMOTOHANA}|HirokiKobayashi{KOBAYASHIHIROKI}|YukaHarada{HARADAYUKA}|KaitoMimura{MIMURAKAITO}|DaiKeino{KEINODAI}|RintaroOno{ONORINTARO}|YasuoKubota{KUBOTAYASUO}|YokoMizoguchi{MIZOGUCHIYOKO}|KiyotakaIsobe{ISOBEKIYOTAKA}|KeisukeOkuno{OKUNOKEISUKE}|KumikoAndo{ANDOKUMIKO}|ShinichiTsujimoto{TSUJIMOTOSHINICHI}|AtsushiOgawa{OGAWAATSUSHI}|HironoriGoto{GOTOHIRONORI}|TakaoDeguchi{DEGUCHITAKAO}|HidetoIwafuchi{IWAFUCHIHIDETO}|HiroshiMoritake{MORITAKEHIROSHI}|SeishiOgawa{OGAWASEISHI}|MotohiroKato{KATOMOTOHIRO}|AtsushiManabe{MANABEATSUSHI}|KenichiYoshida{YOSHIDAKENICHI}|DaisukeHasegawa{HASEGAWADAISUKE}____Oral Session 1-11BMDS: Basic Research 2____The cGAS-STING pathway promotes leukemic transformation in myelodysplastic syndromes|Samd9L mutation disrupts TGFβ signaling through loss of nuclear actin binding in SAMD9/9L syndromes|RNA metabolism underlies inflammatory adaptation of MDS stem cells|MDS progression is closely linked to intestinal dysregulation, a potential therapeutic target|Genomic and epigenomic analysis of pediatric myelodysplastic syndromes

O1-11B

Oral Session 1-11B
MDS: Basic Research 2

Chair：Ko Kudo

RyunosukeSaiki{SAIKIRYUNOSUKE}|KoFujimoto{FUJIMOTOKO}|ThiThuHienDao{DAOTHITHUHIEN}|BrianSweet{SWEETBRIAN}|FeiHuang{HUANGFEI}____HidehiroItonaga{ITONAGAHIDEHIRO}____RyuyaEdahiro{EDAHIRORYUYA}|KyutoSonehara{SONEHARAKYUTO}|QingboWang{WANGQINGBO}|HoNamkoong{NAMKOONGHO}|TakanoriHasegawa{HASEGAWATAKANORI}|HiromuTanaka{TANAKAHIROMU}|ShuheiAzekawa{AZEKAWASHUHEI}|ShotaroChubachi{CHUBACHISHOTARO}|GoSato{SATOGO}|ShinichiNamba{NAMBASHINICHI}|KenichiYamamoto{YAMAMOTOKENICHI}|NobuyukiKakiuchi{KAKIUCHINOBUYUKI}|YotaroOchi{OCHIYOTARO}|MasahiroNakagawa{NAKAGAWAMASAHIRO}|KoichiWatanabe{WATANABEKOICHI}|AkinoriKimura{KIMURAAKINORI}|SeiyaImoto{IMOTOSEIYA}|SatoruMiyano{MIYANOSATORU}|TakanoriKanai{KANAITAKANORI}|YasunobuNagata{NAGATAYASUNOBU}|HirokiYamaguchi{YAMAGUCHIHIROKI}|KoichiMatsuda{MATSUDAKOICHI}|RyujiKoike{KOIKERYUJI}|TomomiTakano{TAKANOTOMOMI}|KoichiFukunaga{FUKUNAGAKOICHI}|YukinoriOkada{OKADAYUKINORI}|SeishiOgawa{OGAWASEISHI}|KohmeiKubo{KUBOKOHMEI}|HisayukiYokoyama{YOKOYAMAHISAYUKI}|TakafumiNakao{NAKAOTAKAFUMI}|KoichiOnodera{ONODERAKOICHI}|YoshiakiOgawa{OGAWAYOSHIAKI}|SenjiKasahara{KASAHARASENJI}|KojiAndo{ANDOKOJI}|SatoshiYoshihara{YOSHIHARASATOSHI}|MoeKadono{KADONOMOE}|AkiraYokota{YOKOTAAKIRA}|ToshiroKawakita{KAWAKITATOSHIRO}|RyoheiNawata{NAWATARYOHEI}|TomonoriNakazato{NAKAZATOTOMONORI}|TakeharuKotani{KOTANITAKEHARU}|NobuyukiAotsuka{AOTSUKANOBUYUKI}|TakashiOkamura{OKAMURATAKASHI}|HarukoTashiro{TASHIROHARUKO}|TakayukiIkezoe{IKEZOETAKAYUKI}|HariprasadMadhamshetty{MADHAMSHETTYHARIPRASAD}|KyotakaMatsumoto{MATSUMOTOKYOTAKA}|WataruHongo{HONGOWATARU}|ShizukaNakasako{NAKASAKOSHIZUKA}|YasushiMiyazaki{MIYAZAKIYASUSHI}|ThienNgonHuynh{HUYNHTHIENNGON}|HoangThienDang{DANGHOANGTHIEN}|ThiBichHuyenHuynh{HUYNHTHIBICHHUYEN}|ThiXinhPhan{PHANTHIXINH}|ChiDungPhu{PHUCHIDUNG}|JessyThomas{THOMASJESSY}|GeneFelber{FELBERGENE}|ErosPapademetriou{PAPADEMETRIOUEROS}|RohitTyagi{TYAGIROHIT}|JosephEid{EIDJOSEPH}|ZhongxunShi{SHIZHONGXUN}|JianyongLi{LIJIANYONG}|WenyiShen{SHENWENYI}____Oral Session 1-11CMDS: Clinical____Subtype-specific inflammatory dysregulation in clonal hematopoiesis drives severe COVID-19 risk|Eltrombopag in Japanese lower-risk MDS patients with platelet transfusion dependence: Phase II study|Real-world outcomes of combination therapy with eltrombopag in hypoplastic myelodysplastic syndrome|Real-world experience with imetelstat (IME) in lower-risk (LR) MDS: insights from US claims data|Venetoclax combined with azacitidine and homoharringtonine in secondary acute myeloid leukemia

O1-11C

Oral Session 1-11C
MDS: Clinical

Chair：Hidehiro Itonaga

YuyaOshima{OSHIMAYUYA}|YusukeOkayama{OKAYAMAYUSUKE}|MakotoMoriguchi{MORIGUCHIMAKOTO}|KensukeUsuki{USUKIKENSUKE}|HideakiNakajima{NAKAJIMAHIDEAKI}____MotoshiIchikawa{ICHIKAWAMOTOSHI}____KatsuhiroIo{IOKATSUHIRO}|AnMatsumoto{MATSUMOTOAN}|RyuTakakura{TAKAKURARYU}|MasahiroYoshimoto{YOSHIMOTOMASAHIRO}|SumireInoue{INOUESUMIRE}|YutoUeda{UEDAYUTO}|AyakoIwama{IWAMAAYAKO}|KazukiYoshioka{YOSHIOKAKAZUKI}|BuntaKakihara{KAKIHARABUNTA}|TokikoHoshiyama{HOSHIYAMATOKIKO}|YosukeKondo{KONDOYOSUKE}|JunIchikawa{ICHIKAWAJUN}|YukieTsubokura{TSUBOKURAYUKIE}|KensukeNakao{NAKAOKENSUKE}|KiyotakaIzumi{IZUMIKIYOTAKA}|HideakiYoshimura{YOSHIMURAHIDEAKI}|AzusaNagao{NAGAOAZUSA}|MasaakiHotta{HOTTAMASAAKI}|TomoyaKitagawa{KITAGAWATOMOYA}|TakahisaNakanishi{NAKANISHITAKAHISA}|ShinyaFujita{FUJITASHINYA}|AtsushiSatake{SATAKEATSUSHI}|MasayaOkada{OKADAMASAYA}|KazuyoshiIshii{ISHIIKAZUYOSHI}|YusukeTanada{TANADAYUSUKE}|MasayukiHino{HINOMASAYUKI}|TeruhitoTakakuwa{TAKAKUWATERUHITO}|KensukeOta{OTAKENSUKE}|TsubasaUeda{UEDATSUBASA}|TatsunoriIshikawa{ISHIKAWATATSUNORI}|SachiyoOkamoto{OKAMOTOSACHIYO}|TaroMasunari{MASUNARITARO}|NobuoSezaki{SEZAKINOBUO}|MasanoriMakita{MAKITAMASANORI}|TaigaKuroi{KUROITAIGA}|SenjiKasahara{KASAHARASENJI}|ShoOkamoto{OKAMOTOSHO}|JunyaKuroda{KURODAJUNYA}|MotoshiIchikawa{ICHIKAWAMOTOSHI}|TatsuoIchinohe{ICHINOHETATSUO}|TakayukiIkezoe{IKEZOETAKAYUKI}|AkihisaImanishi{IMANISHIAKIHISA}|KazunariMiyairi{MIYAIRIKAZUNARI}|YukaKagawa{KAGAWAYUKA}|TakahiroYamauchi{YAMAUCHITAKAHIRO}|ShinyaKimura{KIMURASHINYA}|DavidBeck{BECKDAVID}|MaelHeilig{HEILIGMAEL}|KatjaSockel{SOCKELKATJA}|MartinKrusche{KRUSCHEMARTIN}|SinisaSavic{SAVICSINISA}|MatteoGiovanniDellaPorta{PORTAMATTEOGIOVANNIDELLA}|JasmineSahni{SAHNIJASMINE}|CatherineEllis{ELLISCATHERINE}|AntaraMajumdar{MAJUMDARANTARA}|MeenakshiSrinivasan{SRINIVASANMEENAKSHI}|DwaipayanPatnaik{PATNAIKDWAIPAYAN}|MrinalPatnaik{PATNAIKMRINAL}____Oral Session 1-11DMDS: Drug Therapy____Retrospective analysis of luspatercept for myelodysplastic syndromes in clinical experience|Real-world outcomes and predictors of luspatercept in myelodysplastic syndromes|Real-world outcomes of luspatercept in myelodysplastic syndrome: a multicenter retrospective study|Phase I study of OP-2100, an oral prodrug of decitabine, for patients with R/R HR-MDS and CMML|ATLAS: A phase 2/3 study assessing momelotinib's safety and efficacy in patients with VEXAS syndrome

O1-11D

Oral Session 1-11D
MDS: Drug Therapy

Chair：Motoshi Ichikawa

YayoiIchikawa{ICHIKAWAYAYOI}|KeijiNogami{NOGAMIKEIJI}|KazuyaOkada{OKADAKAZUYA}|ChiaiNagae{NAGAECHIAI}____ShokoFurukawa{FURUKAWASHOKO}____MakikoMori{MORIMAKIKO}|YuKato{KATOYU}|MasayukiIijima{IIJIMAMASAYUKI}|YoshitakaMizushima{MIZUSHIMAYOSHITAKA}|TatsuyaKamitori{KAMITORITATSUYA}|MamoruHonda{HONDAMAMORU}|YuichiMitani{MITANIYUICHI}|KoichiOshima{OSHIMAKOICHI}|KoheiFukuoka{FUKUOKAKOHEI}|YutakaTanami{TANAMIYUTAKA}|KatsuakiTaira{TAIRAKATSUAKI}|YukiArakawa{ARAKAWAYUKI}|KatsuyoshiKoh{KOHKATSUYOSHI}|MasatoBingo{BINGOMASATO}|TazukoTokugawa{TOKUGAWATAZUKO}|KenichiOgiwara{OGIWARAKENICHI}|AkikoIoka{IOKAAKIKO}|NaotoHattori{HATTORINAOTO}|SuguruHarada{HARADASUGURU}|KeisukeIwasaki{IWASAKIKEISUKE}|NobuakiSuzuki{SUZUKINOBUAKI}|ErikaUmakoshi{UMAKOSHIERIKA}|NaokiTakahashi{TAKAHASHINAOKI}|ReonInoue{INOUEREON}|MioNashima{NASHIMAMIO}|KentaroNagae{NAGAEKENTARO}|HitomiTsuchida{TSUCHIDAHITOMI}|ShuIto{ITOSHU}|MasatoshiMinakuchi{MINAKUCHIMASATOSHI}|WataruMurakami{MURAKAMIWATARU}|MiyuiFujieda{FUJIEDAMIYUI}|FuyukiMukaizawa{MUKAIZAWAFUYUKI}|TomokoImanaka{IMANAKATOMOKO}|JunkoNakamura{NAKAMURAJUNKO}|RyosukeTakaya{TAKAYARYOSUKE}|TakashiNagayama{NAGAYAMATAKASHI}|HiroyukiMuranushi{MURANUSHIHIROYUKI}|TakayukiSato{SATOTAKAYUKI}|TatsuhitoOnishi{ONISHITATSUHITO}|TakeshiMaeda{MAEDATAKESHI}|YasunoriUeda{UEDAYASUNORI}|NarutoShimonishi{SHIMONISHINARUTO}|YutoNakajima{NAKAJIMAYUTO}|MitsumasaOsuna{OSUNAMITSUMASA}|NarumiMizuno{MIZUNONARUMI}|YutaKamei{KAMEIYUTA}|RyotaKobayashi{KOBAYASHIRYOTA}|MidoriShima{SHIMAMIDORI}|Yeu-ChinChen{CHENYEU-CHIN}|KeijiNogami{NOGAMIKEIJI}|Sheng-ChiehChou{CHOUSHENG-CHIEH}|SatoshiHigasa{HIGASASATOSHI}|MasahiroTakeyama{TAKEYAMAMASAHIRO}|Ming-ChingShen{SHENMING-CHING}|TakuyaMiwa{MIWATAKUYA}|Chun-AnChen{CHENCHUN-AN}|TakeshiMiyake{MIYAKETAKESHI}|YutoAizawa{AIZAWAYUTO}____Oral Session 1-12AHemophiliacs: Emicizumab and Others____Emicizumab in hemophilia A: a single-center study of 23 cases at a pediatric hospital|Interim analysis of study on anti-emicizumab antibodies, emicizumab levels and coagulation tests|Real-world outcome of emicizumab in acquired hemophilia A: breakthrough bleeding and 1-year survival|Major surgeries in people with hemophilia A under NXT007 prophylaxis: NXTAGE phase I/II study|Safety, PD, and efficacy of NXT007 after switching from emicizumab in PwHA with/without inhibitors

O1-12A

Oral Session 1-12A
Hemophiliacs: Emicizumab and Others

Chair：Shoko Furukawa

TeruhisaFujii{FUJIITERUHISA}|KazuhoMorichika{MORICHIKAKAZUHO}|EiKinai{KINAIEI}|KagehiroAmano{AMANOKAGEHIRO}|TadashiMatsushita{MATSUSHITATADASHI}____RieShirayama{SHIRAYAMARIE}____AllisonWheeler{WHEELERALLISON}|PantepAngchaisuksiri{ANGCHAISUKSIRIPANTEP}|ShashikantApte{APTESHASHIKANT}|GaryBenson{BENSONGARY}|ReneeBrownFrandsen{BROWNFRANDSENRENEE}|AnthonyK.C.Chan{CHANANTHONYK.C.}|HermannEichler{EICHLERHERMANN}|MohamedSalimNekkal{NEKKALMOHAMEDSALIM}|SonataSaulyteTrakymiene{SAULYTETRAKYMIENESONATA}|AliceTrinchero{TRINCHEROALICE}|SenthilVel{VELSENTHIL}|JanAstermark{ASTERMARKJAN}|MahitoYamashiro{YAMASHIROMAHITO}|YukaIrei{IREIYUKA}|YutaroYokota{YOKOTAYUTARO}|MichihitoUema{UEMAMICHIHITO}|TsubasaMiyagi{MIYAGITSUBASA}|RikoMiyagi{MIYAGIRIKO}|SakikoKitamura{KITAMURASAKIKO}|TakuyaFukushima{FUKUSHIMATAKUYA}|HiroakiMasuzaki{MASUZAKIHIROAKI}|VictorJimenez-Yuste{JIMENEZ-YUSTEVICTOR}|MariaFernandaMartinezGarcia{MARTINEZGARCIAMARIAFERNANDA}|LauraVillarrealMartinez{MARTINEZLAURAVILLARREAL}|LynnMalec{MALECLYNN}|JerzyWindyga{WINDYGAJERZY}|CedricHermans{HERMANSCEDRIC}|SanjayAhuja{AHUJASANJAY}|HazzaAlzahrani{ALZAHRANIHAZZA}|CihanAy{AYCIHAN}|PeterKampmann{KAMPMANNPETER}|SamyaObaji{OBAJISAMYA}|SophieSusen{SUSENSOPHIE}|CiprianIonutTomuleasa{IONUTTOMULEASACIPRIAN}|LizeVanVulpen{VANVULPENLIZE}|AmalieRhodeHoghNielsen{RHODEHOGHNIELSENAMALIE}|IlgizRakhmatullin{RAKHMATULLINILGIZ}|CarmenEscuriola-Ettingshausen{ESCURIOLA-ETTINGSHAUSENCARMEN}|StevenRLentz{RLENTZSTEVEN}|AbyAbraham{ABRAHAMABY}|AnthonyKcChan{KCCHANANTHONY}|JohannesOldenburg{OLDENBURGJOHANNES}|MariaElisaMancuso{ELISAMANCUSOMARIA}|JohnnyMahlangu{MAHLANGUJOHNNY}|RenchiYang{YANGRENCHI}|PratimaChowdary{CHOWDARYPRATIMA}____Oral Session 1-12BHemophiliacs: Concizumab and Denecimig____Annualized bleeding rates in non-inhibitor hemophilia A/B and target joints: Concizumab explorer8|Impact of risk modification on d dimer dynamics in patients with hemophilia treated with concizumab|Non-joint bleeds in haemophilia A/B patients without inhibitors: Concizumab phase 3 explorer8 study|52-week patient-reported outcomes with denecimig (Mim8) in hemophilia A: FRONTIER2|Denecimig (Mim8) prophylaxis with hemophilia A: 52-week efficacy and safety outcomes from FRONTIER2

O1-12B

Oral Session 1-12B
Hemophiliacs: Concizumab and Denecimig

Chair：Rie Shirayama

MasakiIino{IINOMASAKI}|KentaSakurai{SAKURAIKENTA}|MayuMatsushita{MATSUSHITAMAYU}|RyomaShimazu{SHIMAZURYOMA}|TomiteruTogano{TOGANOTOMITERU}____KenjiYokoyama{YOKOYAMAKENJI}____HirokiYamaguchi{YAMAGUCHIHIROKI}|JunYamanouchi{YAMANOUCHIJUN}|HarumiKamiya{KAMIYAHARUMI}|HelenaAhlin{AHLINHELENA}|PoojaIyer{IYERPOOJA}|NinaSkuban{SKUBANNINA}|YoshiakiTomiyama{TOMIYAMAYOSHIAKI}|ShimonOtake{OTAKESHIMON}|ReoIshii{ISHIIREO}|YoshihisaSugasawa{SUGASAWAYOSHIHISA}|YoshiyukiHayashi{HAYASHIYOSHIYUKI}|TakahiroNamiki{NAMIKITAKAHIRO}|TakashiIchinohe{ICHINOHETAKASHI}|HironaoNukariya{NUKARIYAHIRONAO}|ShunIto{ITOSHUN}|ToshihideEndo{ENDOTOSHIHIDE}|KazuyaKurihara{KURIHARAKAZUYA}|TakashiKoike{KOIKETAKASHI}|TakashiHamada{HAMADATAKASHI}|MasaruNakagawa{NAKAGAWAMASARU}|HiromichiTakahashi{TAKAHASHIHIROMICHI}|NoriyoshiIriyama{IRIYAMANORIYOSHI}|KatsuhiroMiura{MIURAKATSUHIRO}|HidekiNakamura{NAKAMURAHIDEKI}|KyoheiMisawa{MISAWAKYOHEI}|NorihideIzumi{IZUMINORIHIDE}|NoriakiIwao{IWAONORIAKI}|MichiakiKoike{KOIKEMICHIAKI}|HinaTakano{TAKANOHINA}|ToshikiYamada{YAMADATOSHIKI}|HisashiTsurumi{TSURUMIHISASHI}|YukiSakaida{SAKAIDAYUKI}|EmiSawazaki{SAWAZAKIEMI}|ShunTsunoda{TSUNODASHUN}|WataruKamata{KAMATAWATARU}|ShukuSato{SATOSHUKU}|RyujiTanosaki{TANOSAKIRYUJI}____Oral Session 1-12CITP Treatment____A phase 3 study in Japan of avatrombopag for chronic immune thrombocytopenia: final analysis|Real-world outcomes of avatrombopag in ITP: a two-center retrospective study|Adult ITP management and remission after TPO-RA discontinuation: a single-center retrospective study|Initial treatment of immune thrombocytopenia with high-dose dexamethasone at our institution|Early response and durability of avatrombopag after switching in immune thrombocytopenia

O1-12C

Oral Session 1-12C
ITP Treatment

Chair：Kenji Yokoyama

HisashiKato{KATOHISASHI}|RanWatanabe{WATANABERAN}|ShimonOtake{OTAKESHIMON}|SatoshiYamasaki{YAMASAKISATOSHI}____KeigoAkuta{AKUTAKEIGO}____KohyaKudo{KUDOKOHYA}|TomokiIto{ITOTOMOKI}|KenjiYokoyama{YOKOYAMAKENJI}|JunYamanouchi{YAMANOUCHIJUN}|ShinyaYamada{YAMADASHINYA}|EmikoSakaida{SAKAIDAEMIKO}|AkiyoshiTakami{TAKAMIAKIYOSHI}|HajimeYoshisue{YOSHISUEHAJIME}|TaeheonKim{KIMTAEHEON}|YukariShirasugi{SHIRASUGIYUKARI}|AkariGoto{GOTOAKARI}|HonomiTsuji{TSUJIHONOMI}|MinaBaba{BABAMINA}|MotoharuMinami{MINAMIMOTOHARU}|YuzufumiSekiguchi{SEKIGUCHIYUZUFUMI}|ShotaroShirato{SHIRATOSHOTARO}|SaoriIbuki{IBUKISAORI}|MasahiroYoshida{YOSHIDAMASAHIRO}|HirotoHoriguchi{HORIGUCHIHIROTO}|SatoshiIyama{IYAMASATOSHI}|MarieOgawa{OGAWAMARIE}|TsuyoshiSaito{SAITOTSUYOSHI}|MasayoshiKobune{KOBUNEMASAYOSHI}|ShugoKowata{KOWATASHUGO}|YaokiSonohara{SONOHARAYAOKI}|RyosukeNishi{NISHIRYOSUKE}|ShinichiNakamuta{NAKAMUTASHINICHI}|YoshihisaSugasawa{SUGASAWAYOSHIHISA}|TakahiroNamiki{NAMIKITAKAHIRO}|TakashiIchinohe{ICHINOHETAKASHI}|ShunIto{ITOSHUN}|HironaoNukariya{NUKARIYAHIRONAO}|ToshihideEndo{ENDOTOSHIHIDE}|KazuyaKurihara{KURIHARAKAZUYA}|TakashiHamada{HAMADATAKASHI}|HiromichiTakahashi{TAKAHASHIHIROMICHI}|KatsuhiroMiura{MIURAKATSUHIRO}|MakyoUeda{UEDAMAKYO}|SaoriOishi{OISHISAORI}|KatsueSuzuki-Inoue{SUZUKI-INOUEKATSUE}|HidekiNakamura{NAKAMURAHIDEKI}|MichitoshiHashiguchi{HASHIGUCHIMICHITOSHI}|NaoYoshida-Sakai{YOSHIDA-SAKAINAO}|HirotoJojima{JOJIMAHIROTO}|KoichiOsaki{OSAKIKOICHI}|TakashiOkamura{OKAMURATAKASHI}|YutakaImamura{IMAMURAYUTAKA}____Oral Session 1-12DITP and Thrombocytopenia____Health related quality of life and depressive symptoms in Japanese patients with chronic ITP|Clinical characteristics and maternal outcomes of pregnancies complicated by immune thrombocytopenia|Physician-patient perception gaps in ITP: treatment preferences and symptom perception|Evaluation of soluble CLEC-2 as a thromboembolic risk marker in immune thrombocytopenia (ITP)|Optimizing thrombocytopenia diagnosis via bone marrow and immature platelet fraction integration

O1-12D

Oral Session 1-12D
ITP and Thrombocytopenia

Chair：Keigo Akuta

TaroTochigi{TOCHIGITARO}|TatsunoriGoto{GOTOTATSUNORI}|AtsushiUeda{UEDAATSUSHI}|TomoyasuJo{JOTOMOYASU}|MasayaSuematsu{SUEMATSUMASAYA}____KatsuyoshiKoh{KOHKATSUYOSHI}____ShigeoFuji{FUJISHIGEO}|KimikazuYakushijin{YAKUSHIJINKIMIKAZU}|NorikoDoki{DOKINORIKO}|TakahiroFukuda{FUKUDATAKAHIRO}|TetsuyaNishida{NISHIDATETSUYA}|SatoshiYoshihara{YOSHIHARASATOSHI}|YutaHasegawa{HASEGAWAYUTA}|NaoyukiUchida{UCHIDANAOYUKI}|YutaKatayama{KATAYAMAYUTA}|NoboruAsada{ASADANOBORU}|YoshinobuKanda{KANDAYOSHINOBU}|JunyaKanda{KANDAJUNYA}|KenTabuchi{TABUCHIKEN}|YoshikoAtsuta{ATSUTAYOSHIKO}|TetsuyaEto{ETOTETSUYA}|TakayoshiTachibana{TACHIBANATAKAYOSHI}|SenjiKasahara{KASAHARASENJI}|MasashiSawa{SAWAMASASHI}|MakotoOnizuka{ONIZUKAMAKOTO}|TakaakiKonuma{KONUMATAKAAKI}|HitoshiKiyoi{KIYOIHITOSHI}|YukiyasuOzawa{OZAWAYUKIYASU}|MasatsuguTanaka{TANAKAMASATSUGU}|YasuyukiNagata{NAGATAYASUYUKI}|NobuyukiAotsuka{AOTSUKANOBUYUKI}|AyumuIto{ITOAYUMU}|KazutakaOzeki{OZEKIKAZUTAKA}|NobuhiroKanemura{KANEMURANOBUHIRO}|KoichiOnodera{ONODERAKOICHI}|MitsutakaNishimoto{NISHIMOTOMITSUTAKA}|YasunoriUeda{UEDAYASUNORI}|MihoNara{NARAMIHO}|HiroatsuIida{IIDAHIROATSU}|TakahideKikuchi{KIKUCHITAKAHIDE}|NobuharuFujii{FUJIINOBUHARU}|YachiyoKuwatsuka{KUWATSUKAYACHIYO}|TakuhiroYamaguchi{YAMAGUCHITAKUHIRO}|SeitaroTerakura{TERAKURASEITARO}|TomokiIemura{IEMURATOMOKI}|TadakazuKondo{KONDOTADAKAZU}|TakeshiMaeda{MAEDATAKESHI}|MitsumasaWatanabe{WATANABEMITSUMASA}|MitsuruItoh{ITOHMITSURU}|KoheiYamashita{YAMASHITAKOHEI}|KanaMatsumoto{MATSUMOTOKANA}|AkifumiTakaori{TAKAORIAKIFUMI}|YasuyukiArai{ARAIYASUYUKI}|MasamitsuYanada{YANADAMASAMITSU}|YoshimitsuShimomura{SHIMOMURAYOSHIMITSU}|KaoruMorita{MORITAKAORU}|SeiyaBamba{BAMBASEIYA}|AtsushiWake{WAKEATSUSHI}|ShuichiOta{OTASHUICHI}|ToshimitsuUeki{UEKITOSHIMITSU}|MasahitoTokunaga{TOKUNAGAMASAHITO}|NaoyukiAnzai{ANZAINAOYUKI}|YuichiroNawa{NAWAYUICHIRO}|HidekiNakasone{NAKASONEHIDEKI}|HirotoshiSakaguchi{SAKAGUCHIHIROTOSHI}|ShunsukeYamamoto{YAMAMOTOSHUNSUKE}|AyakoYamamori{YAMAMORIAYAKO}|TakuroNishikawa{NISHIKAWATAKURO}|AsahitoHama{HAMAASAHITO}|HiroyukiIshida{ISHIDAHIROYUKI}|HidekiSano{SANOHIDEKI}|MasakatsuYanagimachi{YANAGIMACHIMASAKATSU}|DaiichiroHasegawa{HASEGAWADAIICHIRO}|KatsutsuguUmeda{UMEDAKATSUTSUGU}|MoekoHino{HINOMOEKO}|ShoheiYamamoto{YAMAMOTOSHOHEI}|YukiArakawa{ARAKAWAYUKI}____Oral Session 1-13ATransplant Outcomes 1 (Conditioning)____Decision support for conditioning-intensity selection in allo-HCT|G-CSF priming myeloablative conditioning in cord blood transplantation: A phase III G-CONCORD trial|Dose-adjustment based on test-dose reduces the deviation rate in once-daily busulfan administration|Heterogeneous benefit of FLU/BU4/MEL in cord blood transplantation for AML: a causal forest analysis|Impact of busulfan dose adjustment in pediatric acute leukemia patients undergoing allogeneic HSCT

O1-13A

Oral Session 1-13A
Transplant Outcomes 1 (Conditioning)

Chair：Katsuyoshi Koh

DaisukeKoyama{KOYAMADAISUKE}|MasahiroTeramoto{TERAMOTOMASAHIRO}|MasahiroAkimoto{AKIMOTOMASAHIRO}|DaisukeMurakami{MURAKAMIDAISUKE}|KentaroNagae{NAGAEKENTARO}____SouichiShiratori{SHIRATORISOUICHI}____KengoSuzuki{SUZUKIKENGO}|MasahikoFukatsu{FUKATSUMASAHIKO}|JunNakata{NAKATAJUN}|DaisukeMotooka{MOTOOKADAISUKE}|YoshikiNakae{NAKAEYOSHIKI}|ManabuKawakami{KAWAKAMIMANABU}|YutaKatayama{KATAYAMAYUTA}|RyotaImanaka{IMANAKARYOTA}|JunyaKuroda{KURODAJUNYA}|TakuTsukamoto{TSUKAMOTOTAKU}|AtsushiSatake{SATAKEATSUSHI}|HirokiHosoi{HOSOIHIROKI}|TakafumiNakao{NAKAOTAKAFUMI}|ToshiyukiKitano{KITANOTOSHIYUKI}|ShigekiIto{ITOSHIGEKI}|NorimitsuKadowaki{KADOWAKINORIMITSU}|SyuichiOta{OTASYUICHI}|TakeshiMaeda{MAEDATAKESHI}|MasayoshiMasuko{MASUKOMASAYOSHI}|YasuhikoShibasaki{SHIBASAKIYASUHIKO}|KazunoriMurai{MURAIKAZUNORI}|TatsuyaImi{IMITATSUYA}|MasahitoOnizuka{ONIZUKAMASAHITO}|HitoshiHanamoto{HANAMOTOHITOSHI}|NoboruAsada{ASADANOBORU}|YoshihiroOka{OKAYOSHIHIRO}|HaruoSugiyama{SUGIYAMAHARUO}|TakayukiIkezoe{IKEZOETAKAYUKI}|YoshimitsuShimomura{SHIMOMURAYOSHIMITSU}|MasamitsuYanada{YANADAMASAMITSU}|ShoheiMizuno{MIZUNOSHOHEI}|KojiNagafuji{NAGAFUJIKOJI}|HirohisaNakamae{NAKAMAEHIROHISA}|MasaoOgata{OGATAMASAO}|TetsuyaEto{ETOTETSUYA}|ToshihikoAndo{ANDOTOSHIHIKO}|AtsushiWake{WAKEATSUSHI}|MasatsuguTanaka{TANAKAMASATSUGU}|MasashiSawa{SAWAMASASHI}|NaoyukiUchida{UCHIDANAOYUKI}|YutaHasegawa{HASEGAWAYUTA}|MasahitoTokunaga{TOKUNAGAMASAHITO}|HidekiNakasone{NAKASONEHIDEKI}|FumihikoIshimaru{ISHIMARUFUMIHIKO}|JunyaKanda{KANDAJUNYA}|YoshikoAtsuta{ATSUTAYOSHIKO}|TakaakiKonuma{KONUMATAKAAKI}|TakayoshiTachibana{TACHIBANATAKAYOSHI}|ShinichiroMachida{MACHIDASHINICHIRO}|KaitoHarada{HARADAKAITO}|YuhoNajima{NAJIMAYUHO}|HiroakiShimizu{SHIMIZUHIROAKI}|KaoruMorita{MORITAKAORU}|YuheiNagao{NAGAOYUHEI}|KatsuhiroShono{SHONOKATSUHIRO}|KenjiKimura{KIMURAKENJI}|ShokichiTsukamoto{TSUKAMOTOSHOKICHI}|YutoShioiri{SHIOIRIYUTO}|TakahideShindo{SHINDOTAKAHIDE}|ChihiroYamamoto{YAMAMOTOCHIHIRO}|KazukiYoshimura{YOSHIMURAKAZUKI}|KojiYamamoto{YAMAMOTOKOJI}|YoshinobuKanda{KANDAYOSHINOBU}|AtsushiJinguji{JINGUJIATSUSHI}|KyokoHaraguchi{HARAGUCHIKYOKO}|TomomiTobai{TOBAITOMOMI}|NorikoDoki{DOKINORIKO}|ShuntaroIkegawa{IKEGAWASHUNTARO}|TsubasaAndo{ANDOTSUBASA}|AyaKomura{KOMURAAYA}|ToshihiroIsami{ISAMITOSHIHIRO}|YusukeInoue{INOUEYUSUKE}|TakumiKondo{KONDOTAKUMI}|HideakiFujiwara{FUJIWARAHIDEAKI}|KeikoFujii{FUJIIKEIKO}|DaisukeEnnishi{ENNISHIDAISUKE}|NobuharuFujii{FUJIINOBUHARU}|YoshinobuMaeda{MAEDAYOSHINOBU}____Oral Session 1-13BTransplant Outcomes 2____Impact of allogeneic HSCT on survival in AML with mutated TP53: analysis from the WT1-AM-04 study|PTCy-based haploidentical transplantation versus cord blood transplantation in MRD-positive AML|Clinical significance of post-transplant maintenance therapy in FLT3 mutation-negative AML|Comparison of PTCy and steroid + low dose ATG as GVHD Prophylaxis for haploidentical HSCT|Rapid monocyte recovery may contribute to graft-versus-tumor effects in PTCy-haplo PBSCT

O1-13B

Oral Session 1-13B
Transplant Outcomes 2

Chair：Souichi Shiratori

SouichiShiratori{SHIRATORISOUICHI}|ToruMiyajima{MIYAJIMATORU}|AtsushiUehara{UEHARAATSUSHI}|AyakoYamamori{YAMAMORIAYAKO}|AyakoTakarada{TAKARADAAYAKO}____RyoHanajiri{HANAJIRIRYO}____KimikazuYakushijin{YAKUSHIJINKIMIKAZU}|HiroyaIchikawa{ICHIKAWAHIROYA}|KyokoMasuda{MASUDAKYOKO}|ReoTanoshima{TANOSHIMAREO}|HirotoshiSakaguchi{SAKAGUCHIHIROTOSHI}|HidekiNakasone{NAKASONEHIDEKI}|MasatsuguTanaka{TANAKAMASATSUGU}|AtsushiWake{WAKEATSUSHI}|TakahiroFukuda{FUKUDATAKAHIRO}|YutaHasegawa{HASEGAWAYUTA}|NorikoDoki{DOKINORIKO}|ShuichiOta{OTASHUICHI}|MasashiSawa{SAWAMASASHI}|MamikoSakata-Yanagimoto{SAKATA-YANAGIMOTOMAMIKO}|MakiHagihara{HAGIHARAMAKI}|JunyaKanda{KANDAJUNYA}|YoshikoAtsuta{ATSUTAYOSHIKO}|TakanoriTeshima{TESHIMATAKANORI}|DaigoHashimoto{HASHIMOTODAIGO}|ShunsukeSugimura{SUGIMURASHUNSUKE}|AsakoMoriki{MORIKIASAKO}|KeisukeKojima{KOJIMAKEISUKE}|ShihoriTsukamoto{TSUKAMOTOSHIHORI}|TomoeIchiki{ICHIKITOMOE}|YumikaSaito{SAITOYUMIKA}|WenyuLi{LIWENYU}|ZixuanZhang{ZHANGZIXUAN}|ShinpeiHarada{HARADASHINPEI}|HajimeSenjo{SENJOHAJIME}|YukiYokoi{YOKOIYUKI}|HiroyukiOhigashi{OHIGASHIHIROYUKI}|TakahideAra{ARATAKAHIDE}|KiminoriNakamura{NAKAMURAKIMINORI}|KojiTaniguchi{TANIGUCHIKOJI}|NaoyaFukuda{FUKUDANAOYA}|HajimeSakuma{SAKUMAHAJIME}|KazukiNagao{NAGAOKAZUKI}|DaichiTerunuma{TERUNUMADAICHI}|KosukeShima{SHIMAKOSUKE}|MasanoriToho{TOHOMASANORI}|KentaroNarita{NARITAKENTARO}|MasamiTakeuchi{TAKEUCHIMASAMI}|TomoSuzuki{SUZUKITOMO}|KoseiMatsue{MATSUEKOSEI}|HidekiMuramatsu{MURAMATSUHIDEKI}|TaroFukuda{FUKUDATARO}|ToruHiguchi{HIGUCHITORU}|TakashiTamaki{TAMAKITAKASHI}|KotaroOgawa{OGAWAKOTARO}|DaikiYamashita{YAMASHITADAIKI}|DaichiSajiki{SAJIKIDAICHI}|KotaroNarita{NARITAKOTARO}|ShinsukeKataoka{KATAOKASHINSUKE}|SanaeIto{ITOSANAE}|YoshiyukiTakahashi{TAKAHASHIYOSHIYUKI}|NaokiKurita{KURITANAOKI}|RyotaIshii{ISHIIRYOTA}|FumiakiMatsumura{MATSUMURAFUMIAKI}|KenichiMakishima{MAKISHIMAKENICHI}|SakurakoSuma{SUMASAKURAKO}|YusukeKiyoki{KIYOKIYUSUKE}|YasuhitoSuehara{SUEHARAYASUHITO}|KeiichiroHattori{HATTORIKEIICHIRO}|TatsuhiroSakamoto{SAKAMOTOTATSUHIRO}|TakayasuKato{KATOTAKAYASU}|NaoshiObara{OBARANAOSHI}|ShigeruChiba{CHIBASHIGERU}|HidekazuNishikii{NISHIKIIHIDEKAZU}____Oral Session 1-13CHCT: Complications 1____Nationwide survey of defibrotide for sinusoidal obstruction syndrome after allo-HSCT|p300/CBP is a key epigenetic driver of GVHD-induced inflammatory memory in intestinal stem cells|Renal thrombotic microangiopathy after allogeneic transplantation with macrophage infiltration|Secondary tumors in pediatric acquired bone marrow failure syndromes: a single-center cohort study|Factors associated with increased medical costs in allogeneic HSCT: a retrospective study

O1-13C

Oral Session 1-13C
HCT: Complications 1

Chair：Ryo Hanajiri

KohtaMiyawaki{MIYAWAKIKOHTA}|YoshihiroInamoto{INAMOTOYOSHIHIRO}|YuichiMitani{MITANIYUICHI}|YutaHasegawa{HASEGAWAYUTA}|TatsunoriGoto{GOTOTATSUNORI}____HirotoshiSakaguchi{SAKAGUCHIHIROTOSHI}____TakeshiSugio{SUGIOTAKESHI}|KensukeSasaki{SASAKIKENSUKE}|YasuoMori{MORIYASUO}|KoichiAkashi{AKASHIKOICHI}|YoshikaneKikushige{KIKUSHIGEYOSHIKANE}|KojiKato{KATOKOJI}|NorikoDoki{DOKINORIKO}|TatsuoIchinohe{ICHINOHETATSUO}|YoshiakiOgawa{OGAWAYOSHIAKI}|ShigeoFuji{FUJISHIGEO}|TatsunoriGoto{GOTOTATSUNORI}|TadakazuKondo{KONDOTADAKAZU}|ToshiroKawakita{KAWAKITATOSHIRO}|KoichiOnodera{ONODERAKOICHI}|KojiSuzuki{SUZUKIKOJI}|DaisukeTomizawa{TOMIZAWADAISUKE}|KatsuyoshiKoh{KOHKATSUYOSHI}|ShintaroOno{ONOSHINTARO}|KenzoKinami{KINAMIKENZO}|ChuanTian{TIANCHUAN}|HideakiFujiwara{FUJIWARAHIDEAKI}|HirotoshiSakaguchi{SAKAGUCHIHIROTOSHI}|TakahiroKamiya{KAMIYATAKAHIRO}|KyogoSuzuki{SUZUKIKYOGO}|MihoAshiarai{ASHIARAIMIHO}|MaikoShimomura{SHIMOMURAMAIKO}|NaoYoshida{YOSHIDANAO}|AkihiroIguchi{IGUCHIAKIHIRO}|YoshikoHashii{HASHIIYOSHIKO}|TakuroNishikawa{NISHIKAWATAKURO}|KanaWashio{WASHIOKANA}|RitsuoNishiuchi{NISHIUCHIRITSUO}|KatsutsuguUmeda{UMEDAKATSUTSUGU}|DaigoHashimoto{HASHIMOTODAIGO}|ShunsukeSugimura{SUGIMURASHUNSUKE}|AsakoMoriki{MORIKIASAKO}|KeisukeKojima{KOJIMAKEISUKE}|ShihoriTsukamoto{TSUKAMOTOSHIHORI}|ZixuanZhang{ZHANGZIXUAN}|WenyuLi{LIWENYU}|AsaeIchiki{ICHIKIASAE}|YumikaSaito{SAITOYUMIKA}|ToruMiyajima{MIYAJIMATORU}|TakahideAra{ARATAKAHIDE}|TakanoriTeshima{TESHIMATAKANORI}|YukaYamamori{YAMAMORIYUKA}|HirokoOtsuji{OTSUJIHIROKO}|SotaTani{TANISOTA}|TomohiroYamada{YAMADATOMOHIRO}|AtsushiKubo{KUBOATSUSHI}|HarunobuTahara{TAHARAHARUNOBU}|NorieNakatani{NAKATANINORIE}|ChikaGoto{GOTOCHIKA}|MikaMorishita{MORISHITAMIKA}|RyoMaemura{MAEMURARYO}|YusukeKagaya{KAGAYAYUSUKE}|AsahitoHama{HAMAASAHITO}|TetsuyaNishida{NISHIDATETSUYA}____Oral Session 1-13DHCT: Complications 2 (GVHD)____Mucosal immune multiome reveals immunopathology and outcome of acute gut GVHD|Efficacy and safety of axatilimab in Japanese patients with chronic graft-versus-host disease|Real-world outcomes of haplo-HCT with PTCy for pediatric hematological malignancies in Japan|Serum MMP-7 as a specific early biomarker for hepatic graft-versus-host disease|Extracorporeal photopheresis shows activity in joint/fascia and skin in long-standing chronic GVHD

O1-13D

Oral Session 1-13D
HCT: Complications 2 (GVHD)

Chair：Hirotoshi Sakaguchi

－|JiyuanLiao{LIAOJIYUAN}|AkiraKatsumi{KATSUMIAKIRA}|MasahiroKobayashi{KOBAYASHIMASAHIRO}____HirokiKato{KATOHIROKI}____YasushiSoda{SODAYASUSHI}|KiyoshiYamaguchi{YAMAGUCHIKIYOSHI}|NaokazuNakamura{NAKAMURANAOKAZU}|KazuoOgami{OGAMIKAZUO}|ShikikoUeno{UENOSHIKIKO}|YukageKobari{KOBARIYUKAGE}|YukihikoHirai{HIRAIYUKIHIKO}|ToshikiMushino{MUSHINOTOSHIKI}|NobuyoshiHanaoka{HANAOKANOBUYOSHI}|TakashiSonoki{SONOKITAKASHI}|TatsuyaKawaguchi{KAWAGUCHITATSUYA}|YoichiFurukawa{FURUKAWAYOICHI}|TakashiOkada{OKADATAKASHI}|KenzaburoTani{TANIKENZABURO}|YuyaAsanomi{ASANOMIYUYA}|RisaMitsumori{MITSUMORIRISA}|YoshihitoSakai{SAKAIYOSHIHITO}|SoichiYoshiyama{YOSHIYAMASOICHI}|ShogoTamura{TAMURASHOGO}|KouichiOzaki{OZAKIKOUICHI}|JunTakai{TAKAIJUN}|ReonKanazawa{KANAZAWAREON}|YuyaTanaka{TANAKAYUYA}|KeitaKanba{KANBAKEITA}|YokoOkitsu{OKITSUYOKO}|SatoshiIchikawa{ICHIKAWASATOSHI}|JunichiKameoka{KAMEOKAJUNICHI}|TomonoriIshii{ISHIITOMONORI}____Oral Session 1-14ARBC: Basic____Withdrawn|Analysis of genetic alterations associated with hematopoietic dysfunction in PNH|Genome-wide association study of red cell distribution width|Heme represses non-erythroid programs via H3K27me3 and induces ferroptosis protection

O1-14A

Oral Session 1-14A
RBC: Basic

Chair：Hiroki Kato

YutakaShimazu{SHIMAZUYUTAKA}|MachikoFujioka{FUJIOKAMACHIKO}|YuKimizuka{KIMIZUKAYU}|TatsuhiroSakamoto{SAKAMOTOTATSUHIRO}|YoshikiOkuno{OKUNOYOSHIKI}____ToruKawakami{KAWAKAMITORU}____KayokoMizuno{MIZUNOKAYOKO}|ToshikiFukasawa{FUKASAWATOSHIKI}|SatoruIto{ITOSATORU}|YukihiroNishio{NISHIOYUKIHIRO}|MamiShimizu{SHIMIZUMAMI}|KojiKawakami{KAWAKAMIKOJI}|HidehiroItonaga{ITONAGAHIDEHIRO}|AkikoNagano{NAGANOAKIKO}|MikiHashimoto{HASHIMOTOMIKI}|TakafumiFurumoto{FURUMOTOTAKAFUMI}|MasamitsuIchinose{ICHINOSEMASAMITSU}|RenaKamijo{KAMIJORENA}|JunyaMakiyama{MAKIYAMAJUNYA}|AsukaUmemura{UMEMURAASUKA}|AkikoNonoshita{NONOSHITAAKIKO}|YuichiFukuda{FUKUDAYUICHI}|YasushiObase{OBASEYASUSHI}|Koh-IchiroYoshiura{YOSHIURAKOH-ICHIRO}|YukiyoshiMoriuchi{MORIUCHIYUKIYOSHI}|KojiAndo{ANDOKOJI}|DaiKeino{KEINODAI}|ToshiyukiYamamoto{YAMAMOTOTOSHIYUKI}|KeikoYamamoto{YAMAMOTOKEIKO}|HitoshiKanno{KANNOHITOSHI}|YukikoKuroda{KURODAYUKIKO}|TakashiKiyama{KIYAMATAKASHI}|AkitoKawachi{KAWACHIAKITO}|EriHirota{HIROTAERI}|NaotoWakui{WAKUINAOTO}|TomoyaIrikura{IRIKURATOMOYA}|SatoshiYoshimura{YOSHIMURASATOSHI}|AkikoHayashi{HAYASHIAKIKO}|TomokoYokosuka{YOKOSUKATOMOKO}|FuminoriIwasaki{IWASAKIFUMINORI}|HiroakiGoto{GOTOHIROAKI}|MasakatsuYanagimachi{YANAGIMACHIMASAKATSU}|NaoshiObara{OBARANAOSHI}|FumiakiMatsumura{MATSUMURAFUMIAKI}|KenichiMakishima{MAKISHIMAKENICHI}|SakurakoSuma{SUMASAKURAKO}|YusukeKiyoki{KIYOKIYUSUKE}|YasuhitoSuehara{SUEHARAYASUHITO}|KeiichiroHattori{HATTORIKEIICHIRO}|TakayasuKato{KATOTAKAYASU}|NaokiKurita{KURITANAOKI}|HidekazuNishikii{NISHIKIIHIDEKAZU}|MamikoSakata-Yanagimoto{SAKATA-YANAGIMOTOMAMIKO}|HaruyukiFujita{FUJITAHARUYUKI}|GoichiTatsumi{TATSUMIGOICHI}|TomomiSakai{SAKAITOMOMI}|HiroshiKawabata{KAWABATAHIROSHI}____Oral Session 1-14BBone Marrow Failure____Safety and effectiveness of TPO-RAs in aplastic anemia using hospital administrative databases|Poikiloderma with neutropenia associated with a novel homozygous variant in the USB1 gene|Novel KIF23 variant in CDA type III with neonatal-onset transfusion dependence in a male infant|HIF-PH inhibitors in patients with PNH and renal anemia; A single-center experience|A single-center retrospective study of 20 cases with acquired red cell aplasia

O1-14B

Oral Session 1-14B
Bone Marrow Failure

Chair：Toru Kawakami

MakikoMochizuki{MOCHIZUKIMAKIKO}|KhulanTuvshinjargal{TUVSHINJARGALKHULAN}|MioNakanishi{NAKANISHIMIO}|MisakiHada{HADAMISAKI}|MarikoTsuruda{TSURUDAMARIKO}____YoshihiroHayashi{HAYASHIYOSHIHIRO}____AyakoIshizu{ISHIZUAYAKO}|YukoKawano{KAWANOYUKO}|YosukeTanaka{TANAKAYOSUKE}|SatoshiYamazaki{YAMAZAKISATOSHI}|YoshinobuKonishi{KONISHIYOSHINOBU}|KotaroSuzuki{SUZUKIKOTARO}|AsamiKataoka{KATAOKAASAMI}|KenichiIshiyama{ISHIYAMAKENICHI}|MasatoshiIkeda{IKEDAMASATOSHI}|KotaroShirakawa{SHIRAKAWAKOTARO}|AkifumiTakaori-Kondo{TAKAORI-KONDOAKIFUMI}|SaoriMorino-Koga{MORINO-KOGASAORI}|TomomasaYokomizo{YOKOMIZOTOMOMASA}|ShingoUsuki{USUKISHINGO}|KeiichiroYasunaga{YASUNAGAKEIICHIRO}|SayokoFujimura{FUJIMURASAYOKO}|MinetaroOgawa{OGAWAMINETARO}____Oral Session 1-14CHematopoietic Microenvironment 1____FANCD2 regulates fetal liver hematopoietic stem cell in a cell-intrinsic and extrinsic manner|Bone marrow stromal Plxdc2 is critical mediator of inflammatory signal for hematopoietic stem cells|A hematopoietic organoid model of the human fetal liver niche for HSPC maturation|Spatial analysis platform for bone marrow microenvironment via imaging mass cytometry|BMP and endothelial microenvironment signals support HSC induction from hemogenic endothelial cells

O1-14C

Oral Session 1-14C
Hematopoietic Microenvironment 1

Chair：Yoshihiro Hayashi

HarukaSuzuki{SUZUKIHARUKA}|HinakoNotoh{NOTOHHINAKO}|YasutakaHayashi{HAYASHIYASUTAKA}|TsubasaSano{SANOTSUBASA}|AkifumiMastumura{MASTUMURAAKIFUMI}____ErikoNitta{NITTAERIKO}____HirokiMiyachi{MIYACHIHIROKI}|HirokiNishikawa{NISHIKAWAHIROKI}|HiromiEndoh{ENDOHHIROMI}|NatsukaYamada{YAMADANATSUKA}|ShuheiKuno{KUNOSHUHEI}|ShunUemura{UEMURASHUN}|AtsushiIwama{IWAMAATSUSHI}|RyoNitta{NITTARYO}|ErikoNitta{NITTAERIKO}|KohaneTada{TADAKOHANE}|KanonWada{WADAKANON}|NobuakiSuzuki{SUZUKINOBUAKI}|AtsuoSuzuki{SUZUKIATSUO}|ShuichiOkamoto{OKAMOTOSHUICHI}|TakeshiKanematsu{KANEMATSUTAKESHI}|AkiraKatsumi{KATSUMIAKIRA}|TetsuhitoKojima{KOJIMATETSUHITO}|TadashiMatsushita{MATSUSHITATADASHI}|ShogoTamura{TAMURASHOGO}|ShioriShikata{SHIKATASHIORI}|SusumuGoyama{GOYAMASUSUMU}|TeppeiShimamura{SHIMAMURATEPPEI}|NadineLow{LOWNADINE}|TakaoYogo{YOGOTAKAO}|FelicitasGuth{GUTHFELICITAS}|SatoshiYamazaki{YAMAZAKISATOSHI}|YayoiUeda{UEDAYAYOI}|TakashiMoriyama{MORIYAMATAKASHI}|WataruKitamura{KITAMURAWATARU}|MasayaAbe{ABEMASAYA}|TakumiKondou{KONDOUTAKUMI}|KeisukeSeike{SEIKEKEISUKE}|SyunntarouIkegawa{IKEGAWASYUNNTAROU}|HideakiFujiwara{FUJIWARAHIDEAKI}|DaisukeEnnishi{ENNISHIDAISUKE}|NobuharuFujii{FUJIINOBUHARU}|YoshinobuMaeda{MAEDAYOSHINOBU}|NoboruAsada{ASADANOBORU}____Oral Session 1-14DHematopoietic Microenvironment 2____BRM broadly regulates multiple bone marrow niche cell populations to suppress hematopoietic aging|Cellular property of BM-MSC affects a formation efficiency of subcutaneous neo-bone marrow|Development of a co-culture based system for screening microenvironmental regulators|Reversible control of hematopoietic stem cell fate by synthetic polymer microenvironments|Analysis of the effects of iron overload on the bone marrow microenvironment

O1-14D

Oral Session 1-14D
Hematopoietic Microenvironment 2

Chair：Eriko Nitta

YanyiTao{TAOYANYI}|TomsonKosasih{KOSASIHTOMSON}|ShotaroShirato{SHIRATOSHOTARO}|MasaoItahara{ITAHARAMASAO}|CedricHermans{HERMANSCEDRIC}____FumioNakahara{NAKAHARAFUMIO}____HuiLu{LUHUI}|YuHu{HUYU}|LiangVTang{TANGLIANGV}|TatsuyaMorishima{MORISHIMATATSUYA}|SohyeonLee{LEESOHYEON}|JungyeonYoon{YOONJUNGYEON}|KanakoWakahashi{WAKAHASHIKANAKO}|PilhanKim{KIMPILHAN}|AikoSada{SADAAIKO}|HitoshiTakizawa{TAKIZAWAHITOSHI}|IppeiIkegami{IKEGAMIIPPEI}|AyumiTatekoshi{TATEKOSHIAYUMI}|HirotoHoriguchi{HORIGUCHIHIROTO}|SatoshiIyama{IYAMASATOSHI}|TakashiSasaki{SASAKITAKASHI}|ShingoIchimiya{ICHIMIYASHINGO}|MasayoshiKobune{KOBUNEMASAYOSHI}|KyokoMasuda{MASUDAKYOKO}|KojiTerada{TERADAKOJI}|YumaKato{KATOYUMA}|YasutoshiAgata{AGATAYASUTOSHI}|HisashiArase{ARASEHISASHI}|HiroshiKawamoto{KAWAMOTOHIROSHI}|EmilySymington{SYMINGTONEMILY}|MichaelRecht{RECHTMICHAEL}|GiancarloCastaman{CASTAMANGIANCARLO}|WolfgangMiesbach{MIESBACHWOLFGANG}|SandraLeQuellec{LEQUELLECSANDRA}|NathalieW.D.Jansen{JANSENNATHALIEW.D.}|DouglassDrelich{DRELICHDOUGLASS}|FeiWang{WANGFEI}|StevenW.Pipe{PIPESTEVENW.}____Oral Session 1-15AImmunology/Cell/Gene 1____Sustained correction of hereditary antithrombin deficiency in mice by AAV8-mediated gene delivery|Skin-derived G-CSF activates pathological granulopoiesis upon psoriasis|Bob1+ T follicular helper cells support intestinal immunity via IgA production|Prevention of NK cell-mediated rejection by using membrane bound mAbs for inhibitory NK receptors|Durable efficacy and safety in responders from the phase 3 HOPE-B trial of etranacogene dezaparvovec

O1-15A

Oral Session 1-15A
Immunology/Cell/Gene 1

Chair：Fumio Nakahara

YasuyukiArai{ARAIYASUYUKI}|KazutoOmae{OMAEKAZUTO}|NanamiKato{KATONANAMI}|KentaroYamaguchi{YAMAGUCHIKENTARO}|YutaSuzuki{SUZUKIYUTA}____RieYamazaki{YAMAZAKIRIE}____TomoyasuJo{JOTOMOYASU}|ToshioKitawaki{KITAWAKITOSHIO}|NoriyoshiYoshinaga{YOSHINAGANORIYOSHI}|TakashiSakamoto{SAKAMOTOTAKASHI}|JunyaKanda{KANDAJUNYA}|KouheiYamashita{YAMASHITAKOUHEI}|MikiNagao{NAGAOMIKI}|AkifumiTakaoriKondo{TAKAORIKONDOAKIFUMI}|TakuyaNakakura{NAKAKURATAKUYA}|RyosukeHarakawa{HARAKAWARYOSUKE}|MasahitoKatsuki{KATSUKIMASAHITO}|MasahiroIwahashi{IWAHASHIMASAHIRO}|KenkiSaito{SAITOKENKI}|HidekazuAzumi{AZUMIHIDEKAZU}|KazuyaSakai{SAKAIKAZUYA}|MasanoriMatsumoto{MATSUMOTOMASANORI}|TakuyaShiotani{SHIOTANITAKUYA}|KazukiSuzuki{SUZUKIKAZUKI}|ShuolinWang{WANGSHUOLIN}|EmikoKashima{KASHIMAEMIKO}|LinanWang{WANGLINAN}|IsaoTawara{TAWARAISAO}|KyokoMasuda{MASUDAKYOKO}|TakahideShindo{SHINDOTAKAHIDE}|JunjiKoya{KOYAJUNJI}|YuyaKoda{KODAYUYA}|MasatoshiSakurai{SAKURAIMASATOSHI}|EriMatsuki{MATSUKIERI}|RisaInagaki{INAGAKIRISA}|NoriyukiHirabayashi{HIRABAYASHINORIYUKI}|RuiKuroda{KURODARUI}|YasukoKuwahara{KUWAHARAYASUKO}|HirokoMatsuhashi{MATSUHASHIHIROKO}|YasuhiroIgarashi{IGARASHIYASUHIRO}|KeisukeKataoka{KATAOKAKEISUKE}|RieYamazaki{YAMAZAKIRIE}|YasuyukiArai{ARAIYASUYUKI}|HiroyukiMatsui{MATSUIHIROYUKI}|MomokoNishikori{NISHIKORIMOMOKO}|AkifumiTakaori-Kondo{TAKAORI-KONDOAKIFUMI}____Oral Session 1-15BImmunology/Cell/Gene 2____Financial effects of CAR-T|Machine learning-based detection of anti-CD38-mediated interference in RBC antibody screening|Suppressive of established tumors by adoptive transfer of Treg-depleted T cells|Inlet flow dynamics associated with collection efficiency in leukapheresis for CAR-T therapy|Single-center analysis of idecabtagene vicleucel (ide-cel) for relapsed/refractory multiple myeloma

O1-15B

Oral Session 1-15B
Immunology/Cell/Gene 2

Chair：Rie Yamazaki

MakikoSuga{SUGAMAKIKO}|LanyuMa{MALANYU}|EmikoKashima{KASHIMAEMIKO}|KenOhmine{OHMINEKEN}____HarukoTashiro{TASHIROHARUKO}____ShuheiKida{KIDASHUHEI}|YoMizutani{MIZUTANIYO}|YutaYamaguchi{YAMAGUCHIYUTA}|NaokiHosen{HOSENNAOKI}|ToshioKitawaki{KITAWAKITOSHIO}|TakayaMitsuyoshi{MITSUYOSHITAKAYA}|KazunariAoki{AOKIKAZUNARI}|KenichiIshiyama{ISHIYAMAKENICHI}|KosukeYusa{YUSAKOSUKE}|AkifumiTakaori-Kondo{TAKAORI-KONDOAKIFUMI}|LinanWang{WANGLINAN}|YasushiAkahori{AKAHORIYASUSHI}|HiroshiFujiwara{FUJIWARAHIROSHI}|YoshihiroMiyahara{MIYAHARAYOSHIHIRO}|IsaoTawara{TAWARAISAO}|RyosukeUchibori{UCHIBORIRYOSUKE}|HirokoHayakawa{HAYAKAWAHIROKO}|NorikazuTakatama{TAKATAMANORIKAZU}|EtsukoOgawa{OGAWAETSUKO}|KazuyaSato{SATOKAZUYA}|Sin-IchiroFujiwara{FUJIWARASIN-ICHIRO}|AkihiroKume{KUMEAKIHIRO}|MakiTanaka{TANAKAMAKI}|YoshinobuKanda{KANDAYOSHINOBU}|KeiyaOzawa{OZAWAKEIYA}____Oral Session 1-15CCAR T Cell Therapy: Basic 1____Cord blood NK cells with a high-affinity CLL-1 CAR eliminate CLL-1-low AML cells|CRISPR screen identifies LUBAC as a key regulator of tumor sensitivity to CAR-T cells in LBCL|HLA-A24-restricted PRAME-specific hybrid TCR-T cells for AML immunotherapy|Antitumor efficacy of SRG-engineered CAR-T cells in a subcutaneous lymphoma model

O1-15C

Oral Session 1-15C
CAR T Cell Therapy: Basic 1

Chair：Haruko Tashiro

KeisukeKirito{KIRITOKEISUKE}|ShintaroKinoshita{KINOSHITASHINTARO}|JunichiKato{KATOJUNICHI}|RyosukeUchibori{UCHIBORIRYOSUKE}|TakayaMitsuyoshi{MITSUYOSHITAKAYA}____YozoNakazawa{NAKAZAWAYOZO}____AkihiroNakajima{NAKAJIMAAKIHIRO}|GaiMatsumura{MATSUMURAGAI}|SouNakamura{NAKAMURASOU}|MariaAlejandraKanashiro{KANASHIROMARIAALEJANDRA}|SudipKumarPaul{PAULSUDIPKUMAR}|SiJingChen{CHENSIJING}|ShokichiTsukamoto{TSUKAMOTOSHOKICHI}|YusukeTakeda{TAKEDAYUSUKE}|NaoyaMimura{MIMURANAOYA}|KojiEto{ETOKOJI}|EmikoSakaida{SAKAIDAEMIKO}|NaoyaTakayama{TAKAYAMANAOYA}|KyoheiMaruyama{MARUYAMAKYOHEI}|KosukeMatsuzaki{MATSUZAKIKOSUKE}|KensukeYanashima{YANASHIMAKENSUKE}|YoshikiFurukawa{FURUKAWAYOSHIKI}|JunAndo{ANDOJUN}|MikiAndo{ANDOMIKI}|ToshikiOchi{OCHITOSHIKI}|TatsuyaKonishi{KONISHITATSUYA}|MasakiMaruta{MARUTAMASAKI}|ShogoNabe{NABESHOGO}|YuyaMasuda{MASUDAYUYA}|YukihiroMiyazaki{MIYAZAKIYUKIHIRO}|JunYamanouchi{YAMANOUCHIJUN}|KatsutoTakenaka{TAKENAKAKATSUTO}|KenOhmine{OHMINEKEN}|KeiyaOzawa{OZAWAKEIYA}|TsukasaOhmori{OHMORITSUKASA}|ToshioKitawaki{KITAWAKITOSHIO}|TomokiIemura{IEMURATOMOKI}|KenichiIshiyama{ISHIYAMAKENICHI}|MomokoNishikori{NISHIKORIMOMOKO}|AkifumiTakaori-Kondo{TAKAORI-KONDOAKIFUMI}____Oral Session 1-15DCAR T Cell Therapy: Basic 2____Generation of M1-polarized iPSC derived immortalized chimeric antigen receptor macrophage|Dual modulation of GD2 expression on ENKL cells and GD2-CART memory phenotype by EZH1/2 inhibition|Adjustable T-cell redirection therapy via chimeric activation to target immune-resistant lymphoma|EPO-induced in vivo expansion enhances antitumor efficacy of short-term-cultured SRG-CAR-T cells|CCR4-coexpressing CAR T cells in combination with tazemetostat enhance therapeutic efficacy for LBCL

O1-15D

Oral Session 1-15D
CAR T Cell Therapy: Basic 2

Chair：Yozo Nakazawa

JunichiHashiguchi{HASHIGUCHIJUNICHI}|MasanoriToho{TOHOMASANORI}|TakuTsukamoto{TSUKAMOTOTAKU}|KohIzumiyama{IZUMIYAMAKOH}____YasuyukiNagata{NAGATAYASUYUKI}____KohIzumiyama{IZUMIYAMAKOH}|KosukeMiki{MIKIKOSUKE}|TsuyoshiSato{SATOTSUYOSHI}|NaokiMiyashita{MIYASHITANAOKI}|HajimeSenjo{SENJOHAJIME}|TakutoTachita{TACHITATAKUTO}|ShuichiroTakahashi{TAKAHASHISHUICHIRO}|MasayoYamamoto{YAMAMOTOMASAYO}|TetsuyukiIgarashi{IGARASHITETSUYUKI}|TomoyukiSaga{SAGATOMOYUKI}|KoEbata{EBATAKO}|SatoshiIto{ITOSATOSHI}|HirotoHoriguchi{HORIGUCHIHIROTO}|KoheiOkada{OKADAKOHEI}|KentaroWakasa{WAKASAKENTARO}|HidekiGoto{GOTOHIDEKI}|MutsumiTakahata{TAKAHATAMUTSUMI}|TatsuoOyake{OYAKETATSUO}|SatoshiYamamoto{YAMAMOTOSATOSHI}|KatsuyaFujimoto{FUJIMOTOKATSUYA}|YoshihitoHaseyama{HASEYAMAYOSHIHITO}|KazuyaSato{SATOKAZUYA}|ToshiakiHayashi{HAYASHITOSHIAKI}|KazunoriMurai{MURAIKAZUNORI}|TakanoriTeshima{TESHIMATAKANORI}|NaoyaFukuda{FUKUDANAOYA}|KosukeShima{SHIMAKOSUKE}|KazukiNagao{NAGAOKAZUKI}|HajimeSakuma{SAKUMAHAJIME}|AtsushiUehara{UEHARAATSUSHI}|KentaroNarita{NARITAKENTARO}|MasamiTakeuchi{TAKEUCHIMASAMI}|KoseiMatsue{MATSUEKOSEI}|YujiShimura{SHIMURAYUJI}|ShinsukeMizutani{MIZUTANISHINSUKE}|TakahiroFujino{FUJINOTAKAHIRO}|HaruyaOkamoto{OKAMOTOHARUYA}|MitsuhiroItagaki{ITAGAKIMITSUHIRO}|HiroshiHanda{HANDAHIROSHI}|TakayukiShimizu{SHIMIZUTAKAYUKI}|MorioSawamura{SAWAMURAMORIO}|TadaoIshida{ISHIDATADAO}|SatoruKosugi{KOSUGISATORU}|ShuichiOta{OTASHUICHI}|MakotoYoshimitsu{YOSHIMITSUMAKOTO}|YutakaShimazu{SHIMAZUYUTAKA}|IsamuSugiura{SUGIURAISAMU}|HirohikoShibayama{SHIBAYAMAHIROHIKO}|Shin-IchiFuchida{FUCHIDASHIN-ICHI}|HiroyukiTakamatsu{TAKAMATSUHIROYUKI}|AkikoSaito{SAITOAKIKO}|HitoshiKiyoi{KIYOIHITOSHI}|KoichiAkashi{AKASHIKOICHI}|ItaruMatsumura{MATSUMURAITARU}|AkifumiTakaori-Kondo{TAKAORI-KONDOAKIFUMI}|JunyaKuroda{KURODAJUNYA}|ShinsukeIida{IIDASHINSUKE}|RikakoTabata{TABATARIKAKO}|DaisukeIkeda{IKEDADAISUKE}|DaichiTerunuma{TERUNUMADAICHI}|JunichiHashiguchi{HASHIGUCHIJUNICHI}____Oral Session 1-16AMultiple Myeloma Clinical Research for Biomarkers____Impact of concurrent gain(1q)/del(17p) on the prognosis of IGH::CCND1-positive multiple myeloma|Functional 1p-CTC and 1q-BCMA pathways for risk stratification in multiple myeloma|Distinct clinical features of multiple myeloma with t(11;14): a post hoc analysis of JSH-MM-15 study|Integrating sBCMA and physical burden defines phenotypes in multiple myeloma|Discrepancy between immunoelectrophoresis negativity and 90% M-protein reduction in multiple myeloma

O1-16A

Oral Session 1-16A
Multiple Myeloma Clinical Research for Biomarkers

Chair：Yasuyuki Nagata

TomoakiFujisaki{FUJISAKITOMOAKI}|ShigekiIto{ITOSHIGEKI}|KazuhitoSuzuki{SUZUKIKAZUHITO}____YoichiImai{IMAIYOICHI}____VaniaHungria{HUNGRIAVANIA}|MarekHus{HUSMAREK}|VeraZherebtsova{ZHEREBTSOVAVERA}|ChristopherWard{WARDCHRISTOPHER}|PJoyHo{HOPJOY}|AngeloMaiolino{MAIOLINOANGELO}|RomanHajek{HAJEKROMAN}|KihyunKim{KIMKIHYUN}|HanlonSia{SIAHANLON}|AdamBryant{BRYANTADAM}|MarceloPitombeira{PITOMBEIRAMARCELO}|AnnaMariaSuredaBalari{BALARIANNAMARIASUREDA}|BengaKazeem{KAZEEMBENGA}|HenaBaig{BAIGHENA}|NickPirooz{PIROOZNICK}|SybilVarghese{VARGHESESYBIL}|JoeLee{LEEJOE}|PawelRobak{ROBAKPAWEL}|Maria-VictoriaMateos{MATEOSMARIA-VICTORIA}|SuzanneTrudel{TRUDELSUZANNE}|GuldaneCengiz{CENGIZGULDANE}|SosanaDelimpasi{DELIMPASISOSANA}|VladimirVorobyev{VOROBYEVVLADIMIR}|HangQuach{QUACHHANG}|IvanSpicka{SPICKAIVAN}|JakubRadocha{RADOCHAJAKUB}|YoungilKoh{KOHYOUNGIL}|FelipeDeArribaDeLaFuente{FUENTEFELIPEDEARRIBADELA}|EstherGonzalezGarcia{GARCIAESTHERGONZALEZ}|SilviaMangiacavalli{MANGIACAVALLISILVIA}|MargaretPolinkovsky{POLINKOVSKYMARGARET}|JieMa{MAJIE}|KellyBrock{BROCKKELLY}|JoannaGrams{GRAMSJOANNA}|ElisabetE.Manasanch{MANASANCHELISABETE.}|MeletiosA.Dimopoulos{DIMOPOULOSMELETIOSA.}|MeralBeksac{BEKSACMERAL}|EstherGonzalez-Garcia{GONZALEZ-GARCIAESTHER}|KamarajKarunanithi{KARUNANITHIKAMARAJ}|SergeyVoloshin{VOLOSHINSERGEY}|UriiOsipov{OSIPOVURII}|SyedF.Zafar{F.ZAFARSYED}|XinDu{DUXIN}|ElisabetManasanch{MANASANCHELISABET}|TadeuszRobak{ROBAKTADEUSZ}|PelinAytan{AYTANPELIN}|ElenaZagmani{ZAGMANIELENA}|MarieDuggan{DUGGANMARIE}|ElisabetEManasanch{MANASANCHELISABETE}|MeletiosADimopoulos{DIMOPOULOSMELETIOSA}|MicheleCavo{CAVOMICHELE}|SyedZafar{ZAFARSYED}|AinsleeMoore{MOOREAINSLEE}|KristinMorris{MORRISKRISTIN}____Oral Session 1-16BMultiple Myeloma Clinical Research for Antibody-drug Conjugate____Belantamab mafodotin + bortezomib + dexamethasone (BVd): 4-year update of the phase 3 DREAMM-7 trial|Long-term outcomes with sustained minimal residual disease (MRD) negativity: an update from DREAMM-8|Belantamab mafodotin, pomalidomide, dexamethasone (BPd) as second-line therapy in multiple myeloma|DREAMM-8: PFS2 outcome analysis - belantamab mafodotin (belamaf), pomalidomide, dexamethasone (BPd)|Belantamab mafodotin + pomalidomide + dexamethasone (BPd): DREAMM 8 long term responder analysis

O1-16B

Oral Session 1-16B
Multiple Myeloma Clinical Research for Antibody-drug Conjugate

Chair：Yoichi Imai

MikiKiyota{KIYOTAMIKI}|KeiichiAkizuki{AKIZUKIKEIICHI}|YoshiakiKuroda{KURODAYOSHIAKI}|KodaiKunisada{KUNISADAKODAI}|AsahiInoke{INOKEASAHI}____ShinichiFuchida{FUCHIDASHINICHI}____ShinichiFuchida{FUCHIDASHINICHI}|YukaKanayama{KANAYAMAYUKA}|SaekoOta{OTASAEKO}|ChihiroShimazaki{SHIMAZAKICHIHIRO}|MasaakiSekine{SEKINEMASAAKI}|KengoMatsumoto{MATSUMOTOKENGO}|AyukaKuroki{KUROKIAYUKA}|HiroshiKawano{KAWANOHIROSHI}|TakanoriToyama{TOYAMATAKANORI}|SeiichiSato{SATOSEIICHI}|KoshiroNagamine{NAGAMINEKOSHIRO}|RyomaIkeda{IKEDARYOMA}|MasayoshiKarasawa{KARASAWAMASAYOSHI}|YukiTahira{TAHIRAYUKI}|AyakoKamiunten{KAMIUNTENAYAKO}|TakuroKameda{KAMEDATAKURO}|KotaroShide{SHIDEKOTARO}|YokoKubuki{KUBUKIYOKO}|KazuyaShimoda{SHIMODAKAZUYA}|MitsuhiroItagaki{ITAGAKIMITSUHIRO}|MasayaUebo{UEBOMASAYA}|MichikoKida{KIDAMICHIKO}|TakuyaNunomura{NUNOMURATAKUYA}|TetsuroOchi{OCHITETSURO}|TakeshiOkatani{OKATANITAKESHI}|KoheiKyo{KYOKOHEI}|RyotaImanaka{IMANAKARYOTA}|ShinyaKatsutani{KATSUTANISHINYA}|TsuyoshiMuta{MUTATSUYOSHI}|YutaKatayama{KATAYAMAYUTA}|ChiakiMatsumoto{MATSUMOTOCHIAKI}|YukiaFutenma{FUTENMAYUKIA}|HirotoYamashita{YAMASHITAHIROTO}|HidenoriNakayama{NAKAYAMAHIDENORI}|ShotaroSugita{SUGITASHOTARO}|UkyoKondo{KONDOUKYO}|MoeYogo{YOGOMOE}|TomomiTakei{TAKEITOMOMI}|KotaSato{SATOKOTA}|YuAbe{ABEYU}|TakuKikuchi{KIKUCHITAKU}|OsamuHosoya{HOSOYAOSAMU}|TadaoIshida{ISHIDATADAO}|NobuhiroTsukada{TSUKADANOBUHIRO}|TomokiSuichi{SUICHITOMOKI}|ArataIshii{ISHIIARATA}|ShokichiTsukamoto{TSUKAMOTOSHOKICHI}|ShinichiroMatsui{MATSUISHINICHIRO}|AyakaNishihara{NISHIHARAAYAKA}|ShintaroIzumi{IZUMISHINTARO}|ChihiroRi{RICHIHIRO}|NagisaOshima-Hasegawa{OSHIMA-HASEGAWANAGISA}|YusukeTakeda{TAKEDAYUSUKE}|KazuakiKito{KITOKAZUAKI}|KazumikiShibuya{SHIBUYAKAZUMIKI}|MasahiroMori{MORIMASAHIRO}|NaoyaMimura{MIMURANAOYA}|EmikoSakaida{SAKAIDAEMIKO}|SonokoMisawa{MISAWASONOKO}|SatoshiKuwabara{KUWABARASATOSHI}____Oral Session 1-16CMultiple Myeloma Clinical Research on Plasma Cell Dyscrasia and MM-related Diseases____Retrospective analysis of ASCT vs DBCD as initial therapy for systemic light chain amyloidosis|Clinical characteristics and prognosis of AL amyloidosis in real-world practice in multicenter study|Treatment outcomes of DaraCyBorD therapy in 14 patients with primary AL amyloidosis|Single-center retrospective analysis of ASCT for 123 patients with systemic AL amyloidosis|Clinical features and treatment outcomes of possible POEMS syndrome without detectable M-protein

O1-16C

Oral Session 1-16C
Multiple Myeloma Clinical Research on Plasma Cell Dyscrasia and MM-related Diseases

Chair：Shinichi Fuchida

YukiaFutemma{FUTEMMAYUKIA}|YoshiakiMarumo{MARUMOYOSHIAKI}|KentaroFukushima{FUKUSHIMAKENTARO}|AkihiroKawatsuki{KAWATSUKIAKIHIRO}|FuyukiYamagata{YAMAGATAFUYUKI}____TakuKikuchi{KIKUCHITAKU}____TakuKikuchi{KIKUCHITAKU}|ChiakiMatsumoto{MATSUMOTOCHIAKI}|ShotaroSugita{SUGITASHOTARO}|UkyoKondo{KONDOUKYO}|KodaiKunisada{KUNISADAKODAI}|MoeYogo{YOGOMOE}|TomomiTakei{TAKEITOMOMI}|KotaSato{SATOKOTA}|YuAbe{ABEYU}|OsamuHosoya{HOSOYAOSAMU}|TadaoIshida{ISHIDATADAO}|NobuhiroTsukada{TSUKADANOBUHIRO}|TomoakiUeda{UEDATOMOAKI}|TakashiToya{TOYATAKASHI}|ShinsukeKusakabe{KUSAKABESHINSUKE}|SadaoIshida{ISHIDASADAO}|KentaroFukushima{FUKUSHIMAKENTARO}|ShinsukeIida{IIDASHINSUKE}|KohtaMiyawaki{MIYAWAKIKOHTA}|ToshioKitawaki{KITAWAKITOSHIO}|EmikoSakaida{SAKAIDAEMIKO}|SatoshiYoshihara{YOSHIHARASATOSHI}|YoshinobuKanda{KANDAYOSHINOBU}|NorikoDoki{DOKINORIKO}|YujiShimura{SHIMURAYUJI}|NobuharuFujii{FUJIINOBUHARU}|AkiyoYoshida{YOSHIDAAKIYO}|TomoyasuJo{JOTOMOYASU}|HaryoonKim{KIMHARYOON}|HidekiGoto{GOTOHIDEKI}|YoshikoAtsuta{ATSUTAYOSHIKO}|KojiKato{KATOKOJI}|TeruhitoTakakuwa{TAKAKUWATERUHITO}|TadahikoMatsumoto{MATSUMOTOTADAHIKO}|MasaakiHotta{HOTTAMASAAKI}|KyokoYoshihara{YOSHIHARAKYOKO}|MichikoIchii{ICHIIMICHIKO}|YasuyukiArai{ARAIYASUYUKI}|TakuTsukamoto{TSUKAMOTOTAKU}|AtsushiSatake{SATAKEATSUSHI}|YukoKotera{KOTERAYUKO}|LuisVaz{VAZLUIS}|RyosukeHinosugi{HINOSUGIRYOSUKE}|TomokiIto{ITOTOMOKI}|JunyaKuroda{KURODAJUNYA}|AkifumiTakaori-Kondo{TAKAORI-KONDOAKIFUMI}|MasayukiHino{HINOMASAYUKI}|NaokiHosen{HOSENNAOKI}|ToshikiTerao{TERAOTOSHIKI}|TakeruAsano{ASANOTAKERU}|WataruKitamura{KITAMURAWATARU}|NahoNomura{NOMURANAHO}|KyosukeSaeki{SAEKIKYOSUKE}|YusukeMeguri{MEGURIYUSUKE}|ShojiAsakura{ASAKURASHOJI}|HirokiKobayashi{KOBAYASHIHIROKI}|DaisukeEnnishi{ENNISHIDAISUKE}|YoshinobuMaeda{MAEDAYOSHINOBU}|MadokaMiyazaki{MIYAZAKIMADOKA}|HiroakiAkiyama{AKIYAMAHIROAKI}|YoshiyukiFujita{FUJITAYOSHIYUKI}|TomokoKumamoto{KUMAMOTOTOMOKO}|SakiTakahashi{TAKAHASHISAKI}|AtsushiKatayama{KATAYAMAATSUSHI}|HitomiOnomoto{ONOMOTOHITOMI}|HirokiSugiyama{SUGIYAMAHIROKI}|MasahiroTeramoto{TERAMOTOMASAHIRO}|TakayukiInoue{INOUETAKAYUKI}|KatsujiKaida{KAIDAKATSUJI}|TazukoTokugawa{TOKUGAWATAZUKO}|AkihiroSawada{SAWADAAKIHIRO}|JunkoIkemoto{IKEMOTOJUNKO}|SatoshiHigasa{HIGASASATOSHI}|HiroyaTamaki{TAMAKIHIROYA}____Oral Session 1-16DMultiple Myeloma Clinical Research on Immune Cell Therapy____Real-world outcomes of idecabtagene vicleucel in relapsed/refractory multiple myeloma|Risk model for relapsed/refractory multiple myeloma patients treated with idecabtagene vicleucel|Real-world evidence of idecabtagene vicleucel in triple-class-exposed (TCE) RRMM: KMF registry data|A multicenter retrospective study of bispecific antibody therapy in multiple myeloma|Utility and immunologic effects of bispecific antibody bridging before ide-cel in RRMM

O1-16D

Oral Session 1-16D
Multiple Myeloma Clinical Research on Immune Cell Therapy

Chair：Taku Kikuchi

TakeshiHarada{HARADATAKESHI}|JunzheBai{BAIJUNZHE}|YutoShioiri{SHIOIRIYUTO}|KotaroSuzuki{SUZUKIKOTARO}|YoshiakiMarumo{MARUMOYOSHIAKI}____HirotoOhguchi{OHGUCHIHIROTO}____HirotoOhguchi{OHGUCHIHIROTO}|AsukaOda{ODAASUKA}|YusukeInoue{INOUEYUSUKE}|MasafumiNakamura{NAKAMURAMASAFUMI}|ShiyoriKawata{KAWATASHIYORI}|TaikiHori{HORITAIKI}|YusakuMaeda{MAEDAYUSAKU}|RyoheiSumitani{SUMITANIRYOHEI}|MasahiroOura{OURAMASAHIRO}|KimikoSogabe{SOGABEKIMIKO}|HikaruYagi{YAGIHIKARU}|RisaHashida{HASHIDARISA}|ShiroFujii{FUJIISHIRO}|ShingenNakamura{NAKAMURASHINGEN}|HirokazuMiki{MIKIHIROKAZU}|YasuhiroMouri{MOURIYASUHIRO}|TakaomiSanda{SANDATAKAOMI}|MasahiroAbe{ABEMASAHIRO}|Ken-IchiMatsuoka{MATSUOKAKEN-ICHI}|YawaraKawano{KAWANOYAWARA}|TakeshiMasuda{MASUDATAKESHI}|ShihoFujiwara{FUJIWARASHIHO}|NaoNishimura{NISHIMURANAO}|JunichirouYasunaga{YASUNAGAJUNICHIROU}|NaoyaMimura{MIMURANAOYA}|ReiKato{KATOREI}|TakaakiTanami{TANAMITAKAAKI}|ChihiroRi{RICHIHIRO}|AyakaNishihara{NISHIHARAAYAKA}|ShinichiroMatsui{MATSUISHINICHIRO}|ShintaroIzumi{IZUMISHINTARO}|ArataIshii{ISHIIARATA}|NagisaOshima{OSHIMANAGISA}|ShokichiTsukamoto{TSUKAMOTOSHOKICHI}|YusukeTakeda{TAKEDAYUSUKE}|EmikoSakaida{SAKAIDAEMIKO}|YoshinobuKonishi{KONISHIYOSHINOBU}|MasatoshiIkeda{IKEDAMASATOSHI}|AsamiKataoka{KATAOKAASAMI}|KenichiIshiyama{ISHIYAMAKENICHI}|MisakiHada{HADAMISAKI}|HiroakiIto{ITOHIROAKI}|MasahiroHirata{HIRATAMASAHIRO}|HironoriHaga{HAGAHIRONORI}|YusukeOkamoto{OKAMOTOYUSUKE}|JunyaKanda{KANDAJUNYA}|KotaroShirakawa{SHIRAKAWAKOTARO}|AkifumiTakaori-Kondo{TAKAORI-KONDOAKIFUMI}|MasakiRi{RIMASAKI}|HirokazuSasaki{SASAKIHIROKAZU}|ChieKato{KATOCHIE}|TomoyukiNakamura{NAKAMURATOMOYUKI}|YoshikoOshima{OSHIMAYOSHIKO}|TakahiroNakashima{NAKASHIMATAKAHIRO}|TomotakaSuzuki{SUZUKITOMOTAKA}|ShioriKinoshita{KINOSHITASHIORI}|HirokazuKomatsu{KOMATSUHIROKAZU}|ShinsukeIida{IIDASHINSUKE}____Oral Session 1-17AMultiple Myeloma: Basic Research____Targeting ADAR1 p150 triggers IFN-α-induced myeloma cell death: potentiation of selinexor's effect|Proteome-based stratification reveals biologically distinct subgroups across plasma cell neoplasms|CD38+CD69+ NK cells represent an exhausted population in a mouse model of mature B-cell tumors|Spatial analysis reveals hematopoietic niche disruption in relapsed/refractory myeloma|IL-6-dependent BCMA downregulation confers resistance to BCMA-targeted therapy in multiple myeloma

O1-17A

Oral Session 1-17A
Multiple Myeloma: Basic Research

Chair：Hiroto Ohguchi

YusukeInoue{INOUEYUSUKE}|KazukiNagao{NAGAOKAZUKI}|AyaneOhmori{OHMORIAYANE}|MarikoIshibashi{ISHIBASHIMARIKO}|TaikiTashiro{TASHIROTAIKI}____KensukeHachiya{HACHIYAKENSUKE}____TakeshiHarada{HARADATAKESHI}|AsukaOda{ODAASUKA}|MasafumiNakamura{NAKAMURAMASAFUMI}|ShiyoriKawata{KAWATASHIYORI}|TaikiHori{HORITAIKI}|YusakuMaeda{MAEDAYUSAKU}|RyoheiSumitani{SUMITANIRYOHEI}|MasahiroOura{OURAMASAHIRO}|KimikoSogabe{SOGABEKIMIKO}|RisaHashida{HASHIDARISA}|ShiroFujii{FUJIISHIRO}|ShingenNakamura{NAKAMURASHINGEN}|HirokazuMiki{MIKIHIROKAZU}|MasahiroAbe{ABEMASAHIRO}|Ken-IchiMatsuoka{MATSUOKAKEN-ICHI}|MasanoriToho{TOHOMASANORI}|KyokoIto{ITOKYOKO}|NaoyaFukuda{FUKUDANAOYA}|WataruKinoshita{KINOSHITAWATARU}|KosukeShima{SHIMAKOSUKE}|HajimeSakuma{SAKUMAHAJIME}|ShingoTsuji{TSUJISHINGO}|KentaroNarita{NARITAKENTARO}|AyumiFujimoto{FUJIMOTOAYUMI}|MasamiTakeuchi{TAKEUCHIMASAMI}|KoseiMatsue{MATSUEKOSEI}|NobuhikoKobayashi{KOBAYASHINOBUHIKO}|IkukoMatsumura{MATSUMURAIKUKO}|ReiIshihara{ISHIHARAREI}|YukiMurakami{MURAKAMIYUKI}|AkiraMatsumoto{MATSUMOTOAKIRA}|AsumiKojima{KOJIMAASUMI}|MiriKitamura{KITAMURAMIRI}|HinanoKubo{KUBOHINANO}|AkariHatsugai{HATSUGAIAKARI}|LailaZerinTasnim{TASNIMLAILAZERIN}|ManatoSugisaki{SUGISAKIMANATO}|NanamiGotoh{GOTOHNANAMI}|TetsuhiroKasamatsu{KASAMATSUTETSUHIRO}|TakayukiSaitoh{SAITOHTAKAYUKI}|KatsuhikoTsunekawa{TSUNEKAWAKATSUHIKO}|HiroshiHanda{HANDAHIROSHI}|MikaSunakawa-Kii{SUNAKAWA-KIIMIKA}|HidetoTamura{TAMURAHIDETO}|RimpeiMorita{MORITARIMPEI}|MichikoIchii{ICHIIMICHIKO}|MasakoKurashige{KURASHIGEMASAKO}|NaokiHosen{HOSENNAOKI}____Oral Session 1-17BMultiple Myeloma: Basic Research for Tumor Immune Microenvironment____APRIL impairs anti-BCMA bispecific antibody binding to myeloma cells|sBCMA as a global marker for EMD egress: discrepancy with bone marrow findings|Integrin α6 is associated with MAPK signaling activation in multiple myeloma cells|Siglec-15 contributes to an immunosuppressive microenvironment in multiple myeloma|Spatial analysis of interactions between tumor and mesenchymal stromal cells in multiple myeloma

O1-17B

Oral Session 1-17B
Multiple Myeloma: Basic Research for Tumor Immune Microenvironment

Chair：Kensuke Hachiya

HideakiMizuno{MIZUNOHIDEAKI}|KenSuzaki{SUZAKIKEN}|ShoTakeyasu{TAKEYASUSHO}|SakuraKito{KITOSAKURA}|JustinasDaraskevicius{DARASKEVICIUSJUSTINAS}____AkihikoYokoyama{YOKOYAMAAKIHIKO}____YukiNishida{NISHIDAYUKI}|KojiSasaki{SASAKIKOJI}|GuillermoGarcia-Manero{GARCIA-MANEROGUILLERMO}|JaredBurks{BURKSJARED}|RashmiKanagal-Shamanna{KANAGAL-SHAMANNARASHMI}|MichaelAndreeff{ANDREEFFMICHAEL}|KeitaYamamoto{YAMAMOTOKEITA}|JakushinNakahara{NAKAHARAJAKUSHIN}|Yu-HsuanChang{CHANGYU-HSUAN}|SusumuGoyama{GOYAMASUSUMU}|YuyaKurihara{KURIHARAYUYA}|KenSasaki{SASAKIKEN}|TakashiOyama{OYAMATAKASHI}|YutaFukui{FUKUIYUTA}|MichiakiSato{SATOMICHIAKI}|HirokiHayashida{HAYASHIDAHIROKI}|YosukeMasamoto{MASAMOTOYOSUKE}|MineoKurokawa{KUROKAWAMINEO}|TakayasuKato{KATOTAKAYASU}|YuHiramoto{HIRAMOTOYU}|HiroshiOhno{OHNOHIROSHI}|ShingoTsuji{TSUJISHINGO}|MayuInoue{INOUEMAYU}|ToruNanmoku{NANMOKUTORU}|TakashiMatsuzaka{MATSUZAKATAKASHI}|AkioHayashi{HAYASHIAKIO}|MamikoSakata(Yanagimoto){SAKATA(YANAGIMOTO)MAMIKO}|SarahUnterberger{UNTERBERGERSARAH}|KimTheilgaard-Monch{THEILGAARD-MONCHKIM}|KristerWennerberg{WENNERBERGKRISTER}____Oral Session 1-17CAML: Basic 1____Bone marrow spatial proteomics reveals niche-level immune evasion of TP53 mutant AML MRD|Artificial coupling of mutant TP53 with RUNX1 induces anti-tumor effects in acute myeloid leukemia|Heterozygous loss of ETF1 represents a therapeutic vulnerability specific to del(5q) AML|Very long-chain ceramide accumulation as a metabolic vulnerability in acute myeloid leukemia|Co-inhibition of PARP1 and ATM results in synthetic lethality in venetoclax resistant AML

O1-17C

Oral Session 1-17C
AML: Basic 1

Chair：Akihiko Yokoyama

RyutaroTaenaka{TAENAKARYUTARO}|ZongruYang{YANGZONGRU}|YuqiSun{SUNYUQI}|HirokiKawahara{KAWAHARAHIROKI}|AkihikoYokoyama{YOKOYAMAAKIHIKO}____DaikiKarigane{KARIGANEDAIKI}____TeppeiSakoda{SAKODATEPPEI}|YoshikaneKikushige{KIKUSHIGEYOSHIKANE}|KeitaYamamoto{YAMAMOTOKEITA}|RukaShimura{SHIMURARUKA}|HiiroInui{INUIHIIRO}|Yu-HsuanChang{CHANGYU-HSUAN}|SusumuGoyama{GOYAMASUSUMU}|JiantaoXue{XUEJIANTAO}|YujingHuang{HUANGYUJING}|KazuhisaChonabayashi{CHONABAYASHIKAZUHISA}|ShoShibata{SHIBATASHO}|YasukoMatsumura{MATSUMURAYASUKO}|YotaroOchi{OCHIYOTARO}|YasuhitoNannya{NANNYAYASUHITO}|SeishiOgawa{OGAWASEISHI}|YoshinoriYoshida{YOSHIDAYOSHINORI}|AkifumiTakaori-Kondo{TAKAORI-KONDOAKIFUMI}____Oral Session 1-17DAML: Basic 2____CRHBP marks a chemotherapy-associated transcriptional state in LSCs and links to NF-κB signaling|CRISPR-Cas13 screen identifies RBP-encoding transcripts as collateral activity targets in AML|HMGA2 identifies POLDIP3 as a hCD34+ context-dependent effector in acute myeloid leukemia|The significance of coexisting gene mutations in the onset and progression of KMT2A-PTD-positive AML|Mechanisms by which HOXA9 and NUP98::HOXA9 transform hematopoietic progenitors

O1-17D

Oral Session 1-17D
AML: Basic 2

Chair：Daiki Karigane

TakaoYogo{YOGOTAKAO}|GregoryM.Goldgof{GOLDGOFGREGORYM.}|AaronM.Newman{NEWMANAARONM.}|HiroshiKobayashi{KOBAYASHIHIROSHI}|TimmSchroeder{SCHROEDERTIMM}____KeiyoTakubo{TAKUBOKEIYO}|SatoshiYamazaki{YAMAZAKISATOSHI}____SatoshiYamazaki{YAMAZAKISATOSHI}|KeiyoTakubo{TAKUBOKEIYO}____Symposium 2Artificial intelligence-assisted acceleration of hematopoiesis research____Reading cellular time with AI to identify functional human HSCs|Developing end-to-end AI systems for diagnostic hematology and pathology|Decoding single-cell developmental potential in health and cancer with interpretable AI|Foundation-model-guided dissection of the gene regulatory network of aged hematopoietic stem cells|Long-term single live cell quantification: New tools for old questions

SY2

Symposium 2
Artificial intelligence-assisted acceleration of hematopoiesis research

Chair：Keiyo Takubo, Chair：Satoshi Yamazaki

NathaliaS.Goenawan{GOENAWANNATHALIAS.}|YayoiUeda{UEDAYAYOI}|Yu-GuangChen{CHENYU-GUANG}|ChikaTokuda{TOKUDACHIKA}|MinoruKanaya{KANAYAMINORU}____MasaoOgata{OGATAMASAO}____DerenJ.Halim{HALIMDERENJ.}|ToshikiTerao{TERAOTOSHIKI}|KazuhikoYamamoto{YAMAMOTOKAZUHIKO}|ToshiImai{IMAITOSHI}|MasanoriMakita{MAKITAMASANORI}|SoichiroFujii{FUJIISOICHIRO}|TakeruAsano{ASANOTAKERU}|KazutakaSunami{SUNAMIKAZUTAKA}|HiroyukiSugiura{SUGIURAHIROYUKI}|YuichiroNawa{NAWAYUICHIRO}|TomofumiYano{YANOTOMOFUMI}|IsaoYoshida{YOSHIDAISAO}|YasuhiroShiote{SHIOTEYASUHIRO}|MasatoshiUno{UNOMASATOSHI}|HirokiKobayashi{KOBAYASHIHIROKI}|DaisukeEnnishi{ENNISHIDAISUKE}|HideakiFujiwara{FUJIWARAHIDEAKI}|YoshinobuMaeda{MAEDAYOSHINOBU}|Li-WeiWu{WULI-WEI}|Chun-YuLin{LINCHUN-YU}|Chun-HsuanChang{CHANGCHUN-HSUAN}|Cheng-HongTsai{TSAICHENG-HONG}|Ping-HsuanHsieh{HSIEHPING-HSUAN}|TakashiOnaka{ONAKATAKASHI}|KazunoriAriyoshi{ARIYOSHIKAZUNORI}|RyosukeNomura{NOMURARYOSUKE}|YoshihitoHorisawa{HORISAWAYOSHIHITO}|NorikoSugino{SUGINONORIKO}|MasaharuTashima{TASHIMAMASAHARU}|KoheiTada{TADAKOHEI}|KazunoriImada{IMADAKAZUNORI}|ToshihiroMatsukawa{MATSUKAWATOSHIHIRO}|JunichiHashiguchi{HASHIGUCHIJUNICHI}|MasahiroChiba{CHIBAMASAHIRO}|RintaroNozu{NOZURINTARO}|TomokiTakahashi{TAKAHASHITOMOKI}|TakeshiKondo{KONDOTAKESHI}|MasahiroOnozawa{ONOZAWAMASAHIRO}|TetsuzoTauchi{TAUCHITETSUZO}|TakanoriTeshima{TESHIMATAKANORI}____Oral Session 1-18CAML: Clinical 3____Triplet IDH inhibitor therapy: MRD clearance and survival tail architecture in IDH-mutated AML|AZA/VEN and intensive chemotherapy for AML: the multi-center prospective observational study in OHSG|Venetoclax-based bridging chemotherapy before transplant in AML: survival and cost-utility analysis|A retrospective analysis of venetoclax and azacitidine for acute myeloid leukemia at our institution|AZA-VEN with incidental vitamin K2 use: A retrospective study from the Hokkaido Leukemia Net

O1-18C

Oral Session 1-18C
AML: Clinical 3

Chair：Masao Ogata

TomokoMaruhashi{MARUHASHITOMOKO}|YasuhikoHarada{HARADAYASUHIKO}|GoichiYoshimoto{YOSHIMOTOGOICHI}|HirokiKanazawa{KANAZAWAHIROKI}|ShunTsunoda{TSUNODASHUN}____SatoshiWakita{WAKITASATOSHI}____MakikoMizuguchi{MIZUGUCHIMAKIKO}|KumikoKagawa{KAGAWAKUMIKO}|HironobuShibata{SHIBATAHIRONOBU}|ShujiOzaki{OZAKISHUJI}|WakanaTakahashi{TAKAHASHIWAKANA}|ReikaIto{ITOREIKA}|NarukoSuzuki{SUZUKINARUKO}|JunjiHiraga{HIRAGAJUNJI}|HuiyeonChoi{CHOIHUIYEON}|YuKochi{KOCHIYU}|TadafumiIino{IINOTADAFUMI}|YuhoNajima{NAJIMAYUHO}|DaichiSadato{SADATODAICHI}|ChizukoHirama{HIRAMACHIZUKO}|KotaroGaran{GARANKOTARO}|KotaHasegawa{HASEGAWAKOTA}|KairiKojo{KOJOKAIRI}|RikiYamakawa{YAMAKAWARIKI}|KanaKato{KATOKANA}|KeishoKyan{KYANKEISHO}|YukiMori{MORIYUKI}|KoheiShimura{SHIMURAKOHEI}|TatsuyaTsurumoto{TSURUMOTOTATSUYA}|DaisukeMurakami{MURAKAMIDAISUKE}|AtsushiJinguji{JINGUJIATSUSHI}|NaokiShingai{SHINGAINAOKI}|TakashiToya{TOYATAKASHI}|KaoruMorita{MORITAKAORU}|HiroakiShimizu{SHIMIZUHIROAKI}|TomomiToubai{TOUBAITOMOMI}|HironoriHarada{HARADAHIRONORI}|KyokoHaraguchi{HARAGUCHIKYOKO}|YukaHarada{HARADAYUKA}|NorikoDoki{DOKINORIKO}|YukiSakaida{SAKAIDAYUKI}|EmiSawazaki{SAWAZAKIEMI}|WataruKamata{KAMATAWATARU}|ShukuSato{SATOSHUKU}|TomiteruTogano{TOGANOTOMITERU}|RyujiTanosaki{TANOSAKIRYUJI}____Oral Session 1-18DAML: Clinical 4____Prognostic impact of CD7 expression in AML with azacitidine plus venetoclax|Real-world effectiveness of venetoclax compared to conventional treatment in elderly AML patients|VenAza as a bridge to allo-HSCT in AML: impact of CR and maintenance therapy|Venetoclax/azacitidine maintenance after allogeneic transplantation for AML: retrospective study|A retrospective study of venetoclax + azacitidine therapy for transplant unsuitable AML

O1-18D

Oral Session 1-18D
AML: Clinical 4

Chair：Satoshi Wakita

DaisukeEnnishi{ENNISHIDAISUKE}____ShinyaRai{RAISHINYA}________Luncheon Seminar 1-1Molecular pathogenesis and therapeutic strategy of DLBCL____－

LS1-1

Luncheon Seminar 1-1
Molecular pathogenesis and therapeutic strategy of DLBCL

【Sponsored by CHUGAI PHARMACEUTICAL CO., LTD.】

Miguel-AngelPerales{PERALESMIGUEL-ANGEL}____SeitaroTerakura{TERAKURASEITARO}________Luncheon Seminar 1-2US Lessons: Optimizing Outcomes in CAR T Therapy for DLBCL____－

LS1-2

Luncheon Seminar 1-2
US Lessons: Optimizing Outcomes in CAR T Therapy for DLBCL

【Sponsored by Gilead Sciences K.K.】

GuillermoGarcia-Manero{GARCIA-MANEROGUILLERMO}____YasushiMiyazaki{MIYAZAKIYASUSHI}________Luncheon Seminar 1-3An approach to lower risk MDS____－

LS1-3

Luncheon Seminar 1-3
An approach to lower risk MDS

【Sponsored by Bristol Myers Squibb K.K.】

HidekiGoto{GOTOHIDEKI}____MikiAndo{ANDOMIKI}________Luncheon Seminar 1-4Management of Infectious Complications Associated with Cellular Immunotherapy____－

LS1-4

Luncheon Seminar 1-4
Management of Infectious Complications Associated with Cellular Immunotherapy

【Sponsored by Takeda Pharmaceutical Company Limited】

Shun-IchiKimura{KIMURASHUN-ICHI}|JunyaKanda{KANDAJUNYA}____YoshinobuKanda{KANDAYOSHINOBU}________Luncheon Seminar 1-5Rethinking the Management of Fungal Infections in AML____Risk of invasive fungal disease in the era of novel AML therapies and treatment strategies guided by suspected fungal pathogens|Treatment Strategies for Invasive Fungal Disease after Allogeneic Hematopoietic Cell Transplantation: A Focus on Drug–Drug Interactions

LS1-5

Luncheon Seminar 1-5
Rethinking the Management of Fungal Infections in AML

【Sponsored by ASAHI KASEI THERAPEUTICS CORPORATION】

KentaroSerizawa{SERIZAWAKENTARO}____ChiakiNakaseko{NAKASEKOCHIAKI}________Luncheon Seminar 1-6Mastering Infection Control in the Era of CAR-T Cell Therapy and Bispecific Antibodies - The Frontline of Hypogammaglobulinemia Management -____－

LS1-6

Luncheon Seminar 1-6
Mastering Infection Control in the Era of CAR-T Cell Therapy and Bispecific Antibodies - The Frontline of Hypogammaglobulinemia Management -

【Sponsored by CSL Behring K.K.】

SouichiShiratori{SHIRATORISOUICHI}____ShinichiKako{KAKOSHINICHI}________Luncheon Seminar 1-7Current positioning of Belumosudil for the treatment of chronic GVHD____－

LS1-7

Luncheon Seminar 1-7
Current positioning of Belumosudil for the treatment of chronic GVHD

【Sponsored by Meiji Seika Pharma Co., Ltd.】

SachikoKanaji{KANAJISACHIKO}|ShikikoUeno{UENOSHIKIKO}____YoshitakaMiyakawa{MIYAKAWAYOSHITAKA}________Luncheon Seminar 1-8Immune Thrombocytopenia: From Autoantibody-Mediated Pathogenesis to the Clinical Impact of FcRn Inhibitor____Pathogenesis of Autoantibody-Mediated Immune Thrombocytopenia and Its Impact on Platelet Function|Risk-Adapted Treatment Strategies in ITP: Insights into Patient Profiles from Clinical Experience with FcRn Inhibitor

LS1-8

Luncheon Seminar 1-8
Immune Thrombocytopenia: From Autoantibody-Mediated Pathogenesis to the Clinical Impact of FcRn Inhibitor

【Sponsored by argenx Japan K.K.】

HiroyukiKunishima{KUNISHIMAHIROYUKI}|SouheiHarada{HARADASOUHEI}____KoichiAkashi{AKASHIKOICHI}________Luncheon Seminar 1-9____Advances in COVID-19 Management for Patients with Hematologic Diseases: From Prevention of Severe Illness to Long-Term Care|Update on the Treatment of Antimicrobial-Resistant Gram-Negative Bacterial Infections in Patients with Hematologic Malignancies

LS1-9

Luncheon Seminar 1-9

【Sponsored by Shionogi & Co., Ltd.】

YasuyukiArai{ARAIYASUYUKI}|MitsumasaWatanabe{WATANABEMITSUMASA}____MasaoOgata{OGATAMASAO}________Luncheon Seminar 1-10____Expansion of cGVHD treatments in the ECP era|Clinical practice in cGVHD aiming to be steroid-free

LS1-10

Luncheon Seminar 1-10

【Sponsored by Therakos Japan】

NobuhikoYamauchi{YAMAUCHINOBUHIKO}____AyumiFujimoto{FUJIMOTOAYUMI}________Luncheon Seminar 1-12Treatment strategy for PTCL 2026____－

LS1-12

Luncheon Seminar 1-12
Treatment strategy for PTCL 2026

【Sponsored by DAIICHI SANKYO COMPANY, LIMITED.】

MoekoHino{HINOMOEKO}|EiKinai{KINAIEI}____AtsushiManabe{MANABEATSUSHI}________Luncheon Seminar 1-13QOL-Boosting SDM in Haemophilia Care: What Referring Paediatricians and Receiving Haematologists Can Do____“Take it as prescribed” Is Not Enough: SDM to Build Adherence and Smooth Transition|SDM as “Priority Alignment”: Diverse Needs and the Physician-Patient Perception Gap

LS1-13

Luncheon Seminar 1-13
QOL-Boosting SDM in Haemophilia Care: What Referring Paediatricians and Receiving Haematologists Can Do

【Sponsored by Medical Affairs Department, Novo Nordisk Pharma Ltd.】

TomoyukiAsano{ASANOTOMOYUKI}____HideakiNakajima{NAKAJIMAHIDEAKI}________Luncheon Seminar 1-15Targeting IFN-γ in Hyperinflammatory Diseases: Emerging Therapeutic Strategies for HLH/MAS____－

LS1-15

Luncheon Seminar 1-15
Targeting IFN-γ in Hyperinflammatory Diseases: Emerging Therapeutic Strategies for HLH/MAS

【Sponsored by Sobi Japan】

FumiyaWada{WADAFUMIYA}____MotokoYamaguchi{YAMAGUCHIMOTOKO}________Luncheon Seminar 1-16Current Perspectives on the Treatment of Primary CNS Lymphoma: The Role of Thiotepa-Based Autologous Stem Cell Transplantation____－

LS1-16

Luncheon Seminar 1-16
Current Perspectives on the Treatment of Primary CNS Lymphoma: The Role of Thiotepa-Based Autologous Stem Cell Transplantation

【Sponsored by Sumitomo Pharma Co., Ltd.】

AkihikoGoto{GOTOAKIHIKO}____HirokiYamaguchi{YAMAGUCHIHIROKI}________Luncheon Seminar 1-17Practical Perioperative Management in Paroxysmal Nocturnal Hemoglobinuria -Based on the Reference Guide -____－

LS1-17

Luncheon Seminar 1-17
Practical Perioperative Management in Paroxysmal Nocturnal Hemoglobinuria -Based on the Reference Guide -

【Sponsored by Alexion Pharma GK】

ToshikiOchi{OCHITOSHIKI}|HidetoTamura{TAMURAHIDETO}____KenshiSuzuki{SUZUKIKENSHI}________Luncheon Seminar 1-18Treatment of Relapsed/Refractory Multiple Myeloma in the context of the Immune microenvironment____Immunotherapy and Immune Microenvironment of Multiple Myeloma|Revisiting RRMM Treatment Through the Immune Microenvironment

LS1-18

Luncheon Seminar 1-18
Treatment of Relapsed/Refractory Multiple Myeloma in the context of the Immune microenvironment

【Sponsored by Medical Affairs Division, Johnson & Johnson】

TadaoIshida{ISHIDATADAO}____ShigekiIto{ITOSHIGEKI}________Evening Seminar 1-1Current and Emerging Treatments for Relapsed/Refractory Multiple Myeloma____The New Era of Bispecific Antibodies (Teclistamab/Talquetamab)～ Including Combination Therapies～

ES1-1

Evening Seminar 1-1
Current and Emerging Treatments for Relapsed/Refractory Multiple Myeloma

【Sponsored by Johnson & Johnson】

TakuyaNunomura{NUNOMURATAKUYA}|MasakoToyosaki{TOYOSAKIMASAKO}____YoshiakiOgawa{OGAWAYOSHIAKI}________Evening Seminar 1-2____Efficacy and Safety of the Higher Initial Dose and Accelerated dose Titration (HIDAT) BESREMi Regimen in Patients with Polycythemia Vera|The real-world experience of initiating the BESREMi in the clinical practice

ES1-2

Evening Seminar 1-2

【Sponsored by PharmaEssentia Japan KK】

TakahiroKumode{KUMODETAKAHIRO}____NobuhikoUoshima{UOSHIMANOBUHIKO}________Evening Seminar 1-3Current Status of CLL Treatment and the Role of BCL2 Inhibitors____－

ES1-3

Evening Seminar 1-3
Current Status of CLL Treatment and the Role of BCL2 Inhibitors

【Sponsored by AbbVie GK】

KeijiOkinaka{OKINAKAKEIJI}____ShujiOzaki{OZAKISHUJI}________Evening Seminar 1-4Infectious Disease Management in the Era of Novel Immunotherapies: From Infection Risks of Bispecific Antibodies and Other Emerging Therapies to Vaccination and Treatment Strategies____－

ES1-4

Evening Seminar 1-4
Infectious Disease Management in the Era of Novel Immunotherapies: From Infection Risks of Bispecific Antibodies and Other Emerging Therapies to Vaccination and Treatment Strategies

【Sponsored by Pfizer Japan Inc. Medical Affairs】

KatsutoTakenaka{TAKENAKAKATSUTO}|DaigoHashimoto{HASHIMOTODAIGO}____HirohisaNakamae{NAKAMAEHIROHISA}________Evening Seminar 1-5Current Frontiers in the Treatment of MF and GVHD____MF Treatment Strategies Aimed at Improving Overall Survival|Treatment Strategies Using Jakavi for Acute and Chronic GVHD

ES1-5

Evening Seminar 1-5
Current Frontiers in the Treatment of MF and GVHD

【Sponsored by Novartis Pharma K.K.】

HisashiYamamoto{YAMAMOTOHISASHI}____TakehikoMori{MORITAKEHIKO}________Evening Seminar 1-6Management after Allogeneic Hematopoietic Stem Cell Transplantation – GVHD and Infection Control –____－

ES1-6

Evening Seminar 1-6
Management after Allogeneic Hematopoietic Stem Cell Transplantation – GVHD and Infection Control –

【Sponsored by Japan Medical Office, Takeda Pharmaceutical Company Limited.】

NoriyukiKatsumata{KATSUMATANORIYUKI}|MinoruKanaya{KANAYAMINORU}____TakayukiTabayashi{TABAYASHITAKAYUKI}____NoriyukiKatsumata{KATSUMATANORIYUKI}____Evening Seminar 1-7Advancing Patient-Centered Care Through Shared Decision Making____Shared Decision Making in an Expanding Treatment Landscape: Optimizing Decisions Based on Patient Values|What Would You Do? — Challenges and Best Practices in Shared Decision Making

ES1-7

Evening Seminar 1-7
Advancing Patient-Centered Care Through Shared Decision Making

【Sponsored by BeOne Medicines Japan】

MayukoKishimoto{KISHIMOTOMAYUKO}|KazuhoMorichika{MORICHIKAKAZUHO}____KagehiroAmano{AMANOKAGEHIRO}________Evening Seminar 1-8Regional Collaboration in Hemophilia Care- Roles and Future Perspectives of Regional Core Hospitals and Affiliated Care Facilities -____Better Together: Boosting Patient Satisfaction Through Clinic–Hospital Collaboration in Hemophilia Care|The Role of ALTUVIIIO in Hemophilia Patients with Lifestyle-Related Diseases and Comorbidities

ES1-8

Evening Seminar 1-8
Regional Collaboration in Hemophilia Care- Roles and Future Perspectives of Regional Core Hospitals and Affiliated Care Facilities -

【Sponsored by Sanofi K.K.】

DaisukeMinakata{MINAKATADAISUKE}____HiroyukiTakamatsu{TAKAMATSUHIROYUKI}________Evening Seminar 1-9The Frontline of Multiple Myeloma Treatment: Recent Evidence and New Modalities____－

ES1-9

Evening Seminar 1-9
The Frontline of Multiple Myeloma Treatment: Recent Evidence and New Modalities

【Sponsored by GlaxoSmithKline K.K.】

YasuyoshiMorita{MORITAYASUYOSHI}|SeikoIki{IKISEIKO}____MotoshiIchikawa{ICHIKAWAMOTOSHI}________Evening Seminar 1-10Treatment and Perioperative Management of Paroxysmal Nocturnal Hemoglobinuria (PNH)____Patient-Managed PNH Treatment -Pegcetacoplan as a Therapeutic Option-|Experience of Cardiac Surgery in a Patient with PNH Treated with Pegcetacopla

ES1-10

Evening Seminar 1-10
Treatment and Perioperative Management of Paroxysmal Nocturnal Hemoglobinuria (PNH)

【Sponsored by Asahi Kasei Therapeutics Corporation】

DaisukeOgiya{OGIYADAISUKE}|YuichiHorigome{HORIGOMEYUICHI}____MakotoSasaki{SASAKIMAKOTO}________Evening Seminar 1-12A Decade of Carfilzomib in Multiple Myeloma: New Challenges Ahead____Redefining the Scientific Role of Carfilzomib in the Era of CAR-T and Bispecific Antibodies|The Value of Carfilzomib in the Era of CAR-T Cell Therapy and Bispecific Antibodies: Perspectives on Bridging Strategies and the Management of Older Adults

ES1-12

Evening Seminar 1-12
A Decade of Carfilzomib in Multiple Myeloma: New Challenges Ahead

【Sponsored by ONO PHARMACEUTICAL CO., LTD.】

NobuakiSuzuki{SUZUKINOBUAKI}____KotaroShirakawa{SHIRAKAWAKOTARO}________Evening Seminar 1-13Risk–Benefit Profile of Hemophilia Treatment with the Anti-TFPI Therapy Alhemo® (Tentative Title)____－

ES1-13

Evening Seminar 1-13
Risk–Benefit Profile of Hemophilia Treatment with the Anti-TFPI Therapy Alhemo^® (Tentative Title)

【Sponsored by Novo Nordisk Pharma Ltd.】

ShukuSato{SATOSHUKU}____HirohitoYamazaki{YAMAZAKIHIROHITO}________Evening Seminar 1-14Treatment Strategy for Aplastic Anemia: Current Positioning of Romiplostim____－

ES1-14

Evening Seminar 1-14
Treatment Strategy for Aplastic Anemia: Current Positioning of Romiplostim

【Sponsored by Kyowa Kirin Co., Ltd.】

YoshikazuYonemitsu{YONEMITSUYOSHIKAZU}____TsukasaOhmori{OHMORITSUKASA}________Evening Seminar 1-15Current Landscape of Gene Therapy in Japan: Towards Establishing an Appropriate Provision System____－

ES1-15

Evening Seminar 1-15
Current Landscape of Gene Therapy in Japan: Towards Establishing an Appropriate Provision System

【Sponsored by CSL Behring K.K. Medical Affairs】

MasahiroTakeyama{TAKEYAMAMASAHIRO}|KazuyaOkada{OKADAKAZUYA}____YoshinobuSeki{SEKIYOSHINOBU}________Evening Seminar 1-16Standardization and Clinical Practice in Acquired Hemophilia A Management____Key Points in the Diagnosis and Treatment of Acquired Hemophilia A|Our Institutional Strategy for Acquired Hemophilia A: Achieving Rapid Diagnosis and Early Treatment

ES1-16

Evening Seminar 1-16
Standardization and Clinical Practice in Acquired Hemophilia A Management

【Sponsored by CHUGAI PHARMACEUTICAL CO., LTD.】

IlseungChoi{CHOIILSEUNG}____AkihiroTomita{TOMITAAKIHIRO}________Evening Seminar 1-17Potential of HDAC inhibitor for relapsed/refractory PTCL: Focusing on nodal TFH Lymphoma____－

ES1-17

Evening Seminar 1-17
Potential of HDAC inhibitor for relapsed/refractory PTCL: Focusing on nodal TFH Lymphoma

【Sponsored by Meiji Seika Pharma Co., Ltd.】

NobuhiroTsukada{TSUKADANOBUHIRO}____EmikoSakaida{SAKAIDAEMIKO}________Evening Seminar 1-18Real-world experience of Ide-cel for multiple myeloma -the importance of bridging therapy-____－

ES1-18

Evening Seminar 1-18
Real-world experience of Ide-cel for multiple myeloma -the importance of bridging therapy-

【Sponsored by Bristol Myers Squibb K.K.】

－____－________Opening/Award Ceremony____－

NO1

Opening/Award Ceremony

－____－________JSH Business Meeting____－

NO5

JSH Business Meeting